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ABSTRACT: 
Human Foxp3+ regulatory T cells, particularly in vitro induced Tregs (iTregs), have potential 
therapeutic applications in transplantation and autoimmune disease. Induced Tregs have been 
the focus of many recent human in vitro and experimental animal studies, which have 
highlighted their potential therapeutic efficacy and advantages over natural Tregs. More work 
is needed, however, before stable iTregs in sufficient number can be taken for human clinical 
trial. This is the challenge examined in this Thesis. 
Several protocols for generating Foxp3+ induced Tregs have been developed. These 
protocols were claimed to be effective in producing a functionally stable Treg population. 
The methylation status of the Foxp3 gene is currently the best available measure for 
evaluating functional stability of Tregs. Information regarding the methylation status of these 
differently induced Tregs is lacking. Moreover, lack of proper evaluation and comparisons 
between these protocols preclude the identification of the best available protocol and impede 
further advances in the methodology of generating Tregs. 
Here human induced Foxp3+ Tregs were generated using seven different protocols. These 
protocols covered the most commonly used methods and reagents for the induction of 
Foxp3+ Tregs, but also included new additional methods (TGFβ + VitD & Azathioprine).  
Functional and quantitative criteria were used for comparing iTregs generated from different 
protocols.  The methylation status of the Foxp3 gene was used as a measure of Treg 
functional stability and the percentage of CD4+CD25+Foxp3+ cells (iTregs) was used for 
quantification. Foxp3 protein expression level was also measured for all culture conditions, 
but Foxp3 mRNA expression level and suppressive activity of iTregs were measured only in 
some protocols. 
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The seven protocols examined 24 different culture conditions, but only 16 culture conditions 
showed significant increases in the percentage of iTregs (CD4+CD25+Foxp3+) and the level 
of Foxp3 protein expression when compared to control. In addition, only six culture 
conditions had significant increases in the percentage of Foxp3 promoter demethylation. The 
mean percentage of iTregs produced by the 16 culture conditions ranged from15% to 38% 
and the mean percentage of Foxp3 promoter demethylation, ranged from 20% to 36%. The 
comparison analysis revealed that a protocol using naïve CD4+ T cells treated with TGFβ 
and tRA offered the best method for generating Foxp3+ iTregs. The TGFβ + tRA conversion 
protocol consistently promotes Foxp3 expression and demethylation in naïve CD4+ T cells. It 
converted 31% ± 6 of naïve T cells into Foxp3 expressing T cells and induced Foxp3 
demethylation in 36%  ±  3 of total T cell DNA. These Foxp3+ iTregs displayed a high level 
of Foxp3 expression, exhibited 54% demethylation of the Foxp3 promoter and were 
suppressive in vitro. In addition, this protocol has the potential to generate clinical grade 
regulatory T cells for therapeutic use. 
It was also found that azathioprine, an immunosuppressant drug significantly (p<0.05) 
enhanced Foxp3 protein expression and Foxp3 promoter demethylation in naïve CD4+ T 
cells. Although produced in a low frequency (<20%), azathioprine induced Tregs displayed a 
high level of Foxp3 promoter demethylation (64%  ±  6). However, all Foxp3+ iTregs 
generated by these in vitro protocols, displayed partial demethylation of the Foxp3 promoter, 
suggesting transient regulatory function and phenotype. Furthermore, correlation analysis 
showed that the percent of Foxp3 promoter demethylation positively correlated with 
Foxp3mRNA expression (r=0.63, p<0.0001), Foxp3 protein expression (r=0.31, p<0.0001) 
and the frequency of Foxp3+ iTregs (r=0.55, p<0.0001). These findings support the role of 
epigenetic changes as a mechanism for regulating Foxp3 gene expression. 
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In summary, our data identify the methylation status of the Foxp3 gene in different types of 
iTregs and proved that all in vitro induced Tregs displays partial demethylation of the Foxp3 
promoter, which is consistent with a transient suppressive Treg phenotype. In addition, two 
new protocols for generating Tregs in vitro (TGFβ + VitD & Azathioprine) were introduced, 
though did not promote complete demethylation of the Foxp3 promoter, these methods have 
expanded the range of Treg generation protocols and have provided  scientific evidence for 
investigating the molecular mechanisms underlying Foxp3 induction in these protocols. 
Furthermore, this study has identified the combination of TGFβ and all-trans retinoic acid, as 
the most promising protocol for generating Tregs in vitro on the basis of enhanced functional 
stability and improved conversion rate. These findings hold important implications for the in 
vitro methods of Treg generation and provide the basis for future development of more 
effective strategies. 
Clearly, the world still has a distance to go to achieve the goal of generating stable iTregs in 
sufficient number for clinical benefits; it is a goal that deserves continued intensive effort in 
parallel with current attempt of improving the clinical use of natural Tregs. Both approaches 
should have a valuable place in the future. 
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1.1 Summary. 
The therapeutic use of regulatory T cells in immune disorders offers a novel and potentially 
effective approach for the control of T cell activity in a group of human diseases. Therapeutic 
success relies on the ability to purify or generate cells with stable suppressive function and in 
sufficient numbers. The in vitro generation of Tregs provide a potential direction for 
achieving this provided that current technique barriers are overcome. Foxp3+ regulatory T 
cells (Tregs) are a population of CD4+ T lymphocytes that mediate immune-suppression.  
These cells suppress unwanted immune responses by inhibiting the proliferation and effector 
functions of other cells. Foxp3+ Tregs are classified into thymus-derived Tregs (tTregs) and 
peripherally-derived Tregs (pTregs). Cells of the Treg phenotype can also be induced in vitro 
and are termed in vitro-induced Tregs (iTregs).  Tregs are essential for maintaining immune 
tolerance and play an important role in preventing autoimmunity as well as transplant 
rejection.  
Lack of Foxp3 + Tregs due to defective Foxp3 protein results in a fatal disorder with severe 
autoimmunity known as IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-
linked). Furthermore, many autoimmune disorders display alteration in Treg frequency and 
function. For instance, SLE patients with active disease have been found to have reduced 
numbers of Foxp3+ Tregs, while patients with multiple sclerosis and rheumatoid arthritis 
show reduction in Treg suppressive activities. These data support the role of Tregs in the 
pathogenesis of autoimmune diseases and provide the scientific basis for evaluating their 
therapeutic potential. In murine studies, adoptive transfer of natural and in vitro induced 
Tregs successfully prevented the development of autoimmune diseases. However, these 
studies indicated that tTregs were ineffective in treating established disease, particularly 
Th17-mediated autoimmune disorders. In addition, tTregs were shown to be inherently 
unstable especially, in an inflammatory milieu where Tregs can be converted to other 
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proinflammatory cells. Although both antigen-specific and polyclonal Tregs were protective, 
antigen-specific Tregs were consistently superior to polyclonal Tregs in controlling an 
established autoimmune disease. However, in many autoimmune disorders, the exact antigens 
are unknown and therefore polyclonal regulatory T cells may be more useful for therapeutic 
purposes. Several human trials have been conducted using tTreg cellular therapy for the 
treatment and prevention of graft versus host disease (GvHD); all showed no infusional 
toxicity. However, the major hindrance in these trials was obtaining sufficient numbers of 
cells. Though in vitro expansion of tTregs improved the final yield, this procedure has been 
associated with loss of phenotype and suppressive function. This issue is further complicated 
by the lack of specific cellular markers for adequate purification. 
In contrast, in vitro induced Tregs show greater stability in inflammatory conditions and were 
efficient in preventing as well as treating autoimmune diseases in murine studies. In addition, 
iTregs can be easily generated from the more abundant CD4+ T cells and purified in large 
numbers.  Therefore, generating in vitro induced Tregs for cellular therapy presents an ideal 
alternative and an attractive approach. Over the last decade, several cell culturing protocols 
have been developed to generate stable Foxp3+ Tregs from naïve or memory CD4+ T cells.  
These include adding different types of tolerogenic dendritic cells to induce Tregs 
differentiation from other T cells. However, the lack of a standard evaluation of all these 
protocols prevents clear comparison and further advances in Treg-based cellular therapy. 
Hence, this study was conducted to explore these methods and fill this gap of knowledge as 
described further in the project aims and objectives section 
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1.2 Introduction:   
Regulatory T cells are a heterogeneous population of CD4+ T lymphocytes specialized in 
suppressing adaptive and innate immune responses. The three main types are CD25+ Foxp3+ 
T cells, IL-10 producing Tr1 cells and TGFβ producing Th3 cells. The CD25+ Foxp3+ 
regulatory T cells is the subset best characterized (1). 
1.2.1   Foxp3+ regulatory T cells. 
Foxp3+ regulatory T cells are crucial for maintaining immune tolerance and homeostasis. 
First described in the 1970s as suppressor T cells (2), their existence was later dismissed, 
leaving  these cells undefined for more than two decades. The lack of reliable surface markers 
impeded the identification and the study of this population. In 1995, murine T cells with 
suppressive activity were reported, but this time these cells were further characterized by 
their constitutive expression of CD25 (IL-2R). These CD4+CD25+ T cells prevented  
autoimmunity in thymectomized mice and displayed immune-regulatory functions, they were 
therefore, referred to as regulatory T cells (Tregs) (3).  
 Human regulatory T cells with the above features were only recognized in 2001. However, 
only CD4+ T cells with high CD25 expression were suppressive in humans (4).This 
important population constitutes less than 10% of total CD4+ T cells in human peripheral 
blood (5, 6). In contrast to mouse Tregs, human Tregs display phenotypic and functional 
heterogeneity (7).
 
Two years later, forkhead box P3+ (Foxp3) transcription factor was 
identified as a specific marker for Tregs. These cells were then referred to as Foxp3+ 
regulatory T cells. Foxp3 is a nuclear transcription factor that plays an essential role in the 
development and function of Tregs (8, 9). Lack of functional Foxp3+ protein results in a fatal 
disorder known as scurfy in mice and IPEX (Immune dysregulation, Polyendocrinopathy, 
Enteropathy ,X-linked) in humans (10). The severe autoimmunity seen in these disorders is 
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caused by mutations in the Foxp3 gene (11, 12). A similar syndrome of severe autoimmunity 
results from selective depletion of Foxp3+ Tregs (13, 14).  These findings support the 
essential role of Foxp3 in the development and function of Tregs (15-17).
 
Studies have indicated that Foxp3 is not involved in the initial stage of Treg development 
(fate determination from thymocytes), but it is critical for programming Treg differentiation 
(15). Low expression of the α-chain of the IL-7 receptor (CD127) was also suggested as a 
useful marker for discriminating human regulatory from activated T cell (5). These advances 
in Treg immunobiology enabled the recognition of these cells as professional immune 
suppressors and facilitated investigation of their role in health and disease. 
1.2.2   Phenotype of Tregs. 
Human CD4+ regulatory T cells express a high level of CD25 and a low level of CD127. 
These two surface markers enable markedly improved purification of human Tregs isolated 
from peripheral blood (5).  Although Foxp3 is a specific marker for Tregs, its intra-cellular 
location precludes its use for isolation purposes. The high affinity IL-2 receptor α chain 
(CD25) is an activation marker for human T cells and is expressed on activated effector T 
cells. Foxp3 is induced transiently  in human CD4+ T cells after TCR stimulation or in 
proliferating T cells, therefore, it may also act as an activation marker (18, 19). The 
expression levels of CD25 were proportional to those of Foxp3 (20). CD127 expression was 
inversely correlated with Foxp3 expression (21). For the purpose of cell identification in 
culture and for checking purity, most studies have used different combinations of CD4, 
CD25, CD127 and Foxp3. Tregs also express many other cell surface markers these include: 
CD39, CD73, CD103, CD134, CD152 and CD 196 (22-26) . However, none of these surface 
markers seem to be specific to Tregs, as they are also expressed by other cells especially 
activated effector T cells. 
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CD4+ CD25
hi
 Foxp3+ regulatory T cell population from adult peripheral blood has also been 
classified into naive (CD45RA+ Foxp3
lo
) and memory Tregs (CD45RA
 
-Foxp3
hi
) based on 
CD45RA expression. This marker is also helpful in delineating suppressive Tregs from non-
suppressive Foxp3+ T cells which were identified as CD45RA
 
-Foxp3
lo  
T cells (27, 28). It 
seems that memory Tregs are the main subset actively involved and most affected in 
autoimmune diseases (6). Memory Tregs have been further divided into four subpopulations 
based on inducible co-stimulator (ICOS) and HLA-DR expression (29, 30).  
1.2.3   Main Subtypes of Tregs. 
CD4+CD25+CD127
lo
Foxp3+ regulatory T cells have been classified into two major 
subtypes: natural Tregs (thymically-derived) and induced Tregs (peripherally-derived) (31). 
The induced Tregs can be induced in vivo (endogenous) or in vitro (see below). The 
terms/abbreviations currently used to describe different types of Foxp3+ regulatory T cells 
are confusing and imprecise. Recently, several recommendations were developed to improve 
Treg nomenclature (32). These new recommendations offered better terms with more 
informative definition. For this, it was recommended to use thymus-derived Tregs (tTregs ) 
instead of natural Tregs, peripherally derived Tregs (pTregs ) instead of induced or adaptive 
Tregs  and in vitro–induced Tregs (iTregs) for any Foxp3+ Treg population generated ex vivo 
(32). As these terms are simpler and clearer, they will be used through the rest of this thesis.  
 1.2.3.1   Thymus versus peripherally derived Tregs. 
Thymus-derived Tregs  and peripherally derived Tregs share similar  phenotype, stability, 
suppressive function and global gene expression pattern (33). Both require IL-2 for survival 
(34). They also express comparable levels of membrane bound, or actively secreted, TGF-β 
(31, 35). However, they differ in their developmental pathways, activation requirements and 
mechanism of suppression. Thymus-derived Tregs (tTregs) develop in the thymus, but 
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peripherally derived Tregs (pTregs) develop in peripheral lymphoid tissues. Consequently, 
each subset requires different stimuli for their development and activation. tTregs develop 
within the thymic medulla. Their development requires the engagement of TCR with MHC 
molecules loaded with high to medium affinity self-antigens. This occurs in the presence of 
CD28 co-stimulation, IL-2 and TGFβ (31, 36). tTregs then migrate to the periphery to 
maintain peripheral tolerance. tTregs account for 5-10% of the total peripheral CD4+ T cells 
(37, 38). In humans these recently migrated tTregs can be identified by their CD31 
expression (6). 
On the other hand, pTregs develop in the peripheral lymphoid tissues from naïve CD4+ T 
cells during an adaptive immune response. Their development requires suboptimal 
stimulation with self or environmental antigens in the presence of CTLA-4 co-stimulation, 
IL-2 and TGFβ. The sub-immunogenic stimulation of TCR is the key factor for optimal 
conversion. Strong stimulation through TCR results in extensive proliferation and activation 
of the PI3k/Akt/mTOR pathway which inhibits Foxp3 induction and hence conversion to 
pTregs (39, 40). Once pTregs are generated, they remain stable and continue to circulate for 
months in peripheral lymphoid tissues (41, 42) . If pTregs re-encounter the relevant antigen in 
immunogenic condition, they will expand to suppress an unwanted immune response 
(43).Both tTregs and pTregs are completely demethylated at the Foxp3 enhancer region. This 
demethylation maintains and stabilizes Foxp3 expression in these subsets (41, 44). 
Though both Tregs are suppressive cells, the mechanisms of suppression differ between the 
two subsets. pTregs achieve their suppression mainly via  production of suppressive 
cytokines while tTregs use direct cell contact to exert their suppression (18) .This difference 
was also supported by the fact that  TNF-R2 expression was critical for the suppression 
activity of tTregs, but not pTregs (19). Researchers have described several mechanisms of 
suppression displayed by human or mice Tregs.  However, only a few suppressive 
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mechanisms were shared by both species. These include suppression via granzymes A and B, 
CD95-CD95L and adenosine (45-47). 
Suppression through CTLA-4, an inhibitory costimulatory molecule and consumption of IL-2 
by the high expression of CD25 are another two important suppression mechanisms that may 
be applicable to human Tregs (20). It was also proposed that Tregs may have two modes of 
immunosuppression and the choice of particular mechanism depends on the state of the 
surroundings milieu. Under physiological  state,  deprivation of  CD28 signal and IL-2 
cytokine would be sufficient for inhibiting naïve T cell  activation and proliferation, while 
under inflammatory conditions, activated T cells require stronger suppressive mechanism 
such as granenzyme/perforin to be effectively controlled (48).  
Currently, the physiological role of pTregs is not clearly understood and their relative 
contribution in maintaining peripheral immune tolerance is also unknown (49).There is also 
no specific marker that can differentiate tTregs from pTregs.  Helios, an Ikaros family 
transcription factor, was suggested as distinguishing marker. It is expressed by both human 
and murine tTregs however, it is not specific, as it is highly expressed on other T cell subsets 
(Th2 and follicular helper T cells) (50, 51). 
1.2.3.2   In vitro induced Tregs. 
These Tregs are generated in vitro using combinations of stimulation and cytokines to induce 
Foxp3 expression and suppressive capacity in conventional or naive CD4+ T cells.  
Successful generation of human iTregs from naïve T cells requires a clear understanding of 
the key factors that trigger this conversion. There is a general consensus between studies on 
the main elements involved in the induction of Tregs in vitro which requires optimal TCR 
stimulation in the presence of an exogenous supply of IL-2, TGF-β or inhibitors of 
PI3K/AKT/mTOR signaling pathway (49). However, the need for a CD28 co-stimulatory 
21 
 
signal was a controversial issue. In a recent study, it was demonstrated that the importance of 
CD28 signaling depends on the strength of other signals and that differentiation of  Foxp3+  
in vitro  was achieved by the integration of different signals (52).  
TGF-β was the first cytokine used to generate induced Tregs from naïve CD4+ T cells (53).  
Both human and mice naïve CD4+ T cells were successfully induced in vitro to express 
Foxp3 by TGF-β (54, 55). TGF-β also has the ability to induce CD25 expression in CD4+ T 
cells (35, 53). Functionally, TGF-β iTregs were effective in  suppressing  CD8+ T cell 
proliferation in response to alloantigen and were able to inhibit  IgG production when co-
cultured with CD4+ T cells and B-cells (35, 53). Many studies agreed that TGF-β induces 
Foxp3 expression in human T cells, but the main controversy was whether TGF-β can induce 
suppressive activity in CD4+Foxp3+ iTregs. This debate comes from the conflicting results 
of the suppression assay used in these studies. Further studies demonstrated that combining 
TGF-β with other reagents such as all-trans retinoic acid (tRA) or rapamycin can induce 
human Tregs with potent suppressive activity expressed  in vivo and ex vivo (56-58). These 
results strongly argue for the role of TGF-β in the generation of human induced Tregs. Most 
studies used TGF-β for in vitro conversion of naïve CD4+ T cells to iTregs, TGF-β-induced 
Tregs representing the prototype of in vitro induced Tregs. 
Dendritic cells (DCs) are another important player, particularly tolerogenic dendritic cells 
(tDCs). This subset of specialized antigen-presenting cells controls autoimmunity and 
maintains tolerance via different mechanisms.  Peripheral induction of Foxp3+ Tregs from 
naïve T cells is one suggested mechanism (59).  A tolerogenic DC phenotype can be induced 
in vitro by several anti-inflammatory and pharmacological agents including TGF-β, IL-10, 
vitamin D3, rapamycin and dexamethasone (60).  For instance, vitamin D3 induced tDCs  
displayed active transcription of immune tolerance genes, including  indoleamine 2,3-
dioxygenase (IDO), IL-10, TGFβ and genes involved in  PGE2 production which promote 
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Treg differentiation (60). In general, tDCs induce Treg differentiation by providing a low 
stimulatory milieu, producing tolerogenic factors (IL-10, TGFβ and RA) and compromising 
T cells proliferation via IDO action (60). Thus, using dendritic cells to generate induced 
Tregs in vitro presents a valuable alternative method. 
Differentiating in vitro induced Tregs from activated T cells presents a great challenge. 
Activation of conventional CD4+ T cells results in up-regulation of CD25 and down- 
regulation of CD127 (6, 61). Activation also induces Foxp3 expression (18). Therefore, 
phenotypically these two subsets are indistinguishable from each other by Foxp3, CD25 and 
CD127 expressions. A suppression assay was the only way used to tell the difference, as only 
Tregs express suppressive activity. However, this assay is complex, labour intensive, 
technically difficult and lacks standardization.  
The reported studies have used different formats and ratios to express suppressive activity. 
Consequently, positive or negative suppression may happen due to technical error or 
misinterpretation. For instance, failure to check for the viability of Treg population before 
coculture with responder T cells may result in lack of suppression if the putative Tregs are 
dead or dying (62). In addition, variability in the purity of the putative Treg populations can 
significantly affect the final suppression results, particularly if Foxp3 was not used as a 
measure for  Treg purity (63). Furthermore, selection of  high Treg: T cell responder ratios 
such as 1:1 may produce positive suppression, though it may not be physiologically relevant 
while selecting lower ratios such as 1:32 may conceal Treg suppressive activity.  There is 
also a variation in calculating the percentage of suppression from different studies. Many 
studies calculate the percentage of suppression by gating on every peak except the far right 
peak (62, 64) while others used the percentage of undivided cells in the first peak for 
measuring suppressive activity (56, 65). However, for CFSE based assay, calculating the 
division index is the recommended method for reporting the degree of suppression (62). In 
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addition, some studies used PBMCs, CD8 or CD3-depleted PBMCs rather than CD4+ T cells 
as responder cells (57). All these variations make it difficult to compare results from different 
studies and  may explain the conflicting results generated from studies using this assay 
making it an unreliable discriminating method (66). It is also still debatable whether the 
transient expression of Foxp3 on activated T cells induces suppressive function in these cells 
(18, 67, 68). 
Sustainable Foxp3 expression is essential for inducing and maintaining the suppressive 
function of Tregs. Studies showed that maintaining a high level of Foxp3 expression is 
sufficient to induce suppressive capacity in activated T cells (69-71). Subsequently, 
identifying regulatory factors or mechanisms that control Foxp3 expression would provide a 
tool for discriminating Tregs from transiently activated CD4+ T cells. Epigenetic regulation 
of human Foxp3 expression by CpG methylation is one potential tool. The promoter and 
Treg-specific demethylation region (TSDR) in the Foxp3 gene are the main sites of CpG 
methylation. This region is fully methylated in resting conventional T cells and in Foxp3
lo
 
activated conventional T cells (44, 72) 
In vitro-induced Tregs display a comparable level of Foxp3 expression to tTregs (73). These 
cells also share a similar phenotype and suppressive capacity to natural and endogenous 
Tregs (17, 18). However, methylation studies of the Foxp3 gene suggest that Tregs generated 
in vitro lack stable Foxp3 expression as conserved noncoding sequence (CNS) elements in 
these cells remain methylated (72).  For instance, Tregs induced by TGF-β and tRA had 
methylated CpG sites in conserved noncoding sequence elements of the Foxp3 locus (74). 
This is in contrast to tTregs or in vivo induced Tregs, where the same region was completely 
demethylated. It was also reported that these CNS elements remain at least partially 
methylated in TGF-β induced Tregs (41, 44).  This difference in epigenetic profile between in 
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vitro induced and natural or endogenous Tregs generates significant doubt about the stability 
of iTregs in vivo. 
1.2.4   Polyclonal versus Antigen specific Tregs. 
 
Tregs in peripheral blood are a mixture of polyclonal and antigen-specific Tregs. Studies 
have confirmed that both antigen-specific and polyclonal Tregs are protective against 
autoimmune disorders, but antigen-specific Tregs are consistently superior to polyclonal 
Tregs in controlling an ongoing autoimmune process (75, 76). Further, antigen-specific Tregs 
are more potent in suppressing an established immune response and inflammation than 
polyclonal Tregs. In a collagen-induced arthritis (CIA) model, polyclonal Tregs failed to 
suppress the autoimmune response in established disease despite being effective in 
preventing disease development (77-79) . On the other hand, the use of antigen- specific 
Tregs in established CIA, ameliorated the disease (31) . The long term therapeutic benefits of 
antigen-specific Tregs may be attributable to the long term survival of these cells (80) . 
Furthermore, the efficacy of antigen-specific Tregs was observed even in advanced stages of 
an ongoing autoimmune process in a mouse model of autoimmune gastritis (81). However, in 
some autoimmune disorders such as systemic lupus erythematosus (SLE), the exact antigen is 
unknown and therefore polyclonal regulatory T cells are more useful.  For instance, adoptive 
transfer of in vitro induced polyclonal Tregs effectively suppressed murine lupus-like 
syndrome. This was achieved through controlling the expansion of immunogenic dendritic 
cells (DCs) and inducing tolerogenic DCs (82). 
Isolation of antigen-specific Tregs from human peripheral blood is challenging and not 
practical, due to the low frequency of antigen-specific Tregs in peripheral blood and the 
limited availability of proper peptide-MHC multimers for isolating these cells (83). 
Therefore, in vitro induction of antigen-specific Tregs is an attractive alternative. Induction of 
antigen-specific Tregs requires stimulation with specific antigen via MHC molecules from 
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antigen-presenting cells (APCs). However, induction of polyclonal Tregs requires general 
stimulation with non-specific stimulators such as anti-CD3 antibody or anti-CD3/CD28 
beads.  
1.2.5   Pathogenic role of Tregs in autoimmune diseases.  
Foxp3+ Tregs are crucial for maintaining immune tolerance and homeostasis (84). They also 
have an important role in the pathogenesis of autoimmune diseases as dysfunctional mutation 
or  removal of these cells induces spontaneous autoimmunity and systemic inflammation 
(84). These cells suppress self-reactive T cells thereby preventing autoimmunity (85). 
Currently, there are more than 80 autoimmune diseases affecting about 5% of the human 
population (86). These disorders have high morbidity, are often fatal and their incidence 
continues to rise. In addition, the current therapy which consists of immunosuppression 
carries significant risks. Studies have revealed that many autoimmune diseases display 
alteration in Treg frequency and function (6, 87-90) . The quantitative deficit of Tregs seen in 
various autoimmune diseases has also been found to be associated with disease activity (88). 
Patients with active SLE displayed significant reduction in the number of human 
CD4+CD25+ Tregs (87). However, in multiple sclerosis, the number of CD4+CD25+ Tregs 
remained unaltered but the suppressive activity of these cells was markedly  reduced (89, 91) 
Rheumatoid arthritis patients with active disease showed similar reduction in Tregs 
suppressive activity (90). These results indicate that Tregs isolated from these patients carried 
certain intrinsic defects that interfere with their suppressive function. These accumulating 
evidences highlight the likely critical role of Tregs in the pathology of these disorders.  
1.2.6   Therapeutic role of in vitro induced and thymic Tregs in autoimmune diseases. 
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Since defects in Treg frequency or function underlie the pathology of many autoimmune 
disorders, manipulation of Tregs to restore their numbers and function forms the basis of 
Tregs based cellular therapy. Therapeutic roles of Tregs have been investigated in animal 
models through adoptive transfer. Studies revealed that both natural and induced Foxp3+ 
regulatory T cells can prevent autoimmune disease in animal models. However, the efficacy 
of tTregs in treating established autoimmune diseases was questioned by several studies. In 
established collagen-induced arthritis (CIA), the disease progression was not altered 
significantly after adoptive transfer of tTregs (79) . Similarly, in a mouse model of 
established lupus, adoptive transfer of tTregs failed to suppress lupus glomerulonephritis and 
sialoadenitis (92, 93).  
Studies have also indicated that inflammatory cytokines such IL-6 and TNFα, which are 
elevated in conditions like rheumatoid arthritis, may interfere with the suppressive function 
of Tregs (90, 94, 95) . This could explain the failure of tTregs to control an established 
autoimmune disease and indicates that pro-inflammatory cytokines, or the milieu created, can 
induce acquired functional defects in tTregs. Therefore, tTregs appear to be functionally 
unstable under inflammatory conditions. Likewise, tTregs were effective in preventing the 
development of Th17-mediated autoimmune disorders, but, in established disease, Th17 cells 
were completely resistant to tTregs adoptive transfer therapy (31). This suggests that tTregs 
are ineffective in suppressing Th-17 cells activity. Furthermore, treating tTregs with IL-6 
reduced their Foxp3 expression and suppressive function in both in vivo and ex vivo models. 
Moreover, such treatment can convert tTregs to Th17 cells (65, 96). It was also demonstrated 
that an inflammatory milieu was able to convert tTregs to other effector T cells (Th1, Th2 
and Th17) highlighting the plasticity of Foxp3+ Tregs (79, 96-98). The ability of tTregs to 
reprogram to proinflammatory cells has been demonstrated in several studies and in different 
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inflammatory settings (99-101). These data support the idea that tTregs are inherently 
unstable and can lose their functional activity. 
The use of tTregs in adoptive therapy is also associated with other challenges. First, lack of 
specific cellular markers for adequate purification; Foxp3 protein is inaccessible because of 
its intra-nuclear location. The combination of CD25 and CD127 has also proved to be 
insufficient for isolation of pure Tregs (6, 102). The lack of purity is caused by contamination 
with effector T cells and this reduces the potency of the purified Tregs. Second, the need for 
an in vitro expansion step to generate sufficient number of cells for Treg-based cellular 
therapies. This external manipulation induces alteration in tTregs resulting in loss of 
phenotype, suppressive function and production of pro-inflammatory cytokines. These 
alterations are attributed to the loss of Foxp3 expression. This acquired loss occurs after in 
vitro repetitive stimulation or long term culture used for expansion purposes (103). 
Furthermore, initial clinical trials of tTreg therapy in humans revealed that the lack of a 
sufficient number of pure potent Tregs was the main impediment to the success of these trials 
(104-106). Finally, disorders associated with intrinsically defective or dysfunctional Tregs are 
not suitable for tTreg therapy as this protocol required functional tTregs to start with (31). 
On the other hand, in vitro induced Tregs can be easily generated to obtain high numbers of 
cells and adoptive transfer of these cells has been shown to be effective in both preventing 
disease development and controlling established autoimmune disease. The ability of iTregs to 
prevent and treat autoimmune diseases has been confirmed in many studies. Adoptive 
transfer of iTregs generated ex vivo prevented disease development in murine models of 
lupus and autoimmune gastritis (107, 108).  In an asthmatic mouse model, injection of TGF-β 
induced iTregs was effective in preventing house dust mite-induced inflammation and allergy 
(109). In addition, iTregs prevented the development of Th1-mediated colitis and type 1 
diabetes (110, 111). Furthermore, iTregs were as effective as tTregs in preventing 
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experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis 
(112) . In contrast to tTregs, adoptive transfer of iTregs was successful in suppressing or 
reversing an established autoimmune disease. Studies showed that adoptive transfer of iTregs 
effectively  suppressed inflammation and disease progression  in murine models of  EAE, 
autoimmune gastritis, lupus nephritis and type I diabetes(80, 81, 107, 112, 113) .  
In addition, iTregs, particularly TGF-β induced Tregs were proven to be capable of 
ameliorating autoimmune and inflammatory processes in murine models of allergic asthma, 
autoimmune arthritis and lupus like syndrome (82, 114, 115). Infectious tolerance, the 
capacity to transmit suppressive activity and immune modulatory properties to other cells, is 
one suggested mechanism by which iTregs produce immune tolerance, this occurs through 
converting conventional T cells into suppressive T cells (116-118). Infectious tolerance may 
also be achieved through controlling DC maturation in lymphoid tissues and instructing them 
to become tolerogenic DC (31) . In comparisons with tTregs, pro-inflammatory cytokines 
such as IL-6, have no significant effect on the stability and suppressive function of iTregs. 
iTregs treated with IL-6 did not convert to Th17 cells (65, 119). This difference was 
attributed to the loss of IL-6 receptor expression and function induced by IL-2 and TGFβ 
treatment (17). The stability of iTregs was further investigated in the collagen-induced 
arthritis (CIA) model. Results from this in vivo model revealed that iTregs completely 
resisted conversion to other T cell subsets (Th1, Th2 and Th17) (31) . Subsequently, iTregs 
have shown to be more stable in inflammatory conditions. In a study that compared the 
therapeutic benefits of both Tregs types, it was confirmed that only iTregs, particularly TGF-
β induced Tregs, were able to suppress Th17-mediated diseases (120). 
Induced Treg-based therapy is also considered the ideal therapeutic option for patients with 
rheumatoid arthritis and multiple sclerosis where tTregs are dysfunctional and not suitable for 
expansion and transfer therapy. For all these reasons, Tregs generated in vitro are preferred 
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for cellular based therapy. These cells also offer a valuable alternative to tTregs in conditions 
associated with quantitative or functional deficits of tTregs. Currently, the use of in vitro 
iTregs for cellular therapy presents a very attractive and promising approach. 
1.2.7   Molecular Mechanism Regulating Foxp3 Expression and Tregs Differentiation. 
The Foxp3 gene consists of 11 coding and 3 noncoding exons (-1, -2a and -2b) (Figure. 1). Its 
highly conserved promoter is located at 6221 bp upstream of the translation start site.  The 
promoter region contains functional binding sites for nuclear factor of activated T cells 
(NFAT) and activator protein 1 (AP-1). These transcription factors positively regulate Foxp3 
transcription following T cell receptor activation (121). The Foxp3 promoter region also 
contains eight tightly positioned CpG dinucleotides  of which three positions, -43, -65 and -
77, are totally conserved between species (Figure.2) (122). These conserved CpG 
dinucleotides are located between transcription factor binding sites and the Foxp3 
transcription start site. The -2b and -1exons are separated by 5000 bp and possess several 
regulatory cis-elements. These regulatory regions of Foxp3 contain three conserved 
noncoding DNA sequence elements (CNS1-3), also known as enhancers (17, 121). 
Differentiation to iTregs requires induction and maintenance of Foxp3 transcription. These 
two separate processes are controlled by the Foxp3 promoter and the conserved noncoding 
DNA sequence elements (CNS1-3) at the Foxp3 locus (Figure. 3) (121, 123, 124). Mice 
studies identified a particular role for each of three non-coding DNA sequence (CNS1-3) 
elements within the Foxp3 gene (125). Each conserved cis-regulatory element binds to 
specific transcription factors and promotes a specific outcome. CNS1 regulates peripheral 
induction of Foxp3 expression, CNS2 regulates the maintenance of Foxp3 expression and 
CNS3 promotes thymic and peripheral induction of Foxp3 (121, 125).  
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Induction of Foxp3 transcription is regulated by cis-regulatory elements in the Foxp3 locus 
and multiple transcription factors. These factors are activated by various cytokines and 
signaling pathways (86). In vitro studies revealed important inducers of Foxp3 expression in 
peripheral T cells. These include IL-2/IL-2R, T cells receptor (TCR), TGF-β/SMAD, co-
stimulatory signaling pathways and retinoic acid (118, 126).  These inducers activate multiple 
transcription factors that bind the Foxp3 promoter and enhancer to induce Foxp3 expression. 
The IL-2/IL-2R signaling pathway is an important signaling pathway. It facilitates the 
induction of Foxp3 protein and is required for the expansion and survival of Tregs (54, 127). 
The downstream signaling from IL-2 activates STAT5 protein which then forms a dimer. 
STAT5 dimer translocates to the nucleus and binds to the Foxp3 promoter. This will promote 
Foxp3 expression and Treg differentiation. Foxp3+ Tregs are reduced in number in the 
absence of STAT5 (128). In addition, the frequency of Foxp3+  T cells was reduced in a 
murine model deficient in IL-2 and IL-2R (129). 
Another important and well-studied signaling pathway is the TGF-β/SMAD pathway.  In the 
SMAD3 
-/-  
murine model, lack of SMAD3 interferes with the integrity of the TGF-β 
signaling pathway and this enhanced the pro-inflammatory response from contact 
hypersensitivity (130). Furthermore, SMAD3 was found to bind a conserved enhancer site in 
the Foxp3 gene indicating that SMAD3 directly induced Foxp3 transcription (131). However, 
TGF-β can also induce Foxp3 transcription through SMAD-independent pathways (MAPK/ 
ERK/ JNK) (96). Thus, TGF-β facilitates the induction of Foxp3 expression through direct 
and indirect mechanisms, involving SMAD3/2 and NFAT binding to Foxp3-CNS region 
(131). 
A further critical signaling pathway which interferes with in vitro and in vivo induction of 
Foxp3 expression is the PI3K-Akt-mTOR pathway, which  regulates Foxo proteins (132). 
These proteins induce Foxp3 expression by binding to the Foxp3 promoter. Activation or 
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signaling from this pathway inactivates Foxo proteins by phosphorylation, thereby inhibiting 
their binding to the Foxp3 promoter which reduces Foxp3 expression (133, 134). 
Accordingly, inhibiting this pathway would be a useful tool to enhance Foxp3 expression. 
Rapamycin, an mTOR inhibitor,  was found to enhance the induction of Foxp3+ Tregs in 
vitro and in vivo (135) . 
Signaling through the TCR has significant impact on Foxp3 induction and Treg 
differentiation. Studies have shown that suboptimal TCR stimulation facilitates Foxp3 
expression, while strong stimulation inhibits Foxp3 expression (39, 136). Studies also 
revealed that it is the affinity of the TCR ligand that controls peripheral induction and, 
maintenance of Foxp3 expression in vivo.  It was demonstrated that low doses of strong 
agonist ligands generate stable and efficient Foxp3+ Tregs while high doses of poorly 
agonistic ligands induce transient Foxp3+ Tregs (137). TCR activation induced the binding of 
several transcription factors such as AP-1, NFAT and ATF to the Foxp3 promoter which can 
positively regulate Foxp3 transcription (131, 138). 
A strong agonist TCR-ligand is required for conversion of naive T cells into Tregs even 
though it must be delivered under sub-immunogenic conditions,  particularly avoiding 
activation of the PI3K/ Akt/ mTOR pathway (137, 139). The nature of the dendritic cell – T 
cell interaction also has an important role as  strong  and prolonged TCR-peptide-MHC 
interaction can specifically trigger survival signals, effector proliferation and result in 
induction of effector function (140). This interaction depends on the maturation state of  
antigen-presenting cells (APCs) and the potency of the TCR ligand (141). Therefore, a strong 
agonist ligand may provide sub-immunogenic stimulation for efficient and stable Foxp3 
induction in the absence of profound cell division in vivo. Quantitative and qualitative 
differences in the strength of TCR–peptide MHC interactions critically influence signaling 
events far downstream of TCR recognition and thereby the type of cell fate decision 
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instructed in peripheral T cells (142). Immunogenic high doses of antigens can cause T cell 
proliferation and activation of the PI3K/ Akt/ mTOR pathway (132), and interfere with 
peripheral Foxp3 induction (39). 
The outcome of gene transcription is also determined by changes in expression and activity of 
transcription factors themselves. Transcription factors can act as positive or negative 
regulator of Foxp3 expression. This depends on the timing of their recruitment and the 
presence of other transcription modulators. SMAD3 and NFAT bind Foxp3 enhancer (CNS1) 
and activate Foxp3 transcription. These transcription factors are activated through stimulation 
of the TGF-β and TCR signaling pathways (131). Signaling through NF-кB is another key 
regulator of Foxp3 expression as c-Rel binds to the Foxp3 enhancer (CNS3). This binding 
regulates Foxp3 expression and is vital for the development of Foxp3+ Tregs (143). On the 
other hand, IL-6 stimulation activates STAT 3 which binds CNS2 region and inhibits Foxp3 
transcription. 
Maintaining Foxp3 expression is mainly regulated by epigenetic modifications of the cis 
regulatory elements within the Foxp3 gene. These heritable changes regulate the 
transcriptional activity of many genes including Foxp3 gene. Methylation of CpG residues by 
DNA methyltransferses (DNMTs) represents one important epigenetic mechanism. 
Methylated CpG recruits transcriptional repressors which introduce positive charges in 
histones, leading to the formation of a compact nucleosome. This close chromatin structure 
prevents recruitment of transcription factors and prevents gene transcription (17). Histone 
acetylation is another epigenetic regulatory mechanism that plays a role in the regulation of 
Foxp3 function and tends to be affected more during short term induction than CpG 
methylation(17, 144). 
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The second conserved non-coding sequence element (CNS-2), also called the Treg-specific 
demethylation region (TSDR), contains many CpG dinucleotides (125, 138, 145) . These 
CpG motifs are targets for DNA methylation. (41). The methylation status of this region 
could differentiate conventional T cells from tTregs. Thymic and in vivo induced Tregs are 
completely demethylated, while conventional T cells are methylated and TGF-β induced 
Tregs are partially methylated (41, 121). Similarly, the methylation status of CpG motifs in 
the Foxp3 gene promoter determines the transcriptional activity of the Foxp3 gene (121, 122, 
138). tTregs exhibited a completely demethylated promoter region while induced CD4+ 
CD25
hi
 cells as well unstimulated and restimulated CD4+ CD25
lo
 cells exhibited a partially 
methylated promoter region (122). Only complete demethylation of the conserved Foxp3 
promoter region was found to promote stable long term Foxp3 expression in humans (122).   
Therefore, the Foxp3 methylation assay is believed to be the most specific method for 
detecting genuine Tregs (72, 146). This demethylation seems to be required for the binding of 
specific transcription factors that maintain stable Foxp3 expression. Stable Foxp3 expression 
is  necessary for maintaining  suppressive function and  identity of Tregs (70). Demethylation 
of the Foxp3 promoter or the TSDR correlated with a stable Tregs phenotype (122, 145). 
Therefore, it was claimed that the stability of a Treg cell line is controlled by the methylation 
status of its Foxp3 promoter and the use of Foxp3 methylation assay provides a reliable 
method for measuring stability of Foxp3 expression (41, 44, 122). Furthermore, Foxp3 
demethylation is currently used for quantifying Tregs in peripheral blood and other tissues 
(147-149). 
DNA methylation analysis of the Foxp3 gene is based on bisulfite treatment of purified DNA. 
This bisulfite converted DNA is amplified by methylation specific-PCR and sequenced. The 
unmethylated signal is then calculated from the total signal and expressed as a percentage. 
Many studies measured the methylation status of all individual CpG motifs in different 
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conserved region (41, 72, 150, 151). However, CpG position -77 in the Foxp3 promoter 
region was demonstrated to be the best discriminating CpG position, that clearly 
distinguished genuine human Tregs from activated or transiently Foxp3 expressing CD4+ T 
cells (122, 152).  Therefore, DNA methylation analysis of this specific position was utilised 
to evaluate stability of different in vitro induced Tregs generated from in this thesis. 
1.3 Aims and objectives. 
 
The overall goal of the project is to advance the knowledge needed to improve the therapeutic 
potential of Tregs. This will be approached through the following specific aims: 
1- To determine the methylation status of the Foxp3 gene in Tregs induced by 
different methods. 
Several protocols have been developed to generate Foxp3+ Tregs in vitro, these protocols 
successfully induced Foxp3 expression and suppressive function in murine, and human 
conventional T cells (31, 153). The suppressive activity of Foxp3+ induced Tregs was 
also demonstrated in vitro and in vivo (153). However, the stability of suppressive 
function in these iTregs has not been investigated in most previous studies (17). This 
criterion is essential for successful clinical application of Treg based cellular therapy. The 
methylation status of the Foxp3 gene is the best available measure for determining 
functional stability of Tregs (44, 123, 147, 149, 154). Thymic and in vivo induced Tregs 
exhibit complete demethylation of the Foxp3 promoter, while conventional T cells are 
methylated and TGF-β induced Tregs are partially methylated (41, 121, 122).  Therefore, 
determining the methylation status of different types of iTregs will determine if these 
Tregs differ from TGF-β induced Tregs and will provide critical information about the 
efficiency of these protocols.  
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2- To develop new methods or protocols for generating regulatory T cells in vitro. 
Several biological and pharmacological agents have been used to induce Foxp3 expression 
and generate Tregs in vitro, but the interaction between these agents and the molecular 
mechanisms regulating Foxp3 expression are still not fully understood (17, 121, 124). 
Therefore, combining different agents, in addition to investigating new agents may introduce 
novel methods for generating stable Treg population in vitro and improve current protocols. 
3- To identify the best in vitro protocol for generating Foxp3+ Tregs with high 
therapeutic potential. 
There have been several clinical trials of adoptive Treg transfer therapy in humans. These 
clinical trials were based on expanding peripheral blood derived natural or thymic Tregs. 
Although proved to be safe, the difficulty in obtaining adequate number and pure populations 
of thymic Tregs presents a major challenge (105, 106, 155). On the other hand, obtaining 
Tregs from the more abundant naïve CD4+ T cells offer an attractive alternative, particularly 
with the presence of strong supporting evidence from experimental data (31, 153).  Although 
many different types of suppressive iTregs were produced in vitro, there were no comparison 
data between them which makes it difficult to choose a protocol for future clinical application 
of Treg based cellular therapy. The two main criteria for comparing in vitro protocols are 
functional stability and cell frequency/number of Foxp3+ iTregs. These two criteria were 
used in this study to compare all protocols and identify the most promising protocol for 
generating in vitro induced therapeutic Foxp3+ Tregs. 
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Figure 1.  Structure of the Foxp3 gene. The figure was obtained from Lal 2009 (17).   
 
Figure 2. The conserved Foxp3 promoter elements. The figure was obtained from Janson 
2009 (122).  
 
 
Figure 3. Structure of the Foxp3 locus. The figure was obtained from Toker 2011 (123). 
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2.1 Reagents. 
Dulbecco’s Phosphate Buffered Saline (D.PBS): 
D.PBS was purchased from Lonza (Lonza, Walkersville, MD, USA) as 500ml sterile filtered 
solution without calcium or magnesium. PBS was kept sterile and stored at room 
temperature.  
Ficoll-Hypaque: 
Ficoll Paque density gradient medium (VWR, QLD, Australia) was stored in 50 ml sterile 
Falcon tubes (BD Biosciences, Franklin Lakes, NJ, USA) and kept sterile and protected from 
light at room temperature. 
Tissue Culture Medium (TCM): 
This was consisted of X-Vivo 15 and AB serum. Sterile X-Vivo 15 medium was 
supplemented with sterile 1 ml of 200mM L-glutamine, 1ml of 1 M Hepes and 100µl of 2 
mercaptoethanol ( 17.5µl of concentrated solution diluted in 5mls of X-Vivo 15, before 
sterilising by filtration). Then, 2 ml of sterile AB serum (Lonza, Walkersville, MD, USA) 
was added to 98mls of the supplemented medium. TCM was stored in 50 ml sterile Falcon 
tubes at 4°C. 
Crystal Violet: 
0.1% of crystal violet powder (Sigma Aldrich, St Louis, MO, USA) was dissolved in 3% 
acetic acid (Merck, Darmstadt, Germany). This was used to count nucleated cells for cell 
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culture. The acetic acid was included to lyse erythrocytes. The solution was stored at room 
temperature. 
Flow Cytometry staining buffer: 
Flow Cytometry staining buffer consisted of sterile PBS supplemented with sodium azide 
(Merck, Darmstadt, Germany) at a final concentration of 0.05%. 
FACS Fix: 
FACS fix was prepared from PBS and 1% paraformaldehyde (Merck, Darmstadt, Germany). 
This solution is used for fixing cell surface stained blood cells. 
Stem Cell medium: 
Stem cell medium consists of D.PBS supplemented with 2% of foetal bovine serum (FBS) 
(Invitrogen, Mulgrave, Vic, Australia) and 1mM of EDTA (Life Technologies Mulgrave, 
Vic, Australia). 
Milteny Biotec Buffer: 
Milteny Biotec buffer consists of D.PBS supplemented with 0.5 % of bovine serum albumin 
(BSA ) (Thermo Fisher Scientific, Massachusetts, USA ) and 2mM of EDTA. 
A list of specific reagents used to generate Foxp3+ regulatory T cells in all protocols are 
listed in Table 2.1.  
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Table 2.1: List of reagents used for generation of Foxp3+ regulatory T cells in all 
protocols. 
Reagent Preparation 
Interleukin-4 
 
Interleukin-4 (IL-4) was purchased from R&D Systems Inc. 
(Minneapolis, MN) and was stored at -80 °C, in aliquots at a 
concentration of 10µg/ml. Further dilutions were made with tissue 
culture medium (TCM) to make a final concentration of 15  ng/ml. 
Human recombinant 
granulocyte 
macrophage colony-
stimulating factor 
Granulocyte macrophage colony-stimulating factor (GM-CSF) was 
purchased from eBiosciences (San Diego, CA) and was stored at -
80° C, in aliquots at a concentration of 10 µg/ml. Further dilutions 
were made with TCM to make a final concentration of 70 ng/ml. 
Lipopolysaccharide Lipopolysaccharide from E.coli 0127:B8 (LPS) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and stored at -80°C, in 
aliquots at a concentration of 1 mg/ml. Further dilutions were made 
with TCM to make a final concentration of 1 µg/ml. 
Myelin 
oligodendrocyte 
glycoprotein 
Myelin oligodendrocyte glycoprotein (MOG) was purchased from 
Abcam (Cambridge, MA,USA ) and  stored at -80° C, in  aliquots at 
a concentration of  30 µg/ml. Further dilutions were made with TCM 
to make a final concentration of 3 µg /ml. 
Interleukin -2 Interleukin-2 (IL-2) was a gift from Roche (Basel, Switzerland).  
 
This was stored at -80°C, in aliquots of 20,000 U/ml in TCM.  
 
Further dilutions were made with TCM to produce a final  
 
concentration of 50, 100 or 300 U/ml depending on the protocol  
 
used. 
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1α, 25-
dihydroxyvitamin 
D3 
1α, 25-dihydroxyvitamin D3 (VitD) was purchased from Sigma-
Aldrich (St. Louis, MO, USA) and  stored in  aliquots at a 
concentration of 1 mM at -20°C . Further dilutions were made with 
TCM to make a final concentration of 1, 2 or 20 nM depending on 
the protocol used. 
CD3/CD28 beads 
(Dynabeads) 
An antiCD3/CD28 Dynabead suspension was purchased from Life 
Technologies (Carlsbad, CA). This was stored at 4°C and washed 
three times with TCM in a magnet column before use. After 
reconstitution in TCM, a final ratio of 1:1, 1:10, 5:1 or 10:1 (beads 
to cells) was used depending on the relevant protocol. 
Tumor necrosis 
factor-alpha 
Tumor necrosis factor alpha (TNFα) was purchased from e 
Biosciences (San Diego, CA) and stored in aliquots at a 
concentration of 10 µg/ml at -80°C. Further dilutions were made 
with TCM to make a final concentration of 100 ng/ml. 
Interleukin 1 -beta Interleukin 1 beta (IL-1β) was purchased from e Biosciences (San  
 
Diego, CA) and stored in aliquots at a concentration of 10 µg/ml  
 
at -80°C. Further dilutions were made with TCM to make a final  
 
concentration of 10 ng/ml. 
 
Prostaglandin E2 Prostaglandin E2 (PGE2) was purchased from Sapphire Biosciences 
(Waterloo, NSW, Australia) and stored in aliquots at a concentration 
of 10 mM at -20°C. Further dilutions were made with TCM to make 
a final concentration of 1 µM. 
Interferon-βeta Interferon-βeta (IFN-β) was a gift from Biogen Idec (Boston, MA, 
USA). This was stored in aliquots at a concentration of 4000 IU/ml 
at -80°C in TCM. Further dilutions were made with TCM to make a 
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final concentration of 2000 IU/ml. 
Interferon-gamma Interferon-gamma (IFN-γ) was purchased from eBiosciences (San 
Diego, CA) and stored in aliquots at a concentration of 10 µg/ml at -
80°C. Further dilutions were made with TCM to make a final 
concentration of 800 ng/ml. 
Transforming 
Growth Factor-Beta 
Transforming Growth Factor-Beta (TGF-β) was purchased from 
eBioscience (San Diego, CA) and stored in aliquots at a 
concentration of 10 µg/ml in at -80°C. Further dilutions were made 
with TCM to make a final concentration of 5 or 20 ng/ml depending 
on the protocol used. 
All-trans retinoic 
acid 
All-trans retinoic acid (tRA) was purchased from Sigma-Aldrich     
 
(St. Louis, MO, USA). This was dissolve in chloroform and  
 
stored at -20°C in aliquots at a concentration of 166 mM. Further  
 
dilutions were made with tissue culture medium (TCM) to  
 
produce a final concentration of 100 nM. 
Rapamycin Rapamycin (Rapa) was purchased from Sigma-Aldrich (St. Louis,  
 
MO, USA) and stored in aliquots at a concentration of 2.5 mg/ml  
 
at -20°C. Further dilutions were made with TCM to a produce a  
 
final concentration of 100 nM. 
5-Aza 2’ 
deoxycytidine 
5-Aza 2’ deoxycytidine (5Aza) was purchased from Sigma- 
 
Aldrich (St. Louis, MO, USA).This was reconstituted with an  
 
acetic acid and water solution (1:1). It was stored at 4°C in 100 µl  
 
aliquots at a concentration of 219 mM. Further dilutions were  
 
made with TCM to produce a final concentration of 5 µM. 
Azathioprine Azathioprine (AZA) was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). This was stored in aliquots at a concentration of 100 µM 
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at -20°C. Further dilutions were made with TCM to a final 
concentration of 1 µM. 
 
2.2   Human peripheral blood samples. 
Ethics: 
The human blood collection protocol used was approved by Sydney West Area Health 
Service Human Research Ethics Committee; under approval number HREC/2002 9/3.6 
(1425). 
Samples collection: 
Whole blood was collected in EDTA Vacutainer tubes (BD Biosciences, Franklin Lakes, NJ, 
USA) by trained phlebotomists at Westmead Hospital ICPMR blood collection room. 
Samples were obtained between 8 a.m. and 2 p.m. Blood collection record was filled 
regularly by all phlebotomists and maintained for future reference.  
Healthy control samples: 
Peripheral blood was collected in EDTA Vacutainer tubes (BD Biosciences, Franklin Lakes, 
NJ, USA) from healthy individuals after obtaining informed consent (as per HREC/2002/3.6 
(1425)) and according to the National Health and Medical Research Council guidelines. The 
gender and age of each healthy control were recorded and stored in Excel sheet. 
2.3 Methods. 
2.3.1 Cell separation. 
a- Peripheral blood mononuclear cells (PBMCs) separation: 
Blood obtained from a healthy control was processed immediately under sterile conditions in 
a Class II Biological Safety Cabinet. Whole blood from two EDTA Vacutainer tubes was 
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carefully layered on to 15 ml of Ficoll-Hypaque in a sterile 50 ml Falcon tube. The sample 
was centrifuged at 400xg and 15°C for 30 minutes in a Sigma centrifuge, with acceleration 
and deceleration adjusted to 2. Then the plasma layer was removed and the white cell layer 
was washed twice with sterile PBS in a volume of 45 ml at 300xg and 15°C for 10 minutes 
with acceleration and deceleration adjusted to 9. The final pellet was then resuspended in 2ml 
of appropriate buffer depending on the cells to be separated next and which kit will be used. 
The concentration of PBMCs was determined using a haemocytometer. A 20 µl aliquot of the 
suspension was mixed with 180 µl of crystal violet solution and the cells were counted 
manually under the microscope. The final concentration was adjusted according to the 
recommendation of cell separation kit used. 
b- Human monocyte isolation: 
This was performed using EasySep Human CD14 Positive Selection kit (STEMCELL 
Technologies, VIC, Australia) following the manufacturer’s instructions. Mononuclear cell 
suspension was prepared at a concentration of 1 x 10
8
 cells/mL in StemCell medium. The 
cells were placed in a 5 mL (12 x 75 mm) Falcon Polystyrene Round-Bottom Tubes.  
EasySep® Positive Selection Cocktail was added at 100 µL/mL of cells mixed well and 
incubated at room temperature (15 - 25°C) for 15 minutes. Then EasySep® Magnetic 
Nanoparticles were added at 50 µL/mL of cells mixed well and incubated at room 
temperature (15 - 25°C) for 10 minutes. Then the cell suspension was brought up to a total 
volume of 2.5 mL by adding Stem Cell medium. The tube (without cap) was placed into the 
magnet and left aside for 5 minutes. The magnet and tube were inverted in one continuous 
motion pouring off the supernatant fraction. The previous step was repeated for a total of 3 x 
5-minute separations in the magnet. The tube was then removed from the magnet and cells 
were resuspended in an appropriate amount of desired medium. The CD14 positively selected 
cells were then ready for use. The purity of CD14+ cells was >95%. 
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c- Human naïve CD4+ T cells isolation: 
Human naïve CD4+ T cells were separated from PBMCs using EasySep Human Naive CD4+ 
T cell enrichment kit (Negative selection-STEMCELL Technologies, VIC, Australia) 
following the manufacturer’s protocol. A mononuclear cell suspension was prepared at a 
concentration of 5 x 10
7
 cells/mL in Stem Cell medium and placed in a 5 mL (12 x 75 mm) 
polystyrene tube. EasySep™ Biotinylated Anti-CD45RO Antibody was added at 50 µL/mL 
of cells mixed well and incubated at room temperature (15 - 25°C) for 15 minutes. This was 
followed by the addition of the EasySep™ Human Naïve CD4+ T Cell Enrichment Cocktail 
at 50 µL/mL of cells mixed well and incubated at room temperature (15 - 25°C) for 10 
minutes. The EasySep™ Magnetic Nanoparticles was then added at 100 µL/mL of cells 
mixed well and incubated at room temperature (15 - 25°C) for 10 minutes. Next the cell 
suspension was brought up to a total volume of 2.5 mL by adding Stem Cell medium.  The 
tube was placed (without cap) into the magnet and left aside for 10 minutes. The magnet and 
tube were inverted in one continuous motion pouring off the desired fraction into a new 5 mL 
polystyrene tube. The new tube containing the desired cells was placed into the magnet and 
left aside for 10 minutes. A total of 2 separations in the magnet (2 x 10 minutes) then the 
negatively selected, enriched cells in the new tube were ready for use. The enrichment 
cocktail contains a combination of monoclonal antibodies directed against cell surface 
antigens (CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, TCRγ/δ, 
glycophorin A). The purity of CD4+ CD45RA+ T cells was ≥ 95%. 
d- Human memory CD4+ T cells isolation: 
Human memory CD4+ 
 
T cells were separated from PBMCs using EasySep Human Memory 
CD4+ T cell enrichment kit (negative selection-STEMCELL Technologies, VIC, Australia) 
following the manufacturer’s instructions. A mononuclear cell suspension was prepared at a 
concentration of 5 x 10
7
 cells/mL in Stem Cell medium and placed in a 5 mL (12 x 75 mm) 
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polystyrene tube. The EasySep™ Human Memory CD4+ T Cell Enrichment Cocktail (CD8, 
CD14, CD16, CD19, CD20, CD36, CD45RA, CD56, CD123, TCRγ/δ, glycophorin A) was 
added at 50 µL/mL of cells mixed well and incubated at room temperature (15 - 25°C) for 10 
minutes. Next the EasySep™ D Magnetic Particles was added at 50 µL/mL of cells mixed 
well and incubated at room temperature (15 - 25°C) for 5 minutes. The cell suspension was 
brought up to a total volume of 2.5 mL by adding Stem Cell medium. The tube (without cap) 
was placed into the magnet and left aside for 2.5 minutes. The magnet and tube were inverted 
in one continuous motion pouring off the desired fraction into a new 5 mL polystyrene tube. 
Then the negatively selected, enriched cells in the new tube were then ready for use. The 
purity of CD4+ CD45RO+ T cells was ≥ 95%. 
e- Human CD4+CD25+ regulatory T cells isolation: 
Human CD4+D25+ regulatory T cells were separated from PBMCs using Miltenyi Biotec 
human CD4+CD25+CD127
dim/–
 Regulatory T Cell Isolation Kit II (Miltenyi Biotec, Bergisch 
Gladbach, Germany). This was a two-step procedure. First, the non-CD4+ and CD127 high 
were indirectly magnetically labeled with CD4+CD25+CD127
dim/–
 T Cell Biotin-Antibody 
Cocktail II and Anti-Biotin MicroBeads. The labeled cells were subsequently depleted by 
separation over a MACS®LD Column. In the second step, the CD4+CD25+ CD127 
dim/-
 
regulatory T cells were directly labeled with CD25 MicroBeads II and isolated by positive 
selection from the pre-enriched CD4+ T cell fraction over a MACS®MS Column. The 
volume of each reagent used was based on the total cell number. The following volumes were 
based on a total cell of 10
7
. The CD4+CD25+CD127
dim/–
 T Cell Biotin-Antibody Cocktail II 
contains a combination of monoclonal antibodies directed against cell surface antigens (CD8, 
CD19, CD123, CD127). 
The number of PBMCs/mL was determined first, then the cell suspension was centrifuge at 
300×g for 10 minutes, supernatant was discarded and the cell pellet resuspended in 90 µL of 
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buffer. 10 µL of CD4+CD25+CD127
dim/–
 T Cell Biotin-Antibody Cocktail II was added to 
the tube, mixed well and incubated for 5 minutes in the refrigerator (2−8 °C). Then 30 µL of 
buffer and 20 µL of Anti-Biotin MicroBeads were added to the tube, mixed well and 
incubated for an additional 10 minutes in the refrigerator (2−8 °C). The final volume was 
then adjusted to a minimum of 500 µL of buffer.An  LD Column was placed in the magnetic 
field of a suitable MACS Separator and rinsed with 2 mL of buffer. The cell suspension was 
then applied onto the column.  The unlabeled cells (pre-enriched CD4+ cell fraction) were 
collected and the column was washed with 2×1 mL of buffer. The cell suspension was 
centrifuged at 300×g for 10 minutes and supernatant was discarded. The cell pellet was 
resuspended in 90 µL of buffer and 10 µL of CD25 MicroBeads was added to the tube, mixed 
well and incubated for 15 minutes in the dark in the refrigerator (2−8 °C). The cells were 
washed by adding 1−2 mL of buffer and were centrifuged at 300 × g for 10 minutes with the 
supernatant aspirated completely. The cells were resuspended to a density of up to 10⁸ cells 
in 500 µL of buffer. An MS Column was placed in the magnetic field of a suitable MACS 
Separator and rinsed with 500 µL of buffer. The cell suspension was then applied to the 
column and the flow-through containing unlabeled cells was collected. The column was 
washed with 3×500 µL of buffer and the flow-through containing unlabeled cells was 
collected. The column was removed from the separator and placed it on a suitable collection 
tube. 1 mL of buffer was pipetted onto the column and immediately flushed out the 
magnetically labeled cells by firmly pushing the plunger into the column. The eluted fraction 
contained CD4+CD25+CD127
dim/- 
regulatory T cells for further use. The purity of 
CD4+CD25+CD127
 dim/-
 T cells was >95%. 
2.3.2   Flow cytometric staining, acquisition and analysis: 
Antibodies: 
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PBMCs purified from control samples were stained with a collection of cell surface and 
intracellular fluorochrome-conjugated antibodies for flow cytometric analysis. All antibodies 
used were mouse anti-human antibodies and are characterised in Table 2.2. 
Table 2.2: Anti-human antibodies used for flow cytometric analysis 
Human 
ligand 
Antibody 
isotype 
Clone Fluorochrome Volume/test Source 
CD14 Ms IgG1,κ HCD14 FITC 5 Biolegend 
CD4 Ms IgG1,κ RPA-T4 PerCP 5 Biolegend 
CD25 Ms IgG1,κ BC96 eFluor 450 5 eBioscience 
CD3 Ms IgG1,κ UCHT1 FITC 20 BD 
Pharmingen 
CD127 Ms IgG1,κ eBioRDR5 PE 5 eBioscience 
Foxp3 Ms IgG1,κ 236A/E7 APC 20 eBioscience 
CD45RA Ms IgG2b, κ HI100 PE 20 BD 
Pharmingen 
CD45RO Ms IgG2a, κ UCHL1 FITC 20 BD 
Pharmingen 
 
Staining of cell surface markers: 
This was used mainly for a verification and purification check. 50 µl of cell suspension was 
removed and the recommended amount of fluorochrome labelled antibody was added. The 
mixture was then incubated in the dark and at room temperature for 10 minutes. The cells 
were fixed with FACS Fix and data were acquired with LSRII Flow cytometer (BD 
Biosciences, Franklin Lakes, NJ, USA). 
 Intra-cellular staining of Foxp3: 
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Foxp3 intra-cellular staining was performed using Foxp3 Fixation/Permeabilization kit 
(eBioscience, San Diego, USA) following the eBioscience protocol. All washing steps were 
performed at 400 x g for 5 minutes and all incubations were performed at room temperature 
in the dark. Initially, cells were harvested from culture and stained for cell surface antigens 
(CD4, CD25 and CD127) in 5 ml Falcon tube for 10 minutes. Then cells were washed with 
3ml of PBS and centrifuged. The supernatant was discarded and the pellet was vortexed to 
dissociate. The cells were then fixed with 100 µl of 4X intracellular Fixation Buffer, vortexed 
and incubated for 20 minutes. Then, the cells were washed twice with 1X Permeabilization 
buffer. After the last wash, the cells were resuspended in 100 µl of 1X Permeabilization 
buffer. Then 20 µl of APC-labelled Foxp3 antibody was added to the suspension, mixed and 
incubated for 20 minutes. The cells were washed with 1X Permeabilization buffer. The last 
wash was performed with Flow Cytometry staining buffer and the stained cells were 
resuspended in 400 µl of Flow Cytometry staining buffer. The cells were then ready for data 
acquisition on LSRII flow cytometer. 
In vitro suppression assay (CTV-based): 
Suppressive capacity of induced regulatory T cells was examined by incorporating Cell Trace 
Violet (CTV) (Life Technologies, Mulgrave, Vic, Australia). All centrifugation steps were 
performed at 500 x g and room temperature. Naive T cells were isolated by EasySep Human 
Naive CD4+ T cell enrichment kit and washed with sterile D.PBS for 5 minutes. The pellet 
was resuspended in 500 µl of sterile D.PBS in a 5 ml Falcon tube and incubated with 1µl of 
CTV (for 10
6
cells) at 37°C for 10 minutes. 1 ml of tissue culture medium (TCM) was then 
added and the mixture was incubated for another 10 minutes at room temperature. The tube 
was washed again with D.PBS for 5 minutes and the pellet was resuspended in TCM. 50µl of 
the suspension was removed, fixed with 500 µl of FACS Fix and stored as day zero tube. The 
remaining T cells were incubated with anti-CD3/anti-CD28-coated Dynabeads (Life 
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Technologies, Mulgrave, Vic, Australia) at a ratio of 1 bead: 1cell for 48 hours. Next, 5x 10
4
 
of activated CD4+ T cells (responders) were plated in the presence of unlabelled Tregs at 
various ratios of Tregs to responder cells and incubated for 3 days at 37°C in a 5% CO2 
incubator.IL-2 (50 U/ml) was added to the wells on day 0 and then every 48 hrs. On day 3, 
the cells were harvested and data were acquired on LSRII flow cytometer using Pacific Blue 
channel. The proliferation of CD4+ responder T cells was analyzed by calculating the 
division index (Di, the average number of divisions undergone by a cell in the starting 
population) using the FlowJo Proliferation Platform. The percentage of suppression was 
calculated using the following formula: 
% Suppression =	 −		
 	
  	
	 
Dix+n = Division index of responders (x) and Tregs (n) 
Dix = Division index of responders alone (x) 
Flow Cytometry acquisition and analysis: 
Data on healthy control samples were acquired on LSRII flow cytometer (BD Biosciences, 
Franklin Lakes, NJ, USA) and exported in a compensated digital FCS file format. Data were 
then imported in to FlowJo (Tree Star Inc., Ashland, OR, USA) software programme for 
analysis. The gating strategy used to define human CD4
+
CD25
+
CD127
lo
Foxp3
+ 
regulatory T 
cells is shown in Figure 2.1. For simplicity all CD4
+
CD25
+
CD127
lo 
Foxp3+ regulatory T 
cells (Tregs) will be referred to as CD4+CD25+Foxp3+ Tregs. 
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Figure 2.1: Gating strategy for defining human CD4+CD25+Foxp3+ regulatory T cells. 
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2.3.3   Gene Expression: 
a- Cell harvesting and preparation: 
 Cells in culture plates were removed from wells by vigorous pipetting and transferred in to 
sterile Eppendorf tubes. Each well was rinsed twice with 200 µl of D.PBS and combined with 
the contents of their respective wells. The tubes were then washed three times with 800µl of 
sterile D.PBS and spun at 1000 x g for 3 minutes. After the last wash, the supernatant was 
discarded and the tubes were placed on ice. Then each pellet or tube was resuspended with 
100 µl of Cell-to-Signal Buffer (Life Technologies, Mulgrave, Vic, Australia) vortexed and 
stored at -80°C freezer. 
b- Purification of RNA: 
RNA purification was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and 
conducted in the chemical fume hood. Unless otherwise stated, all spins were performed at 
8000xg for 15 seconds and the flow-through was discarded after each spin. 
Buffer RLT was prepared by adding 10 µl of 2-mercaptoethanol (Sigma Aldrich, St Louise, 
MO, USA) per 1 ml of Buffer RLT. Then 350 µl of this mixture was added to all specimens 
and vortexed. 350 µl of 70% ethanol (Sigma-Aldrich, St. Louis, USA) was added to the 
homogenised lysate and mixed well by pipetting. The samples (including any precipitate) 
were then transferred in aliquots of 700 µl to an RNeasy spin column placed in a 2 ml 
collection tube and spun briefly. 700 µl of Buffer RW1 was added to each RNeasy spin 
column and then spun again for 15 s. The columns were washed twice with 500 µl of Buffer 
RPE. The second wash required 2 minutes spin to dry the spin column membrane of ethanol. 
Next, the spin columns were placed in new 2 ml collection tubes and centrifuged at full speed 
for one minute. This step will eliminate any possible carryover of Buffer RPE. The spin 
columns were then placed in new 1.5 ml collection tubes. The purified RNA was then eluted 
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with 30 µl of RNase-free water (supplied with the kit) added directly to the spin column 
membrane and spun for 1 minute. This step was repeated again to elute a total volume of 60 
µl of purified RNA. All collection tubes were stored at -80°C until required. 
c- Preparation of complementary DNA (cDNA): 
All reaction components were placed on ice. The reaction was prepared in 8-strip PCR tubes 
and each tube received 2 µl of qScript cDNA SuperMix (5x) (Gene Target Solutions, NSW, 
Australia), 4 µl of RNA template and 4 µl of RNase/DNase-free water. The mixture was 
vortexed gently and centrifuged briefly. The 8-strip PCR tubes were then placed in a thermo 
cycler with the following incubations: 5 minutes at 25°C, 30 minutes at 42°C, 5 minutes at 
85°C and then hold at 4°C. The cDNA generated from this reaction was then diluted to 100 
µl with RNase-free water and stored at -20°C until required. 
d- Real-Time PCR for determination of gene expression: 
All samples were stored in Cell-to-Signal Buffer. RNA was then purified and reverse 
transcribed to cDNA as previously described. Real time PCR reaction MasterMixes were 
prepared for each primer pair consisting of 42 µl POWER SYBR Green TaqPoly (Life 
Technologies, Mulgrave, Vic, Australia), 7 µl forward primer, 7 µl reverse primer and 7 µl of 
RNase/DNase-free water. The volume was adjusted according to number of samples included 
in each run. GAPDH primers were used in every assay as a house keeping gene. For each 
sample a duplicate was prepared. Similarly, pre-validated control (GAPDH) and no-template 
control (water) were run in duplicate. For each well, 9 µl of Mastermix was added to 3 µl of 
cDNA template. The 48-well plate was then centrifuged briefly and placed on Eco RT-PCR 
machine (Illumina, San Diego, CA).Primers were reconstituted from powder to 100 µM with 
RNase-free water and further diluted to 10 µM with RNase-free water immediately before 
use. A List of the primers used to assess gene expression in regulatory T cells and tolerogenic 
dendritic cells are listed in Table 2.3. 
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Table 2.3: List of all primers used for assessment of regulatory T cells and tolerogenic 
dendritic cells produced by different methods. 
Primer 5’ to 3’ sequence Source 
GAPDH 
forward 
GAPDH 
reverse 
ACGCATTTGGTCGTATTGGG 
TGATTTTGGAGGGATCTCGC 
Sigma Aldrich, St Louis, Mo, 
USA 
Foxp3 forward 
Foxp3 reverse 
CAGCACATTCCCAGAGTTCCT 
GCGTGTAACCAGTGGTAGAT 
Sigma Aldrich, St Louis, Mo, 
USA 
IDO forward 
IDO Reverse 
CAAAGCAGCGTCTTTCAGTG 
CGGACTGAGGGATTTGACTC 
Sigma Aldrich, St Louis, Mo, 
USA 
 
IL-10 forward 
IL-10 Reverse 
TTACCTGAGGAGGTGATGC 
GGCCTTGCTCTTGTTTCAC 
Sigma Aldrich, St Louis, Mo, 
USA 
 
IL-12p35 
forward 
IL-12p35 
Reverse 
CCTCCTGGACCACCTCAGTTTG 
GAACTCCACCTGGTACATCTTCAAGTC 
Sigma Aldrich, St Louis, Mo, 
USA 
IL-12p40 
forward 
IL-12p40 
Reverse 
TCAAAGAGTTTGGAGATGCTGGCC 
TGATGATGTCCCTGATGAAGAAGC 
Sigma Aldrich, St Louis, Mo, 
USA 
 
The PCR cycling conditions were as follows: 96°C for 10 minutes,  5 cycles of 95°C (30 s) , 
64°C (30 s) and 72°C (30 s) , 40 cycles of 95°C (30 s) , 60°C (30 s) and 72°C (30 s), 95°C 
(15 s) , 55°C (15 s) and 95°C (15 s) . Values for levels of expression calculated relative to the 
house keeping gene (GAPDH) from CT values by the following formula: 
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2.3.4   DNA methylation analysis: 
a-  Purification of DNA: 
All samples were stored in Cell-to-Signal Buffer. DNA was then purified using QIAGEN 
DNA Mini kit (QIAGEN, Hilden, Germany). All centrifugation steps were carried out at 
room temperature and for each column a clean 2 ml collection tube was replaced after each 
spin. 20 µl of QIAGEN protease was added to 200 µl of sample placed in a 1.5 ml 
microcentrifuge tube. Sterile PBS was added to samples with less than 200 µl of volume. All 
samples received 200 µl of Buffer AL, vortexed for 15 seconds and incubated at 56°C for 10 
minutes. The tubes were briefly centrifuged and 200 µl of ethanol (96-100%) was added to 
the mixture. The mixture was vortexed and briefly centrifuged before being transferred to 
QIAamp Mini spin column (in a 2 ml collection tube). Spin columns were then spun at 6000 
x g for one minute and the collection tubes were replaced. 500 µl of Buffer AW1 was added 
and the columns were spun again at 6000 x g for one minute. The columns were then washed 
with a 500 µl of Buffer AW2 and spun at full speed (20,000 x g) for 3 minutes. After 
replacing the collection tubes the spin columns were spun at full speed for one minute to 
eliminate any possible carryover of Buffer AW2. The columns were then placed in clean 1.5 
ml microcentrifuge tubes. The DNA was eluted from the membrane by adding 200 µl of 
Buffer AE. The Buffer AE was incubated for 5 minutes at room temperature and the columns 
were then spun at 6000 x g for one minute to elute a purified DNA in a volume of 200 µl. 
Eluted DNA was either used immediately for DNA Ethanol Precipitation or stored at -20°C 
for later use. 
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b- Ethanol precipitation of DNA: 
This technique was used to concentrate the purified DNA from dilute solution and removed 
unwanted salts from DNA samples. All purified DNA samples were concentrated using DNA 
Ethanol Precipitation. All centrifugations were performed at full speed in a 4°C 
microcentrifuge. 20 µl of cold 3 M sodium acetate buffer (pH5.2) and 600 µl of cold ethanol 
(96-100%) were added to 200 µl of purified DNA sample. Then the mixture was incubated at 
-80°C for a minimum of one hour. After one hour, the DNA sample was centrifuged for 15 
minutes. Supernatant was then removed with 1 ml pipet and the sample was recentrifuged for 
another 15 minutes. The remaining supernatant was removed with 200 µl pipet. 200 µl of 
cold ethanol (70%) was added and the microcentrifuge tube was centrifuged for 5 minutes. 
The supernatant was removed with a 200 µl pipet and the remaining ethanol was evaporated 
by incubating the sample in a 60°C heat block for 15 minutes. Finally, the pellet was 
resuspended with 20 µl of RNase-free water. 
c- Sodium Bisulfite conversion of unmethylated Cytosines in DNA: (Demethylation 
assay) 
Bisulfite conversion was performed using EpiTect Bisulfite kit (QIAGEN, Hilden, Germany) 
following the manufacturer’s instructions. Unless otherwise stated, all centrifugation steps 
were performed at maximum speed for one minute and at room temperature. The flow-
through was discarded after each spin and the spin columns were placed back into the 
collection tubes. The reaction was prepared in 200 µl 8-strip PCR tubes. Each tube received 
20 µl of concentrated DNA solution, 85µl of Bisulfite Mix (dissolved in 800µl RNase-free 
water) and 35 µl of DNA Protect Buffer. The 8-strip PCR tubes were briefly vortexed, 
centrifuged and then placed in a thermal cycler with a bisulfite DNA conversion program. 
The bisulfite DNA conversion program had the following incubations: 5 minutes at 95°C, 25 
minutes at 60°C , 5 minutes at 95°C , 85 minutes at 60°C, 5 minutes at 95°C, 172 minutes at 
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60°C and then hold at 20°C. Following conversion, the PCR tubes were briefly centrifuged 
and the contents were transferred to clean 1.5 ml microcentrifuge tubes.  560 µl of freshly 
prepared Buffer BL containing 10 µg/ml carrier RNA was added to each tube, mixed by 
vortexing and then centrifuged briefly. The entire mixture was transferred from each tube to a 
corresponding EpiTect spin column. The columns were then centrifuged. 500 µl of Buffer 
BW was added and the columns were recentrifuged. 500 µl of Buffer BD was added, 
incubated for 15 minutes at room temperature and then centrifuged. The spin columns were 
washed twice with 500 µl of Buffer BW. The columns were placed into new 2 ml collection 
tubes and centrifuged. To enable evaporation of any remaining liquid, the columns with open 
lids were placed into clean 1.5 ml microcentrifuge tubes and incubated for 5 minutes at 56°C 
in a heating block. The 1.5 ml microcentrifuge tubes were replaced with new clean 1.5 ml 
microcentrifuge tubes and 20 µl of Buffer EB was dispensed to each columns. The columns 
were then centrifuged for one minute at 15,000 x g. The yield of eluted DNA was increased 
by repeating the previous step to yield a total of 40 µl of bisulfite modified DNA. 
d- PCR analysis of Foxp3 expression: 
The Foxp3 promoter region was amplified for bisulfite treated DNA by PCR using Foxp3 
primers specific for converted sequence (Table 2.4). The reaction was prepared in 200 µl 8-
strip PCR tubes. Each tube received 1 µl of Foxp3 Forward primer, 1 µl of Foxp3 Reverse 
primer, 4 µl Rnase-free water, 1 µl of MyTaq HS DNA polymerase (Bioline, London, UK) 
and 2 µl of MyTaq reaction buffer (5X). The PCR tubes were placed in a thermal cycler 
using TD62:58 program. The TD62:58 program had the following incubations: 96°C for 2.30 
minutes,  5 cycles of 95°C (30 s) , 62°C (30 s) and 72°C (30 s) , 35 cycles of 95°C (30 s) , 
58°C (30 s) and 72°C (30 s), 72°C for 5 minutes  and then hold at 4°C. 
 
58 
 
Table 2.4: Foxp3 primers used for bisulfite-specific PCR and sequence reactions: 
Primer 5’ to 3’ sequence Source 
Foxp3MF TTTATAATTAAGAAAAGGAGAAATATAGAGAG Sigma Aldrich, St 
Louis, Mo, USA 
Foxp3MR CATCTAATAAAAAAAAACAAAAACACTCAC Sigma Aldrich, St 
Louis, Mo, USA 
 
e- Agarose gel electrophoresis: 
To verify the size of the PCR product generated by the above PCR, 2% agarose gel was 
loaded with 5 µl of PCR product and 2 µl of Ficoll loading dye (Bioline, London, UK) in 
each well. A separate well was loaded with 3 µl of Hyperladder IV (Bioline, London, UK). 
Then, the gel was run at 120 V for 15 minutes. The gel was then visualised under UV light 
using Bio-Rad Gel Doc 
TM 
E2 Imager (Bio-Rad, Hercules, CA) and the size of PCR product 
was checked against standard size ladder. Image Lab software was utilised for gel viewing 
and editing. The actual size of the PCR product generated using the above Foxp3 primers is 
275bp. 
f- ExoSAP-IT: 
Once the size of PCR product was verified, the PCR products were ready for sequencing. 
However, before sequencing an enzymatic clean-up to remove excess nucleotides and 
primers was performed with ExoSAP-IT protocol.  The reaction was prepared in 200 µl 8-
strip PCR tubes. Each tube received 5 µl of DNA and 2 µl of ExoSAP-IT (In Vitro 
Technologies, VIC, Australia). The PCR tubes were then placed in a thermal cycler with the 
followings incubations:  37°C for 45 minutes, 80°C for 15 minutes and then hold at 4°C.  
g- Sequencing: 
For sequencing, 1 µl of Foxp3 Forward primer was added to each sample, mixed briefly and 
then sent to Australian Genome Research Facility (AGRF). Samples were sequenced on AB 
3730xl DNA Analyzer (Applied Biosystems, USA) and the resulting sequence was analysed 
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using Sequence Scanner analysis software (Applied Biosystems, USA). The results were 
expressed as a percent demethylation measured at the -77 CpG position (122).  
h- Calculating the percent of Foxp3 demethylation: 
The percent demethylation was calculated from the cytosine (C) and thymine (T) signals 
using this formula: (T/(C + T)) × 100. This calculation was used to present the proportion of 
Foxp3 promoter demethylation relative to all CD4+ T cells. To calculate the percentage of 
Foxp3 promoter demethylation relative to just Foxp3+ T cells, the signal derived from 
cytosine (C) was corrected by removing the contribution of Foxp3 negative T cells Then the 
new corrected value (N) was used in the above formula (T/(N + T)) × 100 to obtain the 
percent of Foxp3 demethylation. The percentage of Foxp3 negative T cells was derived from 
flow cytometry analysis data. The corrected cytosine signal was derived from the following 
calculation.  
% Foxp3
Neg
  x   C
signal 
 = P 
 C
signal 
- P = N (Corrected C value) 
% Foxp3 demethylation = (T/(N + T)) × 100 
 
Since Foxp3 is an X-linked gene, results from female donors were corrected with a factor of 
two to compensate for random X inactivation (methylation) of one of the two X-
chromosomes in female Tregs (72, 147, 154, 156). 
2.3.5   Final analysis: 
For each protocol, cells from all culture conditions were harvested and evaluated by flow 
cytometric and genetic assays. . The frequency of iTregs was expressed as the percentage of 
CD4+CD127
lo
CD25+Foxp3+ compared to all CD4+ T cells as described in the gating 
strategy (Fig 2.1). Intracellular Foxp3 protein expression was reported as median 
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fluorescence intensity (MFI). Both variables were measured by flow cytometry. The 
methylation status of the Foxp3 promoter in Tregs generated with different treatments was 
expressed as percent demethylation of the Foxp3 promoter at -77 CpG position using bisulfite 
sequencing. The percentage of Foxp3 demethylation was determined relative to all CD4+ T 
cells, and then relative to just the Foxp3+ T cell in the well using a specific calculation as 
described previously. Foxp3 mRNA expression using reverse transcriptase chain reaction was 
also evaluated in some protocols.  
2.4   Statistical analysis: 
All statistical analysis was performed using Prism5 software (GraphicPad, San Diego, 
California). For each protocol, paired student t-test was applied to compare the effect of 
different treatment conditions to that of the control (Medium). For comparing the means from 
all different protocols, Kruskal–Wallis one-way analysis of variance was used.  Then, the 
Mann-Whitney test was to identify which specific pairs are significantly different. 
Correlation analysis was also performed using Spearman correlation to determine the strength 
of the linear relationship between Foxp3 promoter demethylation and other measured 
variables (Foxp3 mRNA expression, Foxp3 protein expression and frequency of 
CD4+CD25+Foxp3+ T cells).  P-values <0.05 were considered significant (*p<0.05, **p< 
0.01, ***p<0.001). 
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Generation of human Foxp3+ iTregs using 1α, 25-dihydroxyvitamin D3 tolerogenic 
dendritic cells 
3.1   Summary: 
Background:  
1α, 25-dihydroxyvitamin D3 (VitD) tolerogenic dendritic cells are potential candidates for 
cell based therapy and offer a promising therapeutic strategy for autoimmune diseases. 
Tolerogenic dendritic cells promoting the conversion of naïve CD4+ T cells to a regulatory T 
cell population, presents an attractive approach for generating regulatory T cells in vitro. 
However, detailed evaluation is needed to assess the suitability of such approach for 
therapeutic uses.  
Aim 
To evaluate the capacity of VitD tolerogenic dendritic cells to generate therapeutic Foxp3+ 
iTregs in vitro. 
Methods: 
Human monocytes from healthy donors were used to generate dendritic cells in vitro under 
stimulation by VitD (tolerogenic DCs) or LPS (control DCs). Autologous naïve CD4+ T cells 
were co-cultured with VitD dendritic cells or LPS dendritic cells in the presence or absence 
of anti-CD3/CD28 beads for five days. The mixture was cultured in tissue culture medium 
supplemented with IL-2. The cells were then harvested and evaluated for Foxp3 protein 
expression and Foxp3 promoter methylation. To evaluate the effect of additional treatments 
on de novo Foxp3 expression, VitD and IL-1β were included. 
Results 
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VitD dendritic cells displayed tolerogenic properties and expressed higher levels of immune 
modulatory cytokines than control (LPS) dendritic cells. Stimulation of naïve CD4+ T cells 
with VitD dendritic cells, in the presence of anti-CD3/CD28 beads, significantly increased 
the frequency of Foxp3+ T cells, when compared to control (LPS) dendritic cells  (p<0.01) 
and VitD dendritic cells alone (p<0.01). These Foxp3+ iTregs also expressed high levels of 
Foxp3 protein (p<0.05). However, stimulation with VitD dendritic cells plus anti-CD3/CD28 
beads failed to enhance the proportion of Foxp3 promoter demethylation when compared 
with other conditions. In addition, Foxp3+ T cells induced by this combination exhibited the 
lowest level of Foxp3 promoter demethylation (p<0.05). The addition of IL-1β or VitD to the 
cocultures also failed to improve the production of Foxp3+ iTregs. Similar results were 
obtained with memory T cells stimulated with dendritic cells. These treated memory T cells 
only displayed a higher proportion of Foxp3 promoter demethylation when compared to 
naïve T cells. 
Conclusion 
VitD dendritic cells alone generated a low frequency of Foxp3+ T cells, which displayed 
partial demethylation of the Foxp3 promoter. The addition of anti-CD3/CD28 beads 
significantly enhanced the frequency of Foxp3+ T cells, but also reduced their Foxp3 
promoter demethylation and, accordingly, their functional stability. Therefore, the use of 
VitD tolerogenic dendritic cells requires improvement in efficiency and practicality before 
consideration as a strategy to generate therapeutic Foxp3+ Tregs. 
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3.2   Introduction: 
Dendritic cells are a heterogeneous population of professional antigen presenting cells (APC) 
that regulate immune responses to self and foreign antigens (157). These cells can initiate an 
inflammatory or tolerogenic immune response to a specific antigen, this depending on the 
origin of the antigen, the stage of maturation and the presence of other signals in the local 
microenvironment (157, 158). Dendritic cells interact directly with T cells and control their 
final immune response via signal modification (157). Dendritic cells are also involved in the 
induction and maintenance of regulatory T cells (159-161). Therefore, these cells present a 
potentially valuable tool for tolerance induction.  
The tolerogenic properties of dendritic cells are thought to be stage-dependent in vivo, 
particularly as they are displayed by immature dendritic cells, which are shown to induce T 
cell anergy and Treg differentiation (162, 163). This tolerogenicity is lost upon the induction 
of maturation by inflammatory signals. In general, studies found that the tolerogenic state of 
dendritic cells is associated with a semi-mature phenotype, an ability to efficiently present 
antigens, expression of immune-modulatory cytokines, resistance to maturation, ability to 
induce a specific T cell profile and prevention of autoimmunity in experimental models 
(163). 
For therapeutic purposes, several approaches have been evaluated for the induction of 
tolerogenic dendritic cells in vitro. Most are based on manipulating monocytes, using IL-4 
and GM-CSF for development, then combining different stimulators for maturation (163). 
The induction of a tolerogenic state has been achieved with several agents including 
rapamycin, dexamethasone, IL-10, TGF-β, vitamin A, vitamin D, growth factors and others 
(158, 164, 165). These induced tolerogenic dendritic cells differ in several aspects, including 
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cytokine production, inhibition of T cell proliferation, induction of Tregs and the expression 
of co-stimulatory and inhibitory molecules (163). 
In comparison with other tolerogenic dendritic cells, vitamin D3 dendritic cells displayed 
superior immunoregulatory functions (163). These human monocyte-derived dendritic cells 
are generated in the presence of VitD, the active form of vitamin D (166-169). VitD induced 
tolerogenicity by binding to the vitamin D receptor (VDR) expressed by dendritic cells, 
which promotes activation of vitamin D responsive genes, particularly those involved in 
tolerogenicity (170, 171). 
Studies have shown that VitD dendritic cells (DCs) displayed a stable, semi-mature 
phenotype, predominantly producing IL-10, expressing the inhibitory molecule PD-L1, 
modulating T cell activation, strongly inhibiting allogeneic T cell proliferation and inducing 
development of Tregs from naïve CD4+ T cells (167, 168, 172-174). The production of IL-
10, by itself, favours the induction of regulatory T cells (175). In addition, Tregs induced by 
VitD DCs were capable of inducing tolerance in pro-inflammatory dendritic cells that can 
promote infectious tolerance (172). Infectious tolerance is a process that involves the transfer 
of tolerogenic properties from one cell population to another (163).  Furthermore, Tregs 
themselves induce and maintain a tolerogenic state of dendritic cells in vivo. This was 
demonstrated in experimental models of asthma and type 1-diabetes, indicating the presence 
of a two-way relationship between the two cell types (176-178). Therefore, Tregs and 
tolerogenic dendritic cells seem to reinforce the functions of each other. Moreover, the ability 
of dendritic cells to synthesize endogenous VitD may further enhance its tolerogenic state 
and promote the induction of regulatory T cells (179, 180). Priming human skin dendritic 
cells with VitD was shown to promote the induction of regulatory T cells with suppressive 
activity in vitro (181). In another study, human VitD monocyte-derived dendritic cells 
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successfully converted CD4+ T cells into suppressive regulatory T cells that displayed 
antigen specificity (12). 
These data provide a strong basis for the use of VitD tolerogenic dendritic cells in the 
generation of regulatory T cells. This study aims to examine the efficacy of such a protocol in 
providing a functionally stable population of regulatory T cells suitable for therapeutic 
purposes. 
3.3    Protocol: 
3.3.1   Protocol Summary: 
This protocol was based on the generation of tolerogenic dendritic cells (tDc) with VitD 
(182). Then co-culturing VitD tolerogenic dendritic cells with CD4+ naïve or memory T cells 
to generate Foxp3+ regulatory T cells.  
3.3.2   Method: Generation of human Foxp3+ iTregs using 1α, 25-dihydroxyvitamin D3 
tolerogenic dendritic cells. 
Monocytes were treated with GM-CSF and IL-4 and, cultured in flat-bottomed 96 well plates 
in a final volume of 200 µl of tissue culture medium (TCM). Cultures were fed with fresh 
medium and cytokines every two days. VitD (1 nM) was added to some wells on day zero 
and day four of culture to produce VitD tolerogenic dendritic cells (VitD-Dc). Maturation of 
1α, 25-dihydroxyvitamin D3-treated monocytes (VitD-Dc) was induced on day four of 
culture with IL-1β (10 ng/ml), TNFα (100 ng/ml) and PGE2 (1 µM). Control dendritic cells 
(LPS-Dc) were treated with LPS (1 µg/ml).  After 48 hours of maturation induction, MOG-
antigen was loaded to all wells and the mixture was incubated for an additional 18 hours. 
Naïve T cells were co-cultured with autologous MOG-loaded LPS-Dc or VitD-Dc in the 
presence or absence of antiCD3/CD28 beads at a final ratio of one dendritic cell to one T cell 
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(1:1) in tissue culture medium supplemented with IL-2 (50 U/ml) for five days. All 
incubations were performed at 37°C and 5% CO2. On Day six, the cells were harvested for 
flow cytometric and genetic assessments. 
The populations studied were naive CD4+ T cells activated with LPS dendritic cells (LPS-
Dc), naïve CD4+ T cells activated with LPS dendritic cells and anti-CD3/CD28 beads (LPS-
Dc +), naïve CD4+ T cells activated with VitD dendritic cells ( VitD-Dc) and naïve CD4 + T 
cells activated with VitD dendritic cells and anti-CD3/CD28 beads (VitD-Dc +). 
For comparison purposes, CD4+ memory T cells were used in some experiments. The 
purified human memory CD4+CD45RO+ T cells were then cultured as naïve CD4+ T cells 
using the same protocol 
3.3.3 Experiments: 
Four experiments from four healthy adult donors were performed using the VitD protocol. 
Due to the length and complexity of these experiments, a single experiment was performed to 
evaluate whether additional combination or changes to the original protocol might increase 
Foxp3 promoter demethylation or protein production. Although not suitable for statistical 
analysis, these additional experiments provide important information and were, therefore, 
included under supplementary results. 
 
3.4   Results: 
3.4.1   Frequency and methylation status of CD4+CD25+Foxp3+ iTregs:  
CD14+ monocytes were separated from purified PBMCs and treated as described in the 
method section to generate LPS control and VitD tolerogenic dendritic cells. The optimal 
dendritic cell: T cell ratio was determined by comparing the frequency of Foxp3+ T cells and 
Foxp3 protein expression generated from different ratios (Figure 1). Results indicated that 
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one dendritic cell to one T cell ratio produced the highest frequency of Foxp3+ T cells and 
the highest level of Foxp3 protein expression.  
Results from all experiments revealed a significant increase in the mean frequency of Foxp3+ 
Tregs (30% ±3.5) in CD4+ T cells, cocultured with VitD dendritic cells in the presence of 
anti-CD3/CD28 beads (p<0.01), when compared to VitD dendritic cells alone (VitD-Dc) and 
control dendritic cells (LPS-Dc) (Figure 2-A). Similarly, Foxp3 protein expression (MFI) was 
significantly enhanced in Tregs induced by VitD dendritic cells in the presence of anti-
CD3/CD28 beads (p<0.05) (Figure 2-B). However, this combination failed to induce 
statistically significant changes in the proportion of Foxp3 promoter demethylation (Figure 2-
C). Furthermore, Foxp3+ T cells, induced by VitD dendritic cells in the presence of anti-
CD3/CD28 beads exhibited the lowest level of Foxp3 promoter demethylation (31% ±6.1), 
when compared to VitD dendritic cells alone and control dendritic cells (LPS-Dc) (p<0.05) 
(Figure 3). 
These data indicate that the presence of anti-CD3/CD28 beads enhanced the frequency of 
Foxp3 expressing T cells and the level of Foxp3 protein expression, but most of these cells 
displayed low levels of Foxp3 promoter demethylation, resulting in low overall mean level, 
of Foxp3 promoter demethylation in Foxp3 expressing T cells. 
3.4.2   Supplementary results:  
3.4.2.1   The effect of adding 1α, 25-dihydroxyvitamin D3 or IL-1β: 
IL-1β is a pro-inflammatory cytokine, but was also reported to promote immune tolerance 
(183, 184). The effect of adding IL-1β or VitD to the dendritic cell-T cell co-culture was 
examined in two independent experiments.  Naïve CD4+ T cells were co-cultured with VitD 
dendritic cells alone or with VitD dendritic cell plus anti-CD3/CD28 beads for five days. IL-
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1β (10 ng/ml) was added to the dendritic cell-T cell co-culture on day two in tissue culture 
medium supplemented with IL-2 (50 U/ml). The cells were harvested on day six and analysed 
by flow cytometry. IL-1β reduced the frequency of Foxp3 expressing T cells (from 26% to 
8%) and the level of Foxp3 protein expression (from 167 to 114) in CD4+ T cells stimulated 
with VitD dendritic cells plus anti-CD3/CD28 beads (Figure 4). The level of Foxp3 protein 
expression was also decreased in CD4+ T cells stimulated with VitD dendritic cells alone. 
In a different experiment, VitD(1 nM) was added to 1α, 25-dihydroxyvitamin D3dendritic 
cell-T cell co-culture on day 2two in tissue culture medium supplemented with IL-2 (50 
U/ml). The cells were harvested on day six and analysed by flow cytometry. The addition of 
VitD did not enhance the frequency of Foxp3 expressing T cells and slightly reduced the 
level of Foxp3 protein expression (Figure 5).  
3.4.2.2   Characteristics of 1α, 25-dihydroxyvitamin D3 dendritic cells: 
VitD dendritic cells generated from this protocol were evaluated for the expression of 
immune modulatory and inflammatory cytokines. The mRNA expression levels of IL-10, IL-
12p40, IL-12p35 and indoleamine2, 3-dioxygenase (IDO) were measured by RT-PCR.  In 
comparison to control or LPS dendritic cells, VitD dendritic cells produced higher mRNA 
expression levels of the immune modulatory cytokines IL-10 and IDO (Figure 6). In addition, 
VitD dendritic cells expressed lower mRNA levels of the inflammatory cytokine IL-12p40 
than LPS dendritic cells. There was no detectable mRNA expression of IL-12p35 in either 
type of dendritic cells. 
3.4.2.3   Memory CD4+CD45RO+ versus Naïve CD4+CD45RA+ T cells: 
The ability of memory CD4+CD45RO+ T cells to up regulate Foxp3 expression, following 
stimulation with monocyte-derived dendritic cells, was also evaluated in a single experiment 
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using the same protocol described previously. VitD dendritic cells or LPS dendritic cells were 
co-cultured with memory CD4+CD45RO+ T cells for five days, then harvested for flow 
cytometric and genetic assessment. Both types of dendritic cells stimulated less than 10% of 
memory T cells to express the Treg phenotype with higher frequency induced by VitD  
dendritic cells (Figure 7). However, the proportion of Foxp3 promoter demethylation in 
memory T cells cocultured with both types of dendritic cells was more than 10%, with a 
higher level in memory T cells co-cultured with LPS dendritic cells. In comparison to naïve 
CD4+ T cells, memory CD4+ T cells stimulated with dendritic cells displayed a higher 
proportion of Foxp3 promoter demethylation, but also showed a small increase in the 
frequency of Foxp3 expressing T cells (Figure 8). 
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Figure 1: Optimization of dendritic cell to T cell ratio in the co-culture. VitD treated 
monocyte-derived dendritic cells were cultured with different numbers of naïve T cells and 
co-cultured for five days in tissue culture medium supplemented with IL-2 (50 U/ml). The 
cells were harvested on day six and analysed by flow cytometry. The frequency of 
CD4+CD25+Foxp3+ T cells and Foxp3 median florescence intensity (MFI) induced by each 
ratio were compared.  
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Figure 2: 1α, 25-dihydroxyvitamin D3 dendritic cells, in the presence of anti-CD3/CD28 
beads, significantly enhanced Foxp3 protein expression, but not Foxp3 promoter 
demethylation in CD4+ T cells. A) The percentage of Foxp3+ T cells induced by LPS or 
VitD dendritic cells in the presence, or absence, of anti-CD3/ CD28 beads obtained by flow 
cytometric analysis. B) Foxp3 protein expression was measured by flow cytometry and 
reported as median fluorescence intensity (MFI). C) The percentage of Foxp3 promoter 
demethylation in CD4+ T cells treated for the different treatment conditions. Results from 
four experiments were expressed as mean ± SEM. p-values <0.05 were considered significant 
(*p<0.05, **p< 0.01, ***p<0.001). The plus (+) sign indicates the presence of anti-
CD3/CD28 beads. 
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Figure 3: Foxp3 demethylation levels in Foxp3+ T cells induced by different conditions. 
Foxp3+ T cells, induced by VitD dendritic cells in the presence of anti-CD3/CD28 beads, 
displayed the lowest level of Foxp3 promoter demethylation. Results from four experiments 
were expressed as mean ± SEM. p-values <0.05 were considered significant (*p<0.05, **p< 
0.01, ***p<0.001). The plus (+) sign indicates the presence of anti-CD3/CD28 beads. 
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Figure 4: IL-1β reduced the frequency of Foxp3+ T cells and the level of Foxp3 
expression in CD4+ T cells treated with 1α, 25-dihydroxyvitamin D3 dendritic cells: IL-
1β (10 ng/ml) was added to VitD dendritic cell-T cell co-culture on day two in the presence 
of IL-2,  then the cells were harvested on day six. A) The percentage of Foxp3+ T cells 
induced by VitD dendritic cells in the presence, or absence, of IL-1β obtained by flow 
cytometric analysis. B) Foxp3 protein expression was measured by flow cytometry and 
reported as median fluorescence intensity (MFI). The plus (+) sign indicates the presence of 
anti-CD3/CD28 beads. 
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Figure 5: The addition of 1α, 25-dihydroxyvitamin D3 to 1α, 25-dihydroxyvitamin D3 
dendritic cell-T cell co-culture failed to enhance the frequency of Foxp3+ T cells and the 
level of Foxp3 expression. VitD (1 nM) was added to a VitD dendritic cell -T cell coculture 
on day two in the presence of IL-2, before the cells were harvested on day six. A) The 
percentage of Foxp3+ T cells induced by VitD dendritic cells in the presence, or absence, of  
VitD obtained by flow cytometric analysis. B) Foxp3 protein expression was measured by 
flow cytometry and reported as median fluorescence intensity (MFI). 
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Figure 6: Characteristics of 1α, 25-dihydroxyvitamin D3 induced dendritic cells: 
VitD dendritic cells characterised by higher mRNA expression of IL-10 and IDO, but lower 
mRNA expression of IL-12p40 than control (LPS) dendritic cells. The mRNA expression of 
IL-10, IL-12 and IDO was measured by RT-PCR in VitD and LPS dendritic cells. 
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Figure 7:  Memory CD4+ T cells co-cultured with 1α, 25-dihydroxyvitamin D3 dendritic 
cells showed a small increase in the frequency of Foxp3+ T cells and a small decrease in 
Foxp3 promoter demethylation when compared to LPS dendritic cells. A) The 
percentage of Foxp3+ memory T cells induced by LPS or VitD dendritic cells obtained by 
flow cytometric analysis. B) The percentage of Foxp3 promoter demethylation in CD4+ 
memory T cells treated for the different treatment conditions 
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Figure 8: Memory CD4+ T cells stimulated with 1α, 25-dihydroxyvitamin D3 or LPS 
dendritic cells displayed a higher proportion of Foxp3 promoter demethylation than 
naïve CD4+ T cells. A) The percentage of Foxp3+ T cells induced by LPS or VitD dendritic 
cells from naïve and memory T cells obtained by flow cytometric analysis. B) Foxp3 protein 
expression was measured by flow cytometry and reported as median fluorescence intensity 
(MFI). C) The percentage of Foxp3 promoter demethylation in memory and naïve CD4+ T 
cells treated for the different treatment conditions. 
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3.5   Discussion and Conclusions: 
VitD is an important immune-regulatory factor that modulates functions of different immune 
cells promoting immune tolerance. This property was demonstrated through promoting 
tolerogenic features in dendritic cells and inducing regulatory activity in T cells. VitD 
tolerogenic dendritic cells themselves are potential candidates for cell based therapy and offer 
a promising therapeutic strategy for autoimmune diseases. In addition, these tolerogenic 
dendritic cells can promote the induction of a regulatory T cell population from CD4+ T 
cells, which presents another therapeutic target for tolerance therapy. In this study, using flow 
cytometric analysis, semi-quantitative RT-PCR and Foxp3 promoter methylation assay, we 
clearly demonstrate that VitD treated dendritic cells displayed tolerogenic properties and 
significantly enhanced the proportion of Foxp3+ T cells in the presence of anti-CD3/CD28 
beads. These iTregs expressed a high level of Foxp3 protein, but low demethylation of the 
Foxp3 promoter, when compared to Tregs induced by VitD treated dendritic cells alone. In 
addition these iTregs displayed only partial demethylation of the Foxp3 promoter. The 
addition of IL-1β or VitD to the co-culture, did not enhance the proportion of Foxp3+ T cells 
or their Foxp3 expression. Furthermore, replacing naïve T cells with memory T cells did not 
seem to improve the induction of Foxp3+ T cells in the co-culture. 
The VitD dendritic cells generated in this study showed an anti-inflammatory cytokine 
profile. This was characterised by high expression of immunomodulatory factors: 
indoleamine 2, 3-dioxygenase (IDO) and IL-10, and low expression of the pro-inflammatory 
cytokine IL-12p40.  The decreased IL-12 and enhanced IL-10 production are consistent 
features of mouse and human VitD treated dendritic cells, and significantly contribute to their 
tolerogenic properties (185-187). The up-regulation of IDO protein expression in VitD 
treated dendritic cells was also reported in several studies (188, 189). IDO is an enzyme that 
degrades the essential amino acid tryptophan inside the IDO-expressing cell, decreasing its 
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intracellular level. This low tryptophan level blocks T cell proliferation, facilitates the 
differentiation of naïve T cells into regulatory T cells and promotes the differentiation of 
monocytes into regulatory dendritic cells (190-192). The importance of VitD treated IDO
+ 
tolerogenic dendritic cells was demonstrated in the murine model of experimental 
autoimmune encephalitis (EAE) (188). Adoptive transfer of these IDO
+
 dendritic cells 
significantly increased the percentage of Foxp3+ T cells in mouse lymph nodes and reduced 
the number of autoreactive T cells in the central nervous system promoting immune 
tolerance. 
The ability of VitD to induce tolerogenic properties was demonstrated in monocyte-derived 
dendritic cells and myeloid dendritic cells, but not plasmacytoid dendritic cells (193). These 
VitD dendritic cells exert their immunomodulatory effect by inhibiting effector T cell 
function, but more importantly, by inducing suppressive Foxp3 positive  and Foxp3 negative 
Tregs (194). In our study, VitD dendritic cells induced Foxp3 expression in a small 
percentage of naïve CD4+ T cells (4.8±1.4) and slightly enhanced Foxp3 protein expression, 
but this was not statistically significant when compared to control (LPS) dendritic cells. 
However, the addition of anti-CD3/CD28 beads produced a dramatic effect on the frequency 
of Foxp3 expressing T cells and their Foxp3 protein expression. The lack of a significant 
number of Foxp3+ T cells induced by VitD treated dendritic cells alone may have two 
possible explanations. First, VitD dendritic cells may not be tolerogenic and may require 
additional modification to enhance their ability to induce Foxp3+ Tregs, though the results of 
the gene expression profile have shown tolerogenic features. Second, VitD dendritic cells 
induced Foxp3 negative Tregs such as Tr1 cells, rather than Foxp3 positive Tregs, which 
were not evaluated in our study. Studies found that the production of IL-10 by VitD treated 
dendritic cells derived type one regulatory T cells (Tr1) (168). Tr1 cells are a subtype of 
regulatory CD4+ T cells that are characterised by a lack of Foxp3 expression, secretion of IL-
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10 and suppression of autoimmune responses (195). VitD treatment induced up-regulation of 
programmed death ligand-1 (PDL-1) on dendritic cells, which then facilitated IL-10 
production promoting Tr1 differentiation (168, 196).  However, VitD treated dendritic cells 
also promoted the induction of Foxp3+ Tregs that displayed suppressive activity and 
promoted transplantation tolerance (197, 198).  
The induction of Foxp3+ Tregs was attributed to the selective up-regulation of the inhibitory 
receptor, immunoglobulin-like transcript 3 (IL-T3) by VitD treated dendritic cells (198-200). 
This up-regulation was demonstrated in human mature and immature monocyte-derived 
dendritic cells after treatment with VitD (198). The enhanced expression of IL-T3 on 
dendritic cells was also demonstrated in psoriatic lesions from five patients after topical 
treatment with calcipotriol (VDR agonist) (198).  However, in this study, the ability of VitD 
to induce Foxp3+ Tregs was based on measurement of Foxp3 mRNA expression in the co-
culture and not the frequency of induced Foxp3 + T cells.  The induction of Foxp3+ Tregs 
was also associated with IDO expression in dendritic cells (188). Therefore, it seems that the 
expression levels of IL-10 and IDO in VitD dendritic cells determine which type of 
regulatory T cells is predominantly induced. The discrepancy observed between studies is 
probably due to small variations in culture techniques resulting in tolerogenic dendritic cells 
with slightly different properties.  
The addition of anti-CD3/CD28 beads was introduced to promote the induction of Foxp3+ 
Tregs through activating more CD4+ T cells in the presence of VitD tolerogenic dendritic 
cells. The change was applied to VitD and LPS dendritic cells. This modification 
significantly enhanced the frequency of Foxp3+ T cells (30% ± 4) and the level of Foxp3 
protein expression in T cells stimulated with VitD dendritic cells (VitD-Dc+) when compared 
to control (LPS-Dc+). However, the high frequency of Foxp3+ T cells does not guarantee the 
presence of high quality Tregs. Therefore, we evaluated the methylation status of the Foxp3 
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promoter in these induced Foxp3+ T cells and showed reduced demethylation. The majority 
of these Foxp3+ T cells displayed low Foxp3 promoter demethylation (31% ± 6) when 
compared with T cells activated with VitD dendritic cells alone (63% ± 6).As the proportion 
of Foxp3 demethylation is an average estimate of level of demethylation in all Foxp3+ T 
cells, the low overall proportion indicates that the majority of Foxp3 expressing cells exhibit 
minimal demethylation change, which is consistent with activation-induced transient Foxp3 
expression.  
The capacity of VitD dendritic cells to convert memory CD4+ CD45RO+ T cells to Foxp3+ 
iTregs was also explored. Interestingly, there were no major differences in their ability to 
induce Foxp3 expression upon stimulation with VitD dendritic cells between naïve and 
memory T cells. However, memory T cells had a higher proportion of Foxp3 promoter 
demethylation than naïve T cells, in both LPS and VitD dendritic cell coculture. This may 
indicate the presence of memory Foxp3+ Tregs in the memory T cell population, rather than 
resulting from stimulation with dendritic cells. This is supported by the study of Wieczorek et 
al. which demonstrated that memory T cells (CD4+ CD45RA-) from human peripheral blood 
displayed a higher level of Foxp3 demethylation than naïve T cells (CD4+ CD45RA+), due 
to the presence of higher fraction of Foxp3+ Tregs (147). 
Certain changes were applied to the dendritic-T cell co-culture to enhance Foxp3 induction in 
CD4+ T cells. These preliminary experiments include the addition of IL-1β or VitD on day 
two of the co-culture. IL-1β is a pro-inflammatory cytokine with pleotropic effects and is 
particularly involved in inflammatory and autoimmune diseases (201-203), but it is also 
reported to enhance the ability of tolerogenic dendritic cells to promote Foxp3 expression 
(183). In addition, IL-1β can act directly on CD4+ T cells activated with anti-CD3 and anti-
CD28 antibodies promoting Foxp3 and TGF-β1 expression (183). Furthermore, IL-1β 
promoted tolerogenic features in rapamycin-treated dendritic cells by rendering them 
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refractory to proinflammatory, maturation-inducing stimuli (184). This refractory condition 
was induced by up regulation of IL-33 receptor, known as ST2L, in rapamycin-treated 
dendritic cells, which endogenously produced IL-1β. In our study, the addition of IL-1β 
reduced the frequency of Foxp3 expressing T cells stimulated with 1α, 25-dihydroxyvitamin 
D3treated dendritic cells and anti-CD3/CD28 beads. Foxp3 protein expression was also 
reduced in IL-1β treated cells. These findings are consistent with the pro-inflammatory effect 
of IL-1β. The inhibition of Foxp3 expression induced by IL-1β can be mediated by direct and 
indirect mechanisms. The direct mechanism is supported by  several studies, which have 
demonstrated that IL-1β can act directly on CD4+ T cells promoting the expansion of effector 
T cells and reducing the function of Foxp3+ Tregs, particularly if used at high concentrations 
(204, 205).  The indirect mechanism may be mediated by 1α, 25-dihydroxyvitamin 
D3dendritic cells. IL-1β is a recognised inducer of dendritic cell maturation and a potent 
modulator of CD40L-induced IL-12 secretion in human monocyte-derived dendritic cells and 
peripheral blood dendritic cells (206-208). Therefore, the addition of IL-1β may modify 1α, 
25-dihydroxyvitamin D3dendritic cells by enhancing their maturation and their pro 
inflammatory properties, which subsequently limit their capacity to induce Foxp3+ Tregs. 
This effect proved significant in these experiments. 
VitD is a potent modulator of the immune system. Studies have  shown that VitD can 
promote the conversion of naïve CD4+  T cells to Tregs by directly acting on activated T 
cells and indirectly through inducing tolerogenic dendritic cells (168, 194).  However, these 
two mechanisms were examined and reported separately. In our study, we assessed these two 
mechanisms simultaneously. VitD treated dendritic cells were co-cultured with naïve CD4+ 
T cells for five days, with VitD (1nM) also added to the co-culture on day two. 
Unexpectedly, this modification did not enhance the production of Foxp3+ Tregs (<5%) or 
the level of Foxp3 protein expression. These results may indicate that only a few T cells were 
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activated by VitD dendritic cells, as only activated T cells can respond to VitD by expressing 
vitamin D receptor (VDR) (209). Therefore, only a few cells were induced to express Foxp3. 
These findings also suggest that optimisation of coculture conditions may improve the 
frequency of Foxp3+ iTregs, but further studies are needed to confirm these preliminary data. 
There are several approaches for generating regulatory T cells in vitro and the use of 
tolerogenic dendritic cells (tDc) represents one approach. This approach provides the 
potential for controlling antigen specificity of the iTregs by supplying professional antigen 
presenting cells that can be loaded with a specific antigen. This was specifically demonstrated 
by VitD dendritic cells which successfully induced robust antigen-specific Tregs (185). 
However, the efficacy of any therapeutic approach or protocol is measured by its ability to 
generate Tregs that display a stable function (complete demethylation of the Foxp3 promoter) 
and that are present in adequate numbers.  
For dendritic cell protocols, most studies generally used low ratios (dendritic cell: T cell) for 
the coculture. The choice of the optimal ratio will depend on the type of dendritic cell, its 
potency and the purpose of the co-culture. For protocols using VitD induced dendritic cells, 
low ratios (1:10 or 1:20) were used to induce Tregs (168, 182).  Another study also suggested 
that partially mature dendritic cells at ratio of 1:10 supported T cell proliferation while lower 
ratios inhibited T cell proliferation (210). However, in this study we found that 1:1 ratio was 
the optimal ratio for induction of Foxp3+ Tregs. 
 The survival potential of generated Tregs was not examined specifically but generally 
activated T cells can survive up to 14 days in vitro with no significant cell death if supplied 
continuously with IL-2 (211). Induced Tregs can also survive at least for 2 weeks in vivo as 
demonstrated in  murine adoptive transfer studies (57, 212). 
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The results from this study indicate that the use of VitD dendritic cells alone, converted only 
a small proportion of CD4+ T cells into Foxp3 expressing T cells. This small percentage of 
Foxp3 expressing T cells that displayed partial demethylation of the Foxp3 promoter is not 
suitable for therapeutic use. Therefore, we tried to improve the outcome of such a protocol by 
adding anti-CD3/CD28 beads to stimulate more T cells in the presence of tolerogenic 
dendritic cells. This modification significantly enhanced the frequency of Foxp3+ T cells, but 
reduced their Foxp3 promoter demethylation, and so their functional stability. Therefore, 
keeping the balance between the quantity (% Foxp3+ T cells) and the quality (Foxp3 
promoter demethylation) of iTregs proved to be difficult to achieve using the dendritic cell 
approach. In addition, the tolerogenic dendritic cell approach for generating regulatory T cells 
is time consuming, labour intensive and yields only a small percentage of Tregs. Therefore, 
this approach is currently not useful for generating Foxp3+ regulatory T cells for therapeutic 
purposes, with more studies needed to modify this approach and improve its final outcome. 
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Generation of human Foxp3+ iTregs with 1α, 25-dihydroxyvitamin D3or interferons. 
4.1   Summary: 
Background:  
Several agents have been reported to display immunomodulatory effects in murine and 
human studies. VitD and interferon-beta (IFN-β), particularly were implicated in promoting 
the function and number of Foxp3+ regulatory T cells in autoimmune diseases. Recently, 
interferon-gamma (IFN-γ) was also proposed to promote the development of regulatory T 
cells in vitro. Therefore, evaluating and comparing the effect of each factor will enhance our 
understanding of Foxp3 regulation and facilitate development of new strategies for 
generating regulatory T cells in vitro. 
Aim:  
To generate Foxp3+ regulatory T cells from naïve or memory CD4+ T cells using different 
stimulants including VitD, IFN-β and IFN-γ .          
Methods: 
 Human naïve or memory CD4+ T cells from healthy donors were cultured with IFN-γ, IFN-
β and VitD for five to six days in the presence of IL-2 and anti CD3/CD28 beads. The cells 
were then harvested and evaluated for Foxp3 protein expression and Foxp3 promoter 
methylation. To evaluate the effect of combined treatments on de novo Foxp3 expression, 
IFN-β and VitD were added simultaneously to naïve T cell culture in an additional 
experiment. 
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Results:  
Treating human naïve CD4+ T cells with VitD significantly enhanced the proportion of 
Foxp3 promoter demethylation when compared to control (p<0.05).In addition, VitD 
treatment increased the frequency of Foxp3+ iTregs (p<0.01) and  their intra-cellular Foxp3 
protein expression (p<0.05). Similarly, treating CD4+ memory T cells with VitD enhanced 
the frequency of Foxp3+ iTregs (p<0.05) and their intra-cellular Foxp3 protein expression 
(p<0.05), but failed to enhance the proportion of Foxp3 promoter demethylation. In both 
types of VitD iTregs the Foxp3 promoter was only partially demethylated. IFN-β treatment of 
naïve and memory T cells also increased the levels of Foxp3 protein expression (p<0.05), but 
the frequency of Foxp3+ iTregs was only enhanced in naïve T cells (p<0.01). In contrast, 
treating naïve or memory T cells with IFN-γ did not promote Foxp3 expression or 
demethylation. An additive effect on Foxp3 protein expression was produced by combining 
VitD and IFN-β, but this combination did not enhance the proportion of Foxp3 promoter 
demethylation. 
Conclusion:  
VitD up-regulates Foxp3 expression efficiently in naïve and memory CD4+ T cells.  IFN-β 
also successfully converted a significant proportion of naïve CD4+ T cells into Foxp3+ T 
cells. However, these iTregs exhibited only a slight increase in demethylation level of the 
Foxp3 promoter, suggesting unstable Foxp3 expression and a transient Treg phenotype. 
Therefore, VitD and IFN-β treatments provide ineffective strategies for generating 
functionally stable Treg populations for therapeutic purpose. 
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4.2   Introduction: 
Foxp3 expression is regulated by complex molecular mechanisms that involve interaction of 
multiple factors and signaling pathways. Increasing evidence suggests that more biological 
factors are implicated in promoting Treg development and functions. Vitamin D and IFN-β 
are examples of such immune modulatory agents, but more interestingly, some well-known 
proinflammatory cytokines such as IFN-γ also promote Treg generation and Foxp3 
expression (213). These factors present potential candidates for generating therapeutic 
Foxp3+ regulatory T cells in vitro. 
The active form of vitamin D, 1α, 25-dihydroxyvitamin D3 is a well- recognised, potent 
modulator of the immune system. Low serum levels of vitamin D are reported in patients 
with autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, type 1 diabetes 
mellitus, systemic lupus erythematosus (SLE) and inflammatory bowel disease (214, 215). 
Administration of VitD to renal transplant patients induced an expansion of circulating Tregs 
(216). Vitamin D supplements also significantly reduced the risk of type-1 diabetes in treated 
infants (217). These studies highlighted the presence of a strong association between vitamin 
D and autoimmunity. VitD can exert its immunomodulation by inhibiting T cell activation, 
particularly Th1 cell proliferation and cytokine production (218-221). VitD can also promote 
the development of tolerogenic dendritic cells and the production of immunosuppressive 
cytokines such as IL-10 and TGF-β (167, 197, 222).  More importantly, VitD can regulate 
and promote Treg development and function (223, 224). Murine studies demonstrated that 
VitD enhanced the expansion and development of Foxp3+ Tregs in vivo (199, 200, 225). 
Furthermore, supplying murine models of different autoimmune diseases with VitD inhibited 
disease progression and occurrence (226-228).  Studies also showed that VitD acts directly on 
conventional T cells converting them into functional Foxp3+ Tregs (169, 224, 229).  
Stimulation of human CD4+CD25- T cells with VitD promoted the development of 
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suppressive  Foxp3+ Tregs that expressed high levels of  the inhibitory receptor CTLA-4 
(229). Similarly, treating human naive CD4+ T cells with VitD analog (TX527) produced a 
population of suppressive CD4+CD25
hi
CD127
lo
 regulatory T cells that expressed high levels 
of  IL-10 and  CTLA-4 (169). Furthermore, VitD treatment of naïve CD4+ T cells enhanced 
Foxp3 and vitamin D receptor (VDR) expression in treated T cells,  converting them into a  
Foxp3+ Treg population (224). However, the methylation status of the Foxp3 gene in these 
induced Tregs was not verified. 
IFN-β is a pleotropic cytokine classified as a type I interferon (IFNs) which also includes 
IFN-α and IFN-ω. This category of interferons is produced mainly in response to viral 
infections, but also in response to cytokines, growth factors and other microorganisms (230). 
IFN-β binds to the type I IFN receptor complex (IFNAR-1/IFNAR-2), which is present on all 
vertebrate cells. This binding results in anti-viral, anti-proliferative and immunomodulatory 
effects (230).  Studies showed that IFN-β inhibits T cell activation and proliferation by 
interfering with critical activation mechanisms, such as the expression of costimulatory 
molecules, antigen processing and cell-cell interactions (231-233). In addition, it inhibited IL-
17 production and Th 17 development (234, 235).  Type I interferon signaling was also 
required to maintain Foxp3 expression and regulatory T cell functions in a mouse model of 
colitis (236). Human IFN-β, as a therapy, was first licensed in USA for the treatment of 
multiple sclerosis (MS), an autoimmune inflammatory demyelinating disease (230, 237). This 
immunomodulatory drug then became the first line treatment for this condition, particularly 
the relapsing remitting form of MS (237). In MS patients, circulating Tregs have reduced 
suppressive function (238), which significantly improves after IFN-β therapy (232). 
Similarly, in vitro treatment of Tregs with IFN-β enhanced their suppressive activity (232). 
This finding was supported by subsequent studies that demonstrated the ability of IFN-β 
therapy to enhance Foxp3 expression, Treg frequency and suppressive function in MS 
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patients (239-242). These findings provide strong evidence for the involvement of IFN-β in 
regulation of Foxp3 expression and function.  
IFN-γ is a proinflammatory cytokine with pleotropic effects and is classified as a type II 
interferon (243). It is produced by innate and adaptive immune cells, particularly CD4+ T 
helper cell type 1 (Th1) (213). IFN-γ binds to IFN-γ receptor which consists of alpha and beta 
chains (213). The alpha chain is constitutively expressed, but the beta chain is expressed at a 
very low level thus, beta chain expression determines cell responsiveness to IFN-γ 
stimulation (213). IFN-γ signaling activates the Jak/Stat pathway and the interferon 
regulation factor (IRF) (243, 244). IFN-γ mediates an immune response against intracellular 
infection and tumour development, but also drives Th1 cell-mediated immune responses, 
causing organ specific autoimmune diseases (245). In contrast, several early reports 
suggested that IFN-γ has anti-inflammatory effects and immune regulatory functions (246-
248). These effects were demonstrated in murine models of experimental autoimmune 
encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU) (249, 250).  Tregs 
from IFN-γ deficient EAE mice showed impaired Foxp3 expression and suppressive activity 
(251). In the same study, IFN-γ treatment converted murine naïve CD4+ T cells into 
functional Foxp3+ T cells, with adoptive transfer of these iTregs suppressing EAE in 
recipient mice (251). IFN-γ treatment also induced Foxp3 expression in human naïve CD4+ T 
cells, converting them into suppressive Tregs (251). Furthermore, production of IFN-γ by 
Foxp3+ Tregs was reported in vivo in inflammatory conditions. IFN-γ production, in this 
case, promoted Treg immune suppressive function and provided protection in a murine model 
of GVHD (252). Studies also suggested that IFN-γ plays a critical role in the development of 
several autoimmune diseases including type 1 diabetes, rheumatoid arthritis and multiple 
sclerosis (213, 253-255). Defects in the IFN-γ signaling pathway were demonstrated in these 
conditions,  inhibiting the anti-proliferative and pro-apoptotic effects of IFN-γ on activated T 
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cells, as well as preventing the conversion of naïve T cells into Foxp3+ regulatory T cells 
may contribute to the pathogenesis of these disorders (246, 247, 256). 
A recent study found that stimulation of peripheral blood lymphocytes with PMA/ionomycin 
and IFN-γ induced a population of CD4+CD25+Foxp3+IFNγ+ regulatory T cells, that 
expressed both IFN-γ and IFN-γ receptors (CD119) (257). These induced Tregs were 
suppressive in vitro and produced immune suppressive cytokines including IL-10 and TGF-β. 
In another study, stimulation of human CD4+CD25- T cells with allogeneic DC, also induced 
Foxp3+IFN-γ+ T cells (258). This population effectively suppressed alloreactive T cell 
proliferation through a cell–cell contact dependent mechanism (258). These studies suggest 
that IFN-γ can have an immune modulatory role, particularly in promoting Foxp3+ regulatory 
T cell development and function. 
VitD, IFN-β and IFN-γ could all induce Tregs under certain conditions. We proposed to 
evaluate all these agents in one protocol to facilitate comparison and development of better 
protocols for generating therapeutic Foxp3+ Tregs in vitro.  
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4.3   Protocol: 
4.3.1   Protocol Summary: 
Human naïve or memory CD4+ T cells were separated from peripheral blood using magnetic 
beads and co-cultured with IFN-β, IFN-γ and VitD in the presence of IL-2 and anti 
CD3/CD28 beads for five to six days to generate Foxp3+ regulatory T cells. The cells were 
then harvested and evaluated by flow cytometry, RT-PCR and a Foxp3 methylation assay. 
4.3.2   Method: Generation of human Foxp3+ iTregs with 1α, 25-dihydroxyvitamin 
D3or interferons. 
Purified naïve T cells were cultured with  anti-human CD3/ CD28 beads (ten beads to 1 cell)  
in  TCM supplemented with IL-2 (100 U/ml).  After 48 hours, the old medium was replaced 
with fresh culture medium supplemented with IL-2 (100 U/ml), IFN-β (2000 IU/ml), IFN-γ 
(400 ng/ml) or VitD (2 nM). Fresh culture medium supplemented with the respective 
additives, was replaced again after 48 hours (day 4). The cells were cultured for five to six 
days in U-bottomed 96 well plates (BD Biosciences) in a final volume of 200 µl of TCM. 
 The populations studied were naïve CD4+ T cells activated with IL-2 (Medium), naïve 
CD4+ T cells activated with IL-2 and IFN-β (IFN-β), naïve CD4+ T cells activated with IL-2 
and VitD (VitD) and naïve CD4+ T cells activated with IL-2 and IFN-γ (IFN-γ). 
For comparison purposes, purified human memory CD4+CD45RO+ T cells were cultured 
with IFN-β, IFN-γ and VitD using the same protocol described for naïve CD4+ T cells. 
 
4.3.3   Experiments:  
A total of four experiments from four healthy adult donors was performed, using this protocol 
for naïve T cells and three experiments from three healthy donors for memory T cells. To 
compare the effect of all treatment conditions, all results were combined and analysed against 
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control (Medium). Due to the length and complexity of these experiments, a single 
experiment was performed to evaluate whether additional combinations or changes to the 
original protocol, were justified. Although, not suitable for statistical analysis, these 
additional experiments provide important information and, therefore, were included under 
supplementary results. 
4.4   Results: 
4.4.1   Frequency and methylation status of CD4+CD25+Foxp3+ iTregs: 
To determine the optimal concentration for induction of Foxp3+ T cells, naïve CD4+ T cells 
were treated with different concentrations of IFN-γ, IFN-β and VitD. Results indicate that 
treating naïve CD4+ T cells with 800 ng/ml IFN-γ, 2000 IU/ml IFN-β and 2 nM VitD 
produced the highest levels of Foxp3+ expressing T cells as determined by flow cytometric 
analysis (Figure 1). An initial experiment was performed to compare the effect of each 
treatment (IFN-γ, IFN-β and VitD ) on the level of Foxp3 expression and demethylation. In 
this experiment, the percentage of Foxp3+ T cells was markedly increased with VitD 
treatment. Similarly, Foxp3 protein expression and the frequency of   Foxp3 promoter 
demethylation were promoted with VitD treatment. IFN-β also enhanced Foxp3 expression in 
naïve T cells but to lesser extent than VitD (Figure 2). 
Results from all experiments revealed a significant increase in the frequency of Foxp3+ Tregs 
induced by IFN-β (p<0.01) and VitD (p<0.01), when compared to control (Medium) (Figure 
3A). In addition, the mean frequency of Foxp3+ T cells, generated with VitD treatment (26%  
±  4), was significantly higher (p<0.01) than that produced by IFN-β (15%  ±  2) treatment. 
Foxp3 protein expression (MFI) was also significantly enhanced in Tregs induced by IFN-β 
(p<0.05) and VitD (p<0.05) (Figure 3B). However, only VitD-treated T cells displayed 
enhanced frequency of Foxp3 promoter demethylation (p<0.05) (Figure 3C). The mean 
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percentage of Foxp3 demethylation was 20%  ±  4 for VitD treatment and 12%  ± 1 for 
control (Medium). Evaluation of the level of Foxp3 promoter demethylation in Foxp3+ T cell 
populations, generated with IFN-β or VitD treatments revealed no significant difference, 
despite the relatively high mean frequency of Foxp3 demethylation in IFN-β induced Foxp3+ 
T cells (Figure 4). Both populations displayed less than 50% demethylation of the Foxp3 
promoter. The mean percentage of Foxp3 demethylation was 47%  ±  8  in IFN-β induced 
Foxp3+ T cells and 28%  ±  1 in VitD induced Foxp3+ T cells. 
Taken together, these data suggest that treating naïve CD4+ T cells with VitD in vitro 
successfully promoted the frequency of Foxp3+ T cells, their Foxp3 expression and their 
Foxp3 demethylation, but these iTregs had only partially demethylated Foxp3 promoter 
indicating a transient Foxp3 expression. 
4.4.2   Frequency and methylation status of memory CD4+CD25+Foxp3+ iTregs: 
An initial experiment was performed to compare the effect of each treatment (IFN-γ, IFN-β 
and VitD) on the level of Foxp3 expression and demethylation in memory T cells. In this 
experiment, the percentage of Foxp3+ memory T cells was only enhanced with VitD (VitD) 
treatment (Figure 5). VitD treatment also enhanced Foxp3 mRNA expression in memory T 
cells, but did not promote the frequency of Foxp3 promoter demethylation in treated memory 
T cells (Figure 7). Treatment with IFN-β enhanced Foxp3 mRNA expression in memory T 
cells, but to lesser extent than VitD . 
Results from all experiments revealed a significant increase in the frequency of Foxp3+ 
memory T cells induced by VitD treatment (p<0.05), when compared to control (Medium) 
(Figure 6A). Foxp3 protein expression (MFI) was also significantly enhanced in memory 
Tregs induced by IFN-β (p<0.05) and VitD (p<0.05) (Figure 6B). However, VitD treatment 
failed to enhance the frequency Foxp3 promoter demethylation when compared to control 
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(Medium) (Figure 6C). Furthermore, IFN-γ treatment significantly reduced (p<0.05) the 
frequency of Foxp3 promoter demethylation, when compared with other treatment conditions 
and control (Medium). The mean percentage of Foxp3 demethylation was 13% ± 0.3 for VitD 
treatment and 14% ± 0.3 for control (Medium). Evaluation of the level of Foxp3 promoter 
demethylation in Foxp3+ memory T cell populations, generated with IFN-β or VitD 
treatments, revealed no significant difference, despite the relatively high mean frequency of 
Foxp3 demethylation in IFN-β induced Foxp3+ memory T cells (Figure 7). Both populations 
displayed less than 50% demethylation of the Foxp3 promoter. The mean percentage of 
Foxp3 demethylation was 48% ± 6  in IFN-β induced Foxp3+ memory T cells and 30% ±  2 
in VitD induced Foxp3+ memory T cells. 
Taken together, these data suggests that in vitro treatment of memory CD4+ T cells with 
VitD successfully promoted the frequency of Foxp3+ T cells and their Foxp3 expression, but 
these iTregs also had only partially demethylated Foxp3 promoter, which indicates a transient 
Foxp3 expression. 
4.4.3   Supplementary results: 
4.4.3.1   The effect of timing on Foxp3 expression: 
To study the effect of longer incubation on the stability of Foxp3 expression, naïve CD4+ T 
cells were treated with IFN-γ, IFN-β and VitD for five days as described in the protocol. 
Some wells were harvested on day six, while the remaining wells, cultured for another five 
days in the presence of IL-2 (100 U/ml). Fresh culture medium supplemented with IL-2 was 
replaced every 48 hours. Flow cytometric analysis was performed on day six and day 12 of 
culture. The results showed marked reduction in the percentage of Foxp3+ induced Tregs in 
all treatment conditions on day 12 (Figure 8).  This drop was more remarkable in VitD 
treated T cells with 88% of Foxp3+ T cells losing their Foxp3 by day 12. 
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4.4.3.2   The effect of combining IFN-β with 1α, 25 dihydroxyvitamin D3: 
The effect of combining IFN-β with VitD was evaluated in one experiment. Naïve CD4+ T 
cells were treated with IFN-β, VitD , or both, for five days as described in the protocol. IFN-β 
(2000 IU/ml) and VitD (2 nM) were added simultaneously to additional wells on day two and 
day four of culture in the presence of IL-2 (100 U/ml). All wells were harvested and analysed 
on day six of culture. Results from this experiment indicate that this combination produced an 
additive effect on the frequency of Foxp3 expressing T cells and their intracellular Foxp3 
expression (Figure 9). However, combining IFN-β with VitD did not enhance the frequency 
of Foxp3 promoter demethylation suggesting a transient Foxp3 expression in the majority of 
Foxp3+ T cells. 
4.4.3.3   Memory CD4+CD45RO+ versus Naïve CD4+CD45RA+ T cells: 
Treating naïve and memory CD4+ T cells with IFN-γ, IFN-β and VitD revealed interesting 
differences and similarities. VitD treatment enhanced the frequency of Foxp3+ T cells and 
the level of Foxp3 protein expression in both cell types (Figure 10). However, the proportion 
of Foxp3 promoter demethylation was only promoted in naïve T cells treated with VitD. On 
the other hand, IFN-β treatment enhanced the frequency of Foxp3+ T cells only in naïve 
treated T cells, but the level of Foxp3 protein expression was enhanced in both cell types. 
IFN-γ treatment had no significant effect on the frequency of Foxp3+ T cells and levels of 
Foxp3 protein expression, but reduced the proportion of Foxp3 promoter demethylation in 
both cell types. Generally, memory T cells had higher proportion of Foxp3 promoter 
demethylation than naïve treated T cells. In addition, VitD treatment of memory T cells 
produced a higher frequency of Foxp3+ T cells and levels of Foxp3 protein expression than 
naïve treated T cells. However, the levels of Foxp3 promoter demethylation in Foxp3+ T cell 
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populations induced by IFN-β, or VitD, treatments were similar in both cell types (Figure 
11). 
Taken together, these data suggest that memory and naïve T cells respond differently to 
different stimulations, but both had the capacity to upregulate Foxp3 expression after 
stimulation with VitD. 
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Figure 1:  Optimisation of IFN-β, IFN-γ and 1α, 25-dihydroxyvitamin 
D3concentrations. Naïve CD4+ T cells were treated with different concentrations of IFN-β, 
IFN-γ and VitD. These cells were then analysed by flow cytometry. The frequency of 
CD4+CD25+Foxp3+ iTregs induced by each concentration was compared. The optimal 
concentration of IFN-β was 2000 IU/ml, IFN-γ was 800 ng/ml and VitD was 2 nM. 
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Figure 2: 1α,25-dihydroxyvitamin D3 treatment enhanced the frequency of Foxp3 
expressing T cells and the proportion of Foxp3 promoter demethylation. An initial 
experiment of naïve CD4+ T cells treated with IFN-γ, IFN-β and VitD and cultured for five 
days. A)  The percentage of Foxp3+ induced Tregs generated from different treatment 
conditions measured by flow cytometry. B) The relative expression of Foxp3 mRNA 
transcripts measured by RT-PCR. C) The percentage of Foxp3 promoter demethylation in 
CD4+ T cells treated for the different treatment conditions.  
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Figure 3: 1α,25- dihydroxyvitamin D3 enhanced the frequency of Foxp3+ T cells and 
the proportion of Foxp3 promoter demethylation. A)  The percentage of Foxp3+ induced 
Tregs generated from different treatment conditions measured by flow cytometry. B) Foxp3 
protein expression measured by flow cytometry and reported as median fluorescence 
intensity (MFI). C) The percentage of Foxp3 promoter demethylation in CD4+ T cells treated 
for the different treatment conditions. Results from 4 experiments were expressed as means ± 
SEM. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 4: Foxp3 promoter demethylation levels in Foxp3+ T cells induced by IFN-β or 
1α, 25 dihydroxyvitamin D3. There was no significant difference between both treatments 
on the level of Foxp3 demethylation within the Foxp3+ T cell population. Results were 
expressed as mean ± SEM. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, 
***p<0.001). 
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Figure 5: 1α, 25-dihydroxyvitamin D3 treatment enhanced the frequency of Foxp3+ 
memory T cells and their Foxp3 expression, but the proportion of Foxp3 promoter 
demethylation remained low. A representative experiment of memory CD4+ T cells treated 
with IFN-γ, IFN-β and VitD and cultured for five to six days. A)  The percentage of Foxp3+ 
induced Tregs generated from different treatment conditions measured by flow cytometry. B) 
The relative expression of Foxp3 mRNA transcripts measured by RT-PCR. C) The 
percentage of Foxp3 promoter demethylation in memory CD4+CD45RO+ T cells treated for 
the different treatment conditions.  
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Figure 6: 1α, 25-dihydroxyvitamin D3promoted Foxp3 protein expression but not 
Foxp3 promoter demethylation, in memory T cells. Memory CD4+ T cells treated with 
IFN-γ, IFN-β, and VitD for five to six days. A)  The percentage of Foxp3+ induced memory 
Tregs generated from different treatment conditions measured by flow cytometry. B) Foxp3 
protein expression measured by flow cytometry and reported as median fluorescence 
intensity (MFI). C) The percentage of Foxp3 promoter demethylation in memory 
CD4+CD45RO+ T cells treated for the different treatment conditions. Results from 3 
experiments were expressed as means ± SEM. p-values <0.05 were considered significant 
(*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 7: Foxp3 promoter demethylation levels in Foxp3+ memory T cells induced by 
IFN-β or 1α, 25 dihydroxyvitamin D3. There was no significant difference between both 
treatments on the level of Foxp3 demethylation induced in the Foxp3+ memory T cell 
population. Results were expressed as mean ± SEM. p-values <0.05 were considered 
significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 8: The frequencies of Foxp3+ T cells treated with different treatment conditions 
on day 6 and day 12 of culture. Naïve CD4+ T cells treated with IFN-γ, IFN-β and VitD 
were harvested on day six of culture and additional wells were cultured for another five days 
in the presence of IL-2. These wells were harvested on day 12 of culture and analysed by 
flow cytometry. 
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Figure 9: The effect of combining IFN-β with 1α, 25-dihydroxyvitamin D3on the levels 
of Foxp3 protein expression and Foxp3 promoter demethylation. Naïve CD4+ T cells 
treated with IFN-β, VitD, or both. A) The percentage of Foxp3+ induced Tregs generated 
from different treatment conditions measured by flow cytometry. B) Foxp3 protein 
expression measured by flow cytometry and reported as median fluorescence intensity (MFI). 
C) The percentage of Foxp3 promoter demethylation in CD4+ T cells treated for all the 
different treatment conditions. Results were derived from a single experiment. 
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Figure 10: 1α, 25-dihydroxyvitamin D3had more enhancing effects on Foxp3 expression 
in memory T cells than in naïve T cells. A)  The percentage of Foxp3+ induced T cells 
generated from different treatment conditions measured by flow cytometry. B) Foxp3 protein 
expression measured by flow cytometry and reported as median fluorescence intensity (MFI). 
C) The percentage of Foxp3 promoter demethylation in naïve and memory CD4+ T cells 
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treated for the different treatment conditions Results were derived from two independent 
experiments of the same donor. 
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Figure 11: The levels of Foxp3 promoter demethylation in Foxp3+ populations induced 
by IFN-β or 1α, 25-dihydroxyvitamin D3were similar in naïve and memory CD4+ T 
cells. There were no significant differences in the levels of Foxp3 promoter demethylation 
between Foxp3+ T cells derived from memory or naïve T cells after IFN-β or VitD treatment. 
Results were expressed as mean ± SEM. p-values <0.05 were considered significant 
(*p<0.05, **p< 0.01, ***p<0.001). 
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4.5   Discussion and Conclusions: 
The immunomodulatory effects of VitD and IFN-β have been illustrated in many studies 
(259, 260). IFN-γ has also exhibited some immunomodulatory properties under certain 
conditions, promoting Foxp3 expression and Treg function (251, 261). In this study, using 
flow cytometric analysis and the Foxp3 promoter methylation assay, we demonstrated that 
treating human naïve or memory CD4+ T cells with 1α, 25-dihydroxyvitamin D3enhanced 
the proportion of Foxp3+ T cells and increased their intracellular Foxp3 protein expression. 
However, the proportion of Foxp3 promoter demethylation was only enhanced in naïve T 
cells treated with VitD. IFN-β treatment also promoted Foxp3 expression in naïve and 
memory CD4+ T cells, but did not increase the proportion of Foxp3 demethylation. These 
induced Foxp3+Tregs displayed only partial demethylation of the Foxp3 promoter (<50%) 
and lost their Foxp3 expression after longer incubation, indicating a transient Foxp3 
expression. In addition, combining VitD with IFN-β did not to enhance the frequency of 
Foxp3 demethylation when compared to VitD alone. In contrast, IFN-γ treatment failed to 
promote Foxp3 expression in both naïve and memory T cells, and reduced the proportion of 
Foxp3 demethylation in memory T cells. 
VitD, the active form of vitamin D has profound effects on innate and adaptive immune cells 
(262). This fat soluble vitamin binds to its nuclear hormone receptor , vitamin D receptor 
(VDR) in activated CD4+ helper T cell  modulating their function and differentiation (262). 
A recent study found that vitamin D supplementation promotes the frequency of Foxp3+ 
regulatory T cell (263). In addition, a positive correlation between vitamin D status and 
regulatory T cell function was observed (223). These findings were supported by other 
studies that demonstrated the capacity of VitD to directly induce a human Foxp3+ Treg 
population from CD4+ T cells (169, 224, 229, 264). The results from our study are in 
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agreement with these studies, VitD, in the presence of IL-2 and T cell receptor stimulation, 
successfully converted naïve CD4+ T cells to Foxp3+ T cells with high levels of Foxp3 
protein expression. Seong et al. group found that stimulation of human naïve CD4+ T cells 
with VitD for five days converted a significant proportion of them into Foxp3+ Tregs with 
suppressive activity (224). This suppression was mediated by a cell contact mechanism and 
depended on Foxp3 expression. Knocking down the Foxp3 gene in the VitD iTregs using 
siRNA, resulted in loss of their suppressive function (224). Similar results were reported by 
Jeffery and colleagues. Stimulation of purified human CD4+ T cells with anti-CD3/CD28 
coated beads and VitD (100 nM) for five days produced a population of Foxp3+ Tregs that 
displayed suppression function and expressed  high levels of the inhibitory molecule, CTLA-
4 (229).  
VitD also promoted the production of IL-10 and inhibited the production of proinflammatory 
cytokines including IFN-γ, IL-17, and IL-21 by VitD treated T cells (229). Baeke and 
colleagues showed comparable results with a vitamin D analog, TX527 (169). In their study, 
stimulation of purified human CD3+ T cells with TX527 triggered the generation of 
suppressive CD4
+
CD25
hi
CD127
lo
 regulatory T cells that expressed high levels of CTLA-4 
and IL-10. In addition, TX527 inhibited T cell proliferation and production of 
proinflammatory cytokines. In a different study, in vitro treatment of human CD4+ T cells 
with VitD promoted the development of Foxp3+ T cells and IL-10+ T cells (264). These two 
distinct populations expressed high levels of CTLA-4 and showed comparable inhibitory 
function. More interestingly, the development of these two populations of regulatory T cells 
was dependent on the concentration of VitD, with higher concentrations required for inducing 
Foxp3+ iTregs. These findings support the use of VitD in the generation of Foxp3+ iTregs in 
vitro. Furthermore, in our study, VitD enhanced the proportion of Foxp3 promoter 
demethylation suggesting a direct positive regulation of the Foxp3 promoter. This finding 
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was a supported by a recent study that revealed the presence of vitamin D response elements 
(VDREs) within the Foxp3 intronic enhancer region, indicating direct binding to the Foxp3 
gene (224). The binding of VitD to the vitamin D receptor induced conformational changes,  
this facilitates its binding to the retinoic X receptor (RXR) (194). The VDR-RXR 
heterodimer then translocates to the nucleus and binds to VDREs in the Foxp3 gene, 
promoting its active transcription (194). Despite enhanced Foxp3 demethylation, VitD 
induced Tregs displayed only partial demethylation of the Foxp3 promoter representing an 
unstable Treg phenotype. These iTregs also lost their Foxp3 protein expression after 11 days 
of culture indicating the transient nature of Foxp3 expression in these induced Foxp3+ T 
cells.  
VitD treatment of memory CD4+ T cells also enhanced the frequency of Foxp3+ T cells and 
their intracellular Foxp3 protein expression. The mean frequency of Foxp3+ memory T cells 
was even higher than that of naïve T cells. These results are supported by Kang and 
colleagues who demonstrated the ability of VitD to promote Foxp3 expression in memory T 
cells (265). This effect was more prominent in memory than naïve T cells and was attributed 
to the high levels of VDR expression in memory T cells. These VitD induced memory Tregs 
also displayed suppression activity and showed enhanced promoter activity of the Foxp3 
gene. 
The immune modulatory effects of IFN-β were demonstrated in patients with multiple 
sclerosis (MS), in particular relapsing remitting MS. Regulatory T cells in untreated patients 
display a significant reduction in their suppressive function (89, 238, 266). IFN-β therapy 
was found to inhibit T cell activation, promote lymphocyte apoptosis and induce Th2 immune 
responses in patients with MS (267-269). However, more importantly, it induced and 
enhanced immune tolerance through promoting Treg generation and function (232, 239, 240, 
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242, 270). The suppressive function of Foxp3+ Tregs from MS patients was significantly 
increased after six months of IFN-β therapy (232, 239). Similar results were obtained after 
adding IFN-β to Treg cultures in vitro (232).  
Our findings support the results from previous studies. In vitro stimulation of naïve CD4+ T 
cells with IFN-β significantly enhanced the frequency of Foxp3+ T cells and their Foxp3 
protein expression. These results suggest that IFN-β positively regulates Foxp3 expression in 
CD4+ T cells. Enhanced Foxp3 expression was also observed in MS patients treated with 
IFN-β therapy for 6 to 12 months (240, 242). In addition, the frequency of CD4+Foxp3+ T 
cells was increased in IFN-β treated MS patients when compared to untreated patients (242). 
Furthermore, peritoneal administration of IFN-β therapy for two months promoted expansion 
of thymic Tregs and ameliorated symptoms in a mouse model of experimental autoimmune 
encephalomyelitis (EAE) (242). This expansion was due to the up-regulation of 
glucocorticoid-induced TNFR family related gene ligand (GITRL) on IFN-β treated dendritic 
cells and not to the conversion of naïve T cells to Foxp3+ Tregs. The binding of GITRL on 
IFN-β treated dendritic cells  to GITR, which is abundant on Foxp3+ regulatory T cells, 
enhanced Treg proliferation and expansion (271). Despite the strong evidence supporting the 
role of IFN-β in promoting Foxp3 expression and function, there were no published data 
evaluating its ability to promote the conversion of naïve CD4+ T cells into Foxp3+ iTregs. In 
a previous murine study, addition of IFN-β (1.5 ng) to mouse naïve CD4+ T cells,  in the 
presence of TGF-β, antiCD3 and antiCD28, failed to enhance the frequency of Foxp3 
expressing T cells, when compared to TGF-β treatment alone (242). However, in that study, 
the effect of IFN-β treatment alone was not evaluated and the culture conditions were not 
optimised. In addition, mouse naïve T cells may react differently to human naïve CD4+ T 
cells in response to IFN-β stimulation. Therefore, peripheral conversion by IFN-β may also 
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contribute to the observed expansion of Foxp3+ Tregs. IFN-β, in our study, promoted Foxp3 
expression in naïve and memory T cells, but had no significant effect on the methylation 
status of the Foxp3 promoter in these cells, suggesting a transient Foxp3 expression. The 
induction of Foxp3 expression may be mediated by histone modifications, and not CpG 
demethylation, but more studies are required to confirm these preliminary findings and 
explore the underlying molecular mechanisms. The suppressive function of IFN-β iTregs also 
needs to be evaluated by the in vitro assay and an in vivo mouse model to complement these 
findings. 
IFN-γ is a potent proinflammatory cytokine, but also has a role in the induction of tolerance, 
with immune modulatory effects demonstrated in murine and human studies. IFN-γ promoted 
the generation of human monocyte-derived tolerogenic dendritic cells (tDCs) that can 
efficiently stimulate the proliferation of Foxp3+ Tregs in vitro (272). It also promoted the 
conversion of mouse and human conventional T cells to Foxp3+ Tregs (245, 251, 257, 258, 
261). In addition, it was demonstrated that regulatory T cells are capable of producing IFN-γ 
under certain condition, and its production seemed to enhance Treg function (252, 273). 
However, in our study, IFN-γ did not induce Foxp3 expression in naïve or memory CD4+ T 
cells, and furthermore, reduced the proportion of Foxp3 promoter demethylation in treated 
memory T cells. These findings are not consistent with the previous studies that demonstrated 
the capacity of IFN-γ to convert naïve CD4+ T cells into Foxp3+ Tregs. This may be 
attributed to differences in the methods used by other studies. In the Wang et al study, human 
naïve CD4+ T cells from ten donors were treated with IFN-γ (25 ng/ml) for 24 hours then 
analysed for Foxp3 expression (251). This method produced Foxp3+ Tregs with suppressive 
activity in the absence of IL-2 supply and TCR stimulation with anti-CD3/CD28 beads. 
Although this group used a low concentration of IFN-γ, they demonstrated that Foxp3 
expression continued to increase even at a concentration of 100 ng/ml. Daniel and colleagues 
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also demonstrated that stimulation of peripheral blood lymphocytes with phorbol 12-
myristate 13-acetate PMA/ionomycin alone or in combination with IFN-γ (800 ng/ml) for 16 
hours induced a population of IFN-γ+Foxp3+CD4+CD25+ T cells (257). These IFNγ 
producing Tregs produced immune-suppressive cytokines and displayed a suppressive 
phenotype. In both studies, short term cultures that lack IL-2 supply and TCR stimulation 
were used. In addition, both studies added IFN-γ on day zero rather than day two of culture, 
which was used in our protocol.  
However, Ouaked and colleagues used a similar protocol to ours (274). In their study, human 
naïve CD4+ T cells were treated with IL-2 (30 ng/ml), IFN-γ (1000 IU/ml) soluble anti-CD3 
(2.5 µg/ml), anti-CD28 (2.5 µg/ml) and were harvested after five days for flow cytometry 
analysis. The frequency of Foxp3 + T cells in IFN-γ treated T cells was 11.2% ± 2.8, which 
did not differ significantly from that of control 11.4% ± 2.4. These findings were similar to 
our results, but interestingly after ten days of culture, their iTregs expressed suppressive 
activity and in the presence of TGF-β, IFN-γ significantly enhanced Foxp3 expression. 
Therefore, longer incubation time and the presence of other cytokine would seem to modulate 
the IFN-γ effect on Foxp3 expression. In the same study, two STAT 1 binding sites were 
identified in the Foxp3 promoter region, suggesting direct regulation of Foxp3 expression by 
STAT 1-activitating cytokines, including IL-27 and IFN-γ (274). In contrast, IFN-γ also 
induced interferon regulatory factor-1 (IRF1) expression in T cells (275). This transcription 
factor directly repressed Foxp3 expression by binding to a highly conserved IRF consensus 
element sequence (IRF-E) in the Foxp3 gene promoter (276). Therefore, the production of 
Foxp3+ Treg by IFN-γ and its immune modulatory effects seem to require a special 
conditioning.  During classical T cell activation (TCR stimulation and IL-2 supply), IFN-γ 
may act differently and acquire a proinflammatory role, while the presence of other signals 
could modify the final outcome.  Further studies are needed to address the optimal conditions 
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for generating Foxp3+ Tregs with IFN-γ and to investigate its underlying molecular 
mechanisms. 
All induced Foxp3+Tregs developed in this study displayed partial demethylation of the 
Foxp3 promoter and lost their Foxp3 expression after longer incubation. The viability of 
activated T cells in vitro depends on continuous IL-2 supply and CD3/CD28 stimulation 
(211). Activated CD4+ T cells maintained in IL-2 was found to  expand significantly after 
day 2 or 3 of culture producing less than 10% of dead cells at day 14 (211). In addition, 
viability of activated T cells at the end of two week of culture or longer was also 
demonstrated in other studies (55, 57). This indicates that most activated T cells will be 
viable for at least 14 days of culture. Therefore, the observed reduction in the percentage of 
Foxp3+ iTregs on day 12 of culture suggests loss of the transient Foxp3 expression from 
Foxp3 expressing T cells rather than cell death following long term culture.  
 Foxp3 regulatory mechanisms are complex and present at different molecular levels (121). 
The integration of different signals also affects the final outcome of gene transcription (124, 
277). Therefore, exploring and understanding the underlying molecular mechanisms involved 
in Foxp3 regulation by different agents will explain the controversies observed between 
different studies.  
In conclusion, this study demonstrated that VitD or IFN-β, in the presence of IL-2 and TCR 
stimulation, promoted Foxp3 expression in naïve CD4+ T cells. In addition, VitD was 
superior to IFN-β in promoting Foxp3 expression and demethylation. Furthermore, VitD 
enhanced Foxp3 expression in memory CD4+T cells. In contrast, IFN-γ treatment in this 
protocol failed to enhance Foxp3 expression. Of all three agents, VitD is the most potent and 
useful factor for generating Foxp3+ Tregs in vitro, despite iTregs generated by VitD in the 
conditions used, lacking complete demethylation of the Foxp3 promoter, characteristic of a 
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stable Treg phenotype. Therefore, more work is needed to optimise these iTregs and convert 
them into a stable therapeutic Treg population 
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Generation of human Foxp3+ iTreg s using 1α, 25-dihydroxyvitamin D3 and TGF-β 
5.1 Summary: 
Background 
Studies have revealed several in vitro approaches for generating Foxp3+ Tregs, particularly 
with TGF-β. There is also growing evidence of the immunomodulatory role of VitD, 
particularly in promoting Foxp3 expression in CD4+ T cells. These two potent immune-
regulatory factors can promote Foxp3 expression and generate Foxp3+ Tregs independently, 
but the effect of combining them has not been studied before. 
Aim 
To generate Foxp3+ regulatory T cells with a protocol that utilised TGF-β and VitD 
simultaneously. 
Methods 
Human naïve CD4+ T cells from healthy donors were cultured with TGF-β only and TGF-β 
plus VitD, for five days in the presence of IL-2 and anti CD3/CD28 beads. The cells were 
harvested and evaluated for Foxp3 protein expression and Foxp3 promoter methylation. To 
evaluate the effect of combined treatment on de novo Foxp3 expression, IL-1β was added to 
TGF-β or VitD plus TGF-β treated T cells. 
Results 
Simultaneous treatment of T cells with TGF-β and VitD significantly enhanced the frequency 
of Foxp3+ iTregs when compared to control (p<0.001) and TGF-β alone (p<0.05). These 
Foxp3+ iTregs also expressed high levels of Foxp3 protein (p<0.05). However, combining 
TGF-β and VitD did not enhance the proportion of Foxp3 promoter demethylation in treated 
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T cells. In addition, TGF-β plus VitD induced Tregs exhibited < 50% demethylation of the 
Foxp3 promoter. Furthermore, the addition of IL-1β to T cells treated with TGF-β plus VitD 
decreased the frequency of Foxp3+ T cells, the level of Foxp3 protein expression and the 
proportion of Foxp3 promoter demethylation. 
Conclusion 
Co-treatment of human naïve CD4+ T cells with TGF-β and VitD synergistically enhanced 
Foxp3 expression and successfully converted a significant proportion of them into Foxp3 
expressing T cells. However, these iTregs exhibited only partial demethylation of the Foxp3 
promoter, indicating unstable Foxp3 expression and accordingly, these iTregs might not be 
suitable for Treg based cellular therapy. 
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5.2   Introduction: 
Generation of Foxp3+ Tregs in vitro has been the focus of many recent studies. These studies 
revealed several in vitro approaches for generating Foxp3+ Tregs, particularly with TGF-β. 
There is also growing evidence of the immunomodulatory role of VitD, particularly in 
promoting Foxp3 expression in CD4+ T cells. These two potent regulatory factors can 
promote Foxp3 expression and generate Foxp3+ Tregs independently, but the effect induced 
by combining them has not been studied before. 
VitD, the active form of  vitamin D, is an important modulator of  adaptive and innate 
immunity (278). It regulates diverse biological processes in different immune cells and 
promotes immune tolerance. The conversion to the active form occurs mainly in the liver and 
the kidney, but also in other cells, such as epithelial and dendritic cells (194). VitD binds to  
the vitamin D receptor (VDR), which then forms a heterodimer with retinoic X receptor that 
translocates to the nucleus and regulates gene transcription (279). The intracellular VDR is 
expressed by dendritic cells, monocytes, and activated B and T cells. Therefore, all these cells 
are likely to be regulated by VitD (194). Vitamin D deficiency has been associated with 
several autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, type 1 
diabetes mellitus, systemic lupus erythematosus (SLE) and inflammatory bowel disease (214, 
215). In addition, the serum level of 25-hydroxyvitamin D was found to correlate with 
regulatory T cell function in patients with multiple sclerosis (223).  
Studies also showed that VitD promoted Foxp3+ Treg development by direct and indirect 
mechanisms. VitD treated human monocyte-derived dendritic cells successfully induced a 
population of Foxp3+ T cells with suppressive function (197, 198). These Foxp3+ Tregs were 
indirectly promoted by VitD-induced tolerogenic dendritic cells. However, a direct effect of 
VitD on CD4+ T cells was also reported by Jeffery et al (229). In their study, stimulation of 
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human CD4+CD25- T cells with VitD promoted the development of functional Foxp3+ T 
cells with high levels of the inhibitory receptor CTLA-4 (229). Similarly, murine studies 
found that VitD enhanced Foxp3+ Treg expansion and development in vivo (199, 200, 225). 
Furthermore, supplementing murine models of different autoimmune diseases with VitD 
inhibited disease progression or occurrence (226-228). These data support the idea that VitD 
has an immunomodulatory effect, in particular in promoting Foxp3+ Treg development. 
TGF-β is another important immune regulatory factor. It is a multifunctional cytokine that is 
critically involved in regulating immune responses (280). TGF-β was the first cytokine used 
to generate Foxp3+ Tregs in vitro (35, 109). It induced Foxp3 expression in murine and 
human naïve CD4+CD25− T cells converting them in to suppressive Foxp3+ Tregs (54, 57, 
281, 282). However, several human studies found that TGF-β induced Foxp3+ Tregs lacked 
suppressive function (55, 283). The molecular mechanisms underlying TGF-β induction of 
Foxp3 expression are not completely understood, but murine and in vitro studies suggested 
potential mechanisms.  TGF-β signaling involves binding of TGF-β to TGF-β receptor II 
which activates TGF-β receptor I (284). This receptor complex phosphorylates SMAD 
protein 3, which forms a heterodimer with SMAD4, and translocates to the nucleus (285, 
286). The SMAD complex then binds to conserved non-coding DNA sequence one (CNS1) 
in the Foxp3 gene, promoting gene transcription (125). The CNS1 region specifically 
contains a SMAD3-NFAT response element, the cooperation of SMAD3 and NFAT induces 
histone acetylation in the enhancer region and induces Foxp3 transcription (131). This 
mechanism suggests that TGF-β regulates Foxp3 transcription in vivo. 
The effect of TGF-β and VitD signaling pathways interacting together on the regulation of 
Foxp3 expression has not been specifically studied. However, a synergistic effect was 
induced by combining TGF-β and VitD on different genes and cells (287-289). For instance, 
combining TGF-β and VitD induced synergistic activation of the human osteocalcin promoter 
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(289). Similarly, synergistic effects of VitD and TGF-β were observed on chondrocyte 
differentiation, matrix production, and proliferation, which were mediated by activation of 
protein kinase C (287, 288)  
On the basis of the above information, both TGF-β and VitD present key factors for 
generating Foxp3+ Tregs in vitro and may have a synergistic effect on promoting Foxp3 
expression. Despite this, there were no published data on the use of both agents for 
generating Foxp3+ regulatory T cells. Therefore, this study was aimed to evaluate Foxp3+ 
Tregs induced by a protocol using TGF-β and VitD simultaneously. 
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5.3   Protocol. 
5.3.1   Protocol Summary: 
Human naïve CD4+ T cells were separated from peripheral blood and cocultured with 
different combinations of IL-2, TGF-β and VitD for five days to generate Foxp3+ regulatory 
T cells. The cells were then harvested and evaluated by flow cytometric and genetic assays. 
5.3.2  Method: Generation of human Foxp3+ iTregs using 1α, 25-dihydroxyvitamin D3 
and TGF-β. 
Purified naïve CD4+ T cells were cultured with anti-human CD3/ CD28 beads  at a ratio of 
10:1 (ten beads to 1 cell) in TCM,  supplemented with IL-2 (300 U/ml) and TGF-β (20 
ng/ml).  After 48 hours of culture, the old culture medium was replaced with fresh culture 
medium supplemented with IL-2 (300 U/ml), TGF-β (20 ng/ml) and VitD (20 nM) in 
different combinations. Fresh culture medium, supplemented with IL-2 (300 U/ml) only, was 
replaced again after 48 hours.   
 The populations studied were naïve CD4+ T cells activated with IL-2 (Medium), naïve 
CD4+ T cells activated with IL-2 and TGF-β ( TGFβ)  and naïve CD4+ T cells activated with 
IL-2, TGF-β and VitD (TGFβ+ VitD). The cells were cultured for five days in U-bottomed 96 
well plates (BD Biosciences) in a final volume of 200 µl of tissue culture medium. In 
additional experiments, IL-1β (10 ng/ml) was added to TCM supplemented with IL-2, TGF-β 
and VitD on day two of culture. 
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5.3.3 Experiments: 
A total of four experiments from four healthy adult donors was performed using this protocol. 
To evaluate the effect of adding TGF-β and VitD simultaneously, all results were combined 
and then analysed against control (Medium). Due to the length and complexity of these 
experiments, a single experiment was performed to evaluate whether additional combination 
or changes to the original protocol might increase Foxp3 promoter demethylation or protein 
production. Although not suitable for statistical analysis, these additional experiments 
provide important information and therefore, were included under supplementary results. 
 
5.4 Results: 
5.4.1   Frequency and methylation status of CD4+CD25+Foxp3+ iTregs: 
An initial experiment was performed to compare the effect of single (VitD) versus combined 
treatment (TGF-β plus VitD) on the level of Foxp3 expression and Foxp3demethylation. In 
this experiment, the percentage of Foxp3+ iTregs was markedly increased after combining 
VitD with TGF-β. Similarly, Foxp3 protein expression was promoted with TGF-β plus 
vitamin D3 co-treatment. However, this combination produced the lowest proportion of 
Foxp3 promoter demethylation (Figure 1). 
Results from all experiments revealed a significant increase in the frequency of Foxp3+ Tregs 
induced by TGF-β only (p<0.05) and TGF-β + VitD (p<0.001) when compared to control 
(Medium) (Figure 2A). In addition, the mean frequency of Foxp3+ T cells generated with 
TGF-β plus VitD combined treatment (38% ± 4) was significantly higher (p<0.05) than that 
produced by TGF-β treatment alone (20% ± 0.7). Foxp3 protein expression (MFI) was also 
significantly enhanced in Tregs induced by TGF-β plus VitD (p<0.05) (Figure 2B). 
However, the proportion of Foxp3 promoter demethylation did not differ significantly from 
control (Medium) (Figure 2C). The mean percentage of Foxp3 promoter demethylation was 
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17% ± 2 for TGFβ + VitD co-treatment and 15% ± 2 for control (Medium). Evaluation of the 
percentage of Foxp3 promoter demethylation in Foxp3+ T cell populations generated from 
TGF-β and TGF-β plus VitD treatments, revealed no significant difference. Both populations 
displayed less than 50% demethylation of the Foxp3 promoter (Figure 3). The mean 
percentage of Foxp3 promoter demethylation was 39% ± 6 in TGF-β induced Foxp3+ T cells 
and 26% ± 6 in TGF-β plus VitD induced Foxp3+ T cells. 
Taken together, these data suggests that treating naïve CD4+ T cells with TGF-β and VitD in 
vitro provides an inefficient mean of generating a stable Foxp3+ Treg population despite 
significantly enhanced the frequency of Foxp3+ T cells and their Foxp3 protein expression  
5.4.2   Supplementary results:  
5.4.2.1   The effect of longer incubation: 
The frequency of Foxp3+ T cells and the proportion of Foxp3 promoter demethylation were 
also evaluated at different points of time (day five versus day nine of culture). The frequency 
of  Foxp3+ T cells induced by TGF-β plus VitD dropped by  24% at day  nine of culture, but 
the proportion of Foxp3 promoter demethylation dropped by 60% . This marked drop in the 
proportion of Foxp3 promoter demethylation probably indicates the death of the highly 
demethylated Foxp3+ T cells due to lack of activation signals derived from TGF-β plus VitD 
and longer incubation (Figure 4). It also indicates lack of stability of these Foxp3 expressing 
T cells after withdrawing the TGF-β and VitD signals. 
5.4.2.2   The effect of adding IL-1β: 
The effect of IL-1β was evaluated by two independent experiments. Naïve CD4+ T cells were 
cultured with TGF-β and VitD in the presence, or absence, of IL-1β for five days. IL-1β (10 
ng/ml) was added to the relevant wells on day two of culture. The percentage of Foxp3+ T 
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cells, intracellular Foxp3 expression and the proportion of Foxp3 promoter demethylation 
were utilised to compare TGF-β plus VitD treated T cells in the presence, or absence, of IL-
1β. Results showed that IL-1β reduced the frequency of Foxp3+ T cells (26%), the level of 
Foxp3 protein expression (15%) and the proportion of Foxp3 promoter demethylation (44%) 
in TGF-β plus VitD treated T cell culture (Figure 5). The percentages here present the 
magnitude of drop from the original value (100%) and not the Foxp3 demethylation. An 
additional experiment was performed to evaluate the effect of IL-1β on TGF-β plus VitD 
treated T cells after five days of culture. IL-1β (10 ng/ml) was added to the relevant wells on 
day six of culture and cells were harvested, and evaluated on day nine (Figure 6). The 
addition of IL-1β at this point in time of culture did not result in any obvious change which 
implies that the negative effect of IL-1β is time dependent. 
 
 
 
 
 
 
 
 
 
 
127 
 
A) 
Medium TGFβ VitD TGFβ+VitD
0
10
20
30
40
50
%
 o
f 
C
D
4
+
C
D
2
5
+
F
O
X
P
3
+
 
B) 
Medium TGFβ VitD TGFβ+VitD
0
200
400
600
800
F
O
X
P
3
 M
F
I
 
C) 
 Medium TGFβ VitD TGFβ+VitD
0
10
20
30
40
%
 o
f 
F
O
X
P
3
 d
e
m
e
th
y
la
ti
o
n
 
Figure 1: Combining 1α, 25-dihydroxyvitamin D3with TGF-β enhanced the frequency 
of Foxp3+ T cells and their Foxp3 expression when compared to 1α, 25-
dihydroxyvitamin D3or TGF-β alone, but reduced the proportion of Foxp3 promoter 
demethylation. A representative experiment of naïve CD4+ T cells treated with TGF-β, VitD 
or both for five days. A)  The percentage of Foxp3+ induced Tregs generated from different 
treatment conditions measured by flow cytometry. B) Foxp3 protein expression measured by 
flow cytometry and reported as median fluorescence intensity (MFI). C) The percentage of 
Foxp3 promoter demethylation in CD4+ T cells treated for all the different conditions.  
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Figure 2: Co-treatment with 1α, 25-dihydroxyvitamin D3 and TGF-β significantly 
enhanced the frequency of Foxp3+ T cells and their Foxp3 expression, but the 
proportion of Foxp3 promoter demethylation remained unchanged. A)  The percentage 
of Foxp3+ induced Tregs generated from different treatment conditions measured by flow 
cytometry. B) Foxp3 protein expression was measured by flow cytometry and reported as 
median fluorescence intensity (MFI). C) The percentage of Foxp3 promoter demethylation in 
CD4+ T cells treated for all the different conditions. Results were expressed as means ± 
SEM. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 3: Foxp3 demethylation levels in Foxp3+ T cells induced by TGF-β and TGF-β 
plus 1α, 25-dihydroxyvitamin D3. There was no significant difference between both 
treatments on the level of Foxp3 demethylation within the Foxp3+ T cell population. Results 
were expressed as mean ± SEM. p-values <0.05 were considered significant (*p<0.05, **p< 
0.01, ***p<0.001). 
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Figure 4: The frequency of Foxp3+ T cells and Foxp3 promoter demethylation reduced 
in all treatment conditions, particularly in TGF-β plus VitD treated T cells, after eight 
days of culture. Naïve CD4+ T cells were cultured with TGF-β, VitD or both for five days as 
described previously. Some wells were harvested on day five, the rest were further cultured 
for additional three days in the presence of IL-2 (300 U/ml) A) and harvested on day nine. 
The percentage of Foxp3+ induced Tregs generated from different treatment conditions 
measured by flow cytometry. B) The percentage of Foxp3 promoter demethylation in CD4+ 
T cells treated for all the different conditions. 
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Figure 5: IL-1β negatively regulated Foxp3 expression and demethylation in TGF-β 
plus VitD treated T cells. Naïve CD4+ T cells were cultured with TGF-β and VitD in the 
presence, or absence, of IL-1β for five days as described in the protocol, then cells were  
harvested for analysis by flow cytometry and a Foxp3 methylation assay A) The percentage 
of Foxp3+ induced Tregs generated from different treatment conditions measured by flow 
cytometry. B) Foxp3 protein expression was measured by flow cytometry and reported as 
median fluorescence intensity (MFI). C) The percentage of Foxp3 promoter demethylation in 
CD4+ T cells treated for all the different conditions. Results were derived from two 
independent experiments and expressed as means ± SEM. 
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Figure 6: The addition of IL-1β to TGF-β or TGF-β plus 1α, 25-dihydroxyvitamin 
D3after the first five days of culture had no significant effect on the frequency of 
Foxp3+ T cells and their intracellular Foxp3 protein expression.  Naïve CD4+ T cells 
were cultured with TGF-β and TGF-β plus VitD for five days as described previously. IL-1β 
was added on day six of culture and the cells were harvested on day nine for analysis by flow 
cytometry. A) The percentage of Foxp3+ induced Tregs generated from different treatment 
conditions measured by flow cytometry. B) Foxp3 protein expression was measured by flow 
cytometry and reported as median fluorescence intensity (MFI). 
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5.5   Discussion and Conclusions: 
The immunomodulatory effects of VitD and TGF-β have been demonstrated in murine and 
human studies (194, 279, 290). Both agents can positively regulate Foxp3 expression and 
promote immune tolerance (224, 291). In this study, using flow cytometric analysis and a 
Foxp3 methylation assay, we demonstrated that treating human naïve CD4+ T cells with 
TGF-β plus VitD significantly enhanced the proportion of Foxp3+ iTregs and their 
intracellular Foxp3 protein expression. However, these cells displayed only partial 
demethylation of the Foxp3 promoter (<50%).  In addition, TGF-β plus VitD co-treatment 
failed to enhance the proportion of Foxp3 promoter demethylation when compared to control 
(Medium). Furthermore, the addition of IL-1β suppressed Foxp3 expression and Foxp3 
promoter demethylation in TGF-β plus VitD treated T cells, but this effect seems to be time 
dependent. 
The findings from this study are in agreement with previous reports that demonstrated the 
capacity of TGF-β or VitD to promote Foxp3 expression in human CD4+ T cells  (55, 224, 
229). Treating human PBMCs with VitD increased the percentage of Foxp3+ T cells and 
treating human naïve CD4+ T cells with VitD plus IL-2 induced Foxp3 expression (229, 
292). These VitD induced Tregs also exhibited suppressive function and inhibited the 
production of proinflammatory cytokines (224, 229). Similarly, T cells treated with a vitamin 
D analogue displayed Treg phenotype and function (169). These results indicate that vitamin 
D regulates Foxp3 expression by a direct mechanism. This was proved in a recent study that 
demonstrated the presence of vitamin D response elements (VDREs) in human Foxp3 CNS-1 
region (224).  VitD is a small lipophilic molecule that diffuses through the cell membrane to 
bind to VDR. The VDR then forms a heterodimer with retinoid X receptor (RXR) and binds 
to VDREs in gene promoter regions to induce transcription of vitamin D-responsive genes 
(194). Likewise TGF-β regulates Foxp3 expression by signaling through SMAD complex 
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which directly binds to SMAD3-NFAT response element in human Foxp3 CNS1 region 
(125). In our study, combining TGF-β with VitD produced a synergistic effect on Foxp3 
expression. This effect was not specifically studied on regulatory T cells, but there are several 
lines evidence indicating the presence of a positive relationship between the two 
immunomodulatory agents. A local increase in TGF-β was noticed after intra-peritoneal 
administration of vitamin D in a murine model of acute colitis (293). Similarly, vitamin D 
increased serum TGF-β in murine model of allergic air way disease (294). In a different 
study, in vitro addition of VitD enhanced TGF-β expression by dendritic cells and Tregs 
(295). Furthermore, vitamin D supplementation was shown to increase serum TGF-β level in 
patients with multiple sclerosis (296). Therefore, VitD seems to promote TGF-β expression 
and production in immune cells which may present an indirect mechanism for enhancing 
Foxp3 expression.  
On the basis of this information, vitamin D can induce Foxp3 expression by directly binding 
to VDREs in the Foxp3 gene and indirectly through promoting TGF-β expression/secretion 
which subsequently activates TGF-β dependent Foxp3 expression.  The synergistic effect of 
VitD and TGF-β observed in our study was also reported in other studies but on different cell 
types. Studies showed that VitD and TGF-β synergistically activated the human osteocalcin 
promoter and promoted chondrocyte differentiation (288, 289). The molecular mechanisms 
by which TGF-β and vitamin D signaling pathways interact were also investigated, but on 
human osteocalcin promoter (289). Their study found that the synergistic effect induced by 
TGF-β and vitamin D required the presence of SMAD binding elements (SBEs) and the 
VDRE in close proximity to the gene promoter (289). The same concept may apply to the 
Foxp3 gene, as both elements are present in the human Foxp3 CNS-1 region, the most 
proximal enhancer region to the Foxp3 promoter but this need to be confirmed by further 
molecular studies. Despite the impressive Foxp3 expression seen in CD4+ T cells treated 
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with TGF-β plus VitD, these Foxp3+ iTregs are partially demethylated. In addition, this 
combination induced only a low proportion of Foxp3 promoter demethylation that further 
reduced after eight days of culture. All suggesting unstable Foxp3 expression in these in vitro 
induced Tregs. Previous studies showed that TGF-β induced Tregs exhibited partial Foxp3 
demethylation and lack suppressive function (55, 72, 122). The methylation status of VitD 
induced Tregs was not documented but VitD plus TGF-β iTregs in our study also displayed 
partial Foxp3 demethylation representing unstable Treg lineage.  
IL-1β is a pleiotropic proinflammatory cytokine that plays an important role in inflammation 
and autoimmune disease. High levels of IL-1β have been observed in several autoimmune 
diseases including juvenile idiopathic arthritis (JIA), auto-inflammatory diseases and Crohn’s 
disease (201, 202). IL-1β also induced inflammatory arthritis in murine models (203). 
However, a recent study proposed that IL-1β promoted Foxp3 expression in both Tregs and 
effector T cells (183). Therefore, we investigated the effect of IL-1β on T cells treated with 
TGF-β and VitD. This evaluation can determine if IL-1β has an immune-modulatory effect 
and provide information about the stability of TGF-β plus VitD induced Tregs in the presence 
of an inflammatory milieu. As expected, the addition of IL-1β reduced the frequency of 
Foxp3+ T cells, their Foxp3 expression and, more importantly, the proportion of Foxp3 
promoter demethylation. This effect was induced by a single treatment of IL-1β, probably 
more frequent treatments and higher concentrations will produce a more profound effect. 
These results are in agreement with other reports that supported the proinflammatory role of 
IL-1β (204, 297, 298). The specific effects of IL-1β on regulatory and effector T cell 
functions in the presence of antigen specific dendritic cells were evaluated in a murine study 
(204).  This group found that IL-1β induced IFN-γ production in regulatory T cells and 
abrogated their ability to suppress T cell proliferation. In addition, IL-1β enhanced effector T 
cell division and resistance to suppression by Foxp3+ Treg. Another group also found that 
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treating human naïve CD4+ T cells with IL-1β (10 ng/ml) induced the differentiation of IL-
17 producing T helper cells (Th-17) and this conversion is further promoted with IL-6 (297). 
These Th-17 cells promote inflammation and are involved in the pathogenesis of  several 
autoimmune diseases (299).  
Furthermore, IL-1β  promoted conversion of human Tregs into Th-17 cells and  induced 
down regulation of Foxp3 protein (300). All these data suggested that IL-1β promotes an 
inflammatory rather than a tolerogenic immune response. Interestingly, the addition of IL-1β 
to T cells treated with TGF-β plus VitD on day six of culture failed to reproduce the same 
inhibitory effect on Foxp3 expression. This indicates that timing is a limiting factor and 
possibly the accessibility of certain transcription factors to Foxp3 promoter is limited after T 
cell receptor (TCR) activation phase. Chromatin remodelling controls the access of the 
transcriptional machinery to the gene promoter and T cells activation is known to promote 
open chromatin conformation of the Foxp3 gene in CD4+CD25- T cells (301) . Therefore, 
activation seems to be a key factor for promoting Foxp3 expression. Subsequently, negative 
or positive transcription factors can easily get access to the Foxp3 promoter and regulate 
Foxp3 transcription after the initial T cell activation, but not afterward. This may explain the 
effect exerted by IL-1β at different points of time. These results also suggested that TGF-β 
plus VitD iTregs are relatively stable in inflammatory conditions mediated by IL-1β and able 
to maintain their Foxp3 expression in vitro for up to nine days. The use of anti- IL-1β 
antibody in early stages of T cell culture activated with TGF-β and VitD may enhance Foxp3 
expression and is worth investigating. 
Further studies are needed to confirm the findings from this study. Measurement of IL-1β in 
the culture supernatant and the use of anti-IL-1β antibody may provide a better understanding 
of the effect of this cytokine on Foxp3 expression and Foxp3 demethylation. Evaluating the 
suppressive function of TGF-β plus VitD iTregs by in vitro and in vivo techniques will also 
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be useful to determine the functionality and potency of these cells. In addition, examining the 
methylation status of the Foxp3 enhancer region as well as histone epigenetic status will 
provide a complete picture of all the epigenetic changes induced by TGF-β and VitD 
combined treatment. Molecular studies also needed to reveal the effect of TGF-β and VitD 
signaling pathways interaction on Foxp3 gene expression. In summary, TGF-β and VitD 
synergistically induced Foxp3 expression in naïve CD4+ T cells, but these iTregs failed to 
display complete demethylation of the Foxp3 promoter suggesting a transient Foxp3 
expression. Therefore, this protocol does not provide a stable Foxp3+ Treg population for 
practical use in Treg based cellular therapy.  
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Generation of human Foxp3+ iTregs using TGF-β and All-trans retinoic acid. 
6.1   Summary: 
Background 
Treg-based cellular therapy using in vitro induced Tregs offers a potential approach for the 
restoration of tolerance in autoimmune disorders. Foxp3+ Tregs induced in vitro by TGF-β 
and tRA showed promising results in murine and human studies. However, iTreg functional 
stability remains an important practical aspect of this protocol that still needs to be clarified. 
Aim 
To evaluate the utility and functional stability of Foxp3+ Tregs induced by TGF-β and tRA 
co-treatment by Foxp3 methylation assay.  
Methods 
Human naïve CD4+ T cells from healthy donors were cultured with TGF-β, tRA and TGF-β 
plus tRA for 5 days, in the presence of IL-2 and anti CD3/CD28 beads. The cells were then 
harvested and evaluated for Foxp3 protein expression and Foxp3 promoter demethylation. To 
evaluate the effect of combined treatments on de novo Foxp3 expression, VitD was included 
in different experiments. Memory CD4+ T cells were also evaluated for Foxp3 expression 
and demethylation. 
Results 
Treatment with TGF-β and tRA significantly enhanced the frequency of Foxp3+ iTregs when 
compared to control (p<0.01), TGF-β (p<0.05) or tRA (p<0.01) separately. These Foxp3+ 
iTregs expressed high levels of Foxp3 protein expression (p<0.01) and Foxp3 mRNA 
transcripts (p<0.05). TGF-β plus tRA co-treatment also significantly enhanced the proportion 
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of Foxp3 promoter demethylation (p<0.05).  TGF-β plus tRA induced Tregs exhibited >50% 
demethylation of the Foxp3 promoter and >70% of these cells remained Foxp3+ after 
restimulation. Memory T cells also expressed Foxp3 after TGF-β plus tRA co-treatment, but 
the proportion of Foxp3 promoter demethylation remained unchanged. Adding VitD to TGF-
β plus tRA reduced the frequency of Foxp3+ iTregs and the proportion of Foxp3 promoter 
demethylation in treated T cells. 
Conclusion 
TGF-β plus tRA co-treatment successfully enhanced Foxp3 expression and Foxp3 promoter 
demethylation in naïve CD4+ T cells. However, these iTregs exhibited only partial 
demethylation of the Foxp3 promoter and probably present a functionally unstable population 
for Treg-based cellular therapy. 
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6.2   Introduction:  
Treg-based cellular therapy using in vitro induced Tregs offers a promising approach for 
restoration of tolerance in autoimmune disorders. Foxp3+ Tregs induced in vitro by TGF-β 
plus tRA have shown promising results in murine and human studies. However, the 
functional stability of iTregs generated by this protocol needs to be investigated. 
Retinoic acid (RA) is the active metabolite of vitamin A and is critically involved in immune 
regulation, particularly Treg differentiation (302). It has several isoforms but the main active 
form is the all-trans isoform, tRA (303).  The role of RA in Treg differentiation was initially 
demonstrated using mucosal CD103
+ 
dendritic cell subsets which potently induced Treg 
differentiation in the absence of exogenous factors (304, 305). These mucosal dendritic cells 
are characterised by their ability to produce TGF-β and RA. This combination enhanced Treg 
differentiation and gut homing in mice (126) and humans (306). Blocking of TGF-β in 
mucosal dendritic cell co-cultures reduced iTreg differentiation (303). Therefore, this 
peripheral conversion was dependent on TGF-β and retinoic acid (RA). Further studies 
showed that RA modulates the TGF-β immune-mediated response. For instance,  in the 
presence of IL-6, TGF-β promotes the differentiation of pro-inflammatory Th-17 cells while 
in the presence of  RA, it promotes Foxp3+ Treg generation (307). RA was also found to 
enhance TGF-β driven phosphorylation of SMAD3, which is an essential transcription factor 
for induction of CNS1-mediated Foxp3 expression (131, 308, 309). It also inhibited IL-6 and 
IL-23 receptor expression which drive the development of Th17 cells (308). 
On the other hand, TGF-β tends to maintain higher RA concentrations in the cells by 
preventing its intracellular degradation (303, 310). Hence, it is likely that TGF-β and tRA 
complement each other’s effect. This also explains the synergistic effect on Foxp3 expression 
generated from combining TGF-β and tRA in culture. Later studies evaluated the direct effect 
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of exogenous RA on CD4+ T cells. In murine studies, RA significantly enhanced Foxp3 
expression in naïve CD4+ T cells stimulated by anti-CD3/CD28 and TGF-β (306, 311, 312). 
The enhanced TGF-β-induced Foxp3 expression by RA was attributed to its direct effect on 
naïve T cells and its indirect effect on memory/effector T cells (311, 313). The direct effect 
was through enhanced TGF-β-driven SMAD3 signaling and the indirect effect was via 
inhibited production of proinflammatory cytokines from memory T cells (308, 313). These 
Foxp3+ induced Tregs exhibited potent suppressive activity in vitro and in vivo (312). 
Retinoic acid also successfully induced mouse Foxp3+ T cells in vivo after seven days of 
subcutaneous injections (306). 
Similarly, treating human naive CD4+ T cells derived from neonatal cord blood with tRA 
significantly enhanced Foxp3 protein and mRNA expression (306). These tRA treated T cells 
displayed a potent suppressive activity with enhanced histone acetylation of the Foxp3 
promoter. The synergistic effect of combining TGF-β and tRA on Foxp3 expression was also 
demonstrated in human peripheral CD4+ T cells (56, 314). Treating naïve CD4+ T cells with 
TGF-β plus tRA significantly enhanced and stabilized Foxp3 expression when compared to 
TGF-β treated T cells (56, 314). This was verified by a stability study that showed more than 
60% of TGF-β plus tRA treated T cells maintained their Foxp3 expression at day nine of 
culture (56). In another study, more than 50% of TGF-β plus tRA treated T cells maintained 
their Foxp3 expression at day 15 of culture (314). Furthermore, the addition of tRA to TGF-β 
produced fully functional suppressor cells that showed protective effect equivalent to 
expanded thymic Tregs (tTreg) in vivo (56). 
 These impressive results from human studies lack an important measure of Treg functional 
stability, Foxp3 methylation status. This piece of information is essential for successful Treg-
based cellular therapy. In this study, we further evaluate the efficacy and stability of Tregs 
induced by TGF-β plus tRA protocol. This evaluation includes measuring the methylation 
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status of the Foxp3 promoter which will provide a better indication about the functional 
stability of these iTregs and the practicality of this protocol for future applications in Treg-
based cellular therapy. 
6.3   Protocol: 
6.3.1   Protocol summary: 
Human naïve CD4+ T cells were separated from peripheral blood and co-cultured with 
different combinations of IL-2, TGF-β and tRA for five days to generate Foxp3+ regulatory T 
cells. The cells were then harvested and evaluated by flow cytometric and genetic assays. 
6.3.2   Method: Generation of human Foxp3+ iTregs with TGF-β and All-trans retinoic 
acid. 
Purified naïve T cells were cultured with anti-human CD3/CD28 beads at a ratio of 1:10 (one 
bead to ten cells) in TCM supplemented with IL-2 (50 U/ml), TGF-β (5 ng/ml) and tRA (100 
nM) in different combinations. The cells were cultured for five days in U-bottomed 96 well 
plate (BD Biosciences) in a final volume of 200 µl of tissue culture medium. Fresh culture 
medium with the corresponding additives was replaced every two days.  
The populations studied were naive CD4+ T cells activated with IL-2 (Medium), naïve CD4+ 
T cells activated with IL-2 and TGF-β (TGF-β), naïve CD4+ T cells activated with IL-2 and 
tRA ( tRA) and naïve CD4 + T cells activated with IL-2, TGF-β and tRA (TGFβ + tRA). In 
some experiments VitD (1 nM) was added to TCM supplemented with IL-2 (50 U/ml), TGF-
β (5 ng/ml) and tRA (100 nM). The cells were cultured for five days in 96 well plates (BD 
Biosciences). Fresh culture medium with the corresponding additives was replaced every two 
days.  
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For comparison purposes, purified human memory CD4+CD45RO+ T cells were cultured 
with TGF-β plus tRA using the same protocol described for naïve CD4+ T cells. 
In vitro suppression assay was also performed. Activated CD4+ T cells labelled with CTV 
(responders) were plated in the presence of unlabelled iTregs from various conditions at a 
ratio of 1:4 (Treg to responder cells) and incubated for three days at 37°C in a 5% CO2 
incubator. The co-culture was analysed by flow cytometry and the proliferation of CD4+ 
responder T cells was calculated using the division index, then the percentage of suppression 
was calculated as described in Chapter Two (Materials & Methods). 
6.3.3  Experiments: 
A total of eight experiments from six healthy adult donors was performed using this protocol. 
To evaluate the effect of TGF-β and tRA treatment, all results were combined and then 
analysed against control (Medium). An additional three experiments from two healthy donors 
were performed for evaluating the effect of VitD. Due to the length and complexity of these 
experiments, a single experiment was performed to evaluate whether additional combination 
or changes to the original protocol are worth doing or investigating further. Although not 
suitable for statistical analysis, these additional experiments provide important information 
and therefore, were included under supplementary results. 
6.4   Results: 
6.4.1   Frequency and methylation status of CD4+CD25+Foxp3+   iTregs: 
 An initial experiment was performed to compare the effect of single (TGF-β or tRA) versus 
combined treatments (TGF-β+tRA) on the level of Foxp3 expression and demethylation. In 
this experiment, the frequency of Foxp3+ iTregs was markedly increased (60%) after 
combining TGF-β with tRA. Similarly, the frequency of Foxp3 demethylation was enhanced 
with TGF-β+tRA co-treatment and these cells produced the highest level of Foxp3 mRNA 
expression (Figure 1). The suppressive capacity of Foxp3+ iTregs produced by different 
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treatment conditions was evaluated by flow cytometry using Cell-Trace Violet (CTV).  
Foxp3+ Tregs induced by the TGFβ and tRA combined treatment markedly suppressed the 
proliferation of activated CD4+ T cells and produced the highest percentage of suppression 
(84%)  and the lowest division index  at 1:4 (Treg: responder) ratio (Figure 2).  However, 
Foxp3+ Tregs induced by TGF-β or tRA were also suppressive in vitro, TGF-β iTregs 
suppressed 69% and tRA iTregs suppressed 78% of activated T cells. 
Results from all experiments revealed a significant increase in the frequency of Foxp3+ Tregs 
induced by the following treatments: TGF-β (p<0.05) and TGFβ+tRA (p<0.01) when 
compared to control (Medium) (Figure 3A). In addition, the mean frequency of Foxp3+ Tregs 
generated with TGFβ + tRA combined treatment (31% ± 6) was significantly higher (p<0.05) 
than that produced by TGF-β (19% ± 3) or tRA (8.7% ± 3) separately. Foxp3 protein 
expression (MFI) was also significantly increased in Tregs induced by TGFβ + tRA co-
treatment (p<0.01) (Figure 3B). Likewise the proportion of Foxp3 promoter demethylation 
was significantly enhanced in naïve T cells treated with TGFβ + tRA (p<0.05) (Figure 3C). 
The mean percentage of Foxp3 promoter demethylation was 36%  ± 3 for the TGFβ + tRA 
co-treatment. Evaluation of the degree of demethylation within the Foxp3+ T cells 
populations generated with TGF-β or TGFβ + tRA co-treatment, showed no significant 
difference. Both populations displayed more than 50% demethylation of the Foxp3 promoter 
(Figure 5). The mean percentage of Foxp3 promoter demethylation was 67% ± 7.8 in TGF-β 
induced Foxp3+ Tregs and 54% ± 10 in TGFβ + tRA induced Foxp3+ Tregs. 
 These data indicate that TGF-β and tRA combined treatment is more potent than TGF-β or 
tRA alone in inducing Foxp3+ Tregs in vitro. 
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6.4.2   Foxp3 mRNA expression of CD4+CD25+Foxp3+ iTregs: 
Foxp3 mRNA expression for each treatment condition was measured by real time PCR (RT-
PCR).  Results showed that Foxp3+ iTregs generated from treating naïve CD4+ T cells with 
TGF-β and tRA expressed the highest level of Foxp3 mRNA transcripts (Figure 4). In 
addition, the Foxp3 mRNA level was significantly higher than that produced by TGF-β or 
tRA separately (p<0.05).  Tregs induced by TGFβ + tRA displayed the highest level of Foxp3 
mRNA expression and Foxp3 protein expression (MFI). 
6.4.3   Effect of adding 1α, 25 dihydroxyvitamin D3: 
The effect of VitD was evaluated in three independent experiments. VitD was added to naïve 
CD4+ T cells treated with TGF-β plus tRA on day 0, 2 and 4 of culture. Foxp3 protein 
expression (MFI), percentages of Foxp3+ T cells and the proportion of Foxp3 promoter 
demethylation were evaluated in the presence or absence of VitD.  The results showed 
significant reduction (p<0.05) in the percentage of Foxp3+ Tregs in CD4+ T cells treated 
with VitD (Figure 6-A). Similar reduction (p<0.001) was observed in the proportion of Foxp3 
demethylation after treatment with VitD (Figure 6-C). Although VitD treated cells had 
reduced Foxp3 protein expression (MFI), the difference was not statistically significant 
(Figure 6-B).  
6.4.4   Memory CD4+CD45RO+ T cells: 
Human CD4+ CD45RO+ T cells from three healthy donors were stimulated with or without 
TGF-β plus tRA for five days in the presence of IL-2 and anti CD3/CD28 beads. The cells 
were then harvested and evaluated for Foxp3 expression and Foxp3 demethylation. Treating 
memory CD4+ T cells with TGF-β and tRA significantly enhanced the proportion of Foxp3+ 
T cells (p<0.05) (Figure 7). However, there was no significant difference in the proportion of 
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Foxp3 demethylation between memory T cells treated with TGF-β plus tRA and control 
(Medium).This suggests that TGF-β plus tRA treatment can enhance Foxp3 expression in 
proportion of cells without inducing Foxp3 demethylation. 
6.4.5   Supplementary results:  
6.4.5.1   Restimulation of CD4+CD25+Foxp3+ iTregs: 
To evaluate the stability of Foxp3 expression in Tregs induced by TGF-β + tRA co-treatment, 
a restimulation experiment was performed. Naïve CD4+ T cells from two healthy donors 
were treated with TGF-β + tRA and cultured for five days as described in the protocol. On 
day 5, some wells were harvested and the cells were analysed by flow cytometry. The 
remaining wells were restimulated with antiCD3/CD28 beads and IL-2 (100 U/ml) for 
another five days. Cells were harvested on day ten of culture and analysed by flow cytometry 
for the frequency of Foxp3+ T cells and their Foxp3 expression. The results showed a small 
decrease (5-9%) in the percentage of Foxp3+ T cells and a variable increase (8-30%) in their 
Foxp3+ protein expression (MFI) after restimulation (Figure 8). These results indicated that 
more than 70% of Foxp3+ Tregs induced by TGF-β plus tRA maintained their Foxp3 
expression after restimulation.  
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Figure 1: Co-treatment with TGFβ and tRA produced the highest frequency of Foxp3+ 
T cells and Foxp3 promoter demethylation with strong Foxp3 mRNA expression. A) The 
percentage of Foxp3+ Tregs induced with TGF-β, tRA and TGFβ + tRA obtained by flow 
cytometric analysis. B) Foxp3 mRNA expression in naïve CD4+ T cells treated with TGF-β, 
tRA and TGFβ + tRA measured by RT-PCR.C). The percentage of Foxp3 promoter 
demethylation in CD4+ T cells treated for the different treatment conditions. 
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Suppression assay: 
   
A)  
                                                                           C) 
                
         
 
B) 
 
a) Medium  
 
 
b)   TGF-β 
 
c) tRA  
 
d) TGFβ+tRA 
 
 
Figure 2: Tregs generated with TGF-β and tRA co-treatment exhibited the highest 
suppressive activities (84%). A) Shows the proliferation of CD4+ responder T cells in the 
absence of iTregs. B) Shows the proliferation of CD4+ responder T cells in the presence of 
iTregs generated by different treatments. C) A summary table of the division index and the 
percentage of suppression of various culture conditions.  
 
 
 
 
 
Culture 
condition 
 Division 
index 
% 
Suppression 
TGF-β 0.83 69 
tRA 0.58 78 
TGF-β+tRA 0.41 84 
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Figure 3: Co-treatment with TGF-β and tRA significantly enhanced the frequency of 
Foxp3+ T cells, the proportion of Foxp3 promoter demethylation and induced strong 
Foxp3 protein expression. A)  The percentage of Foxp3+ induced Tregs generated from 
different treatment conditions measured by flow cytometry. B) Foxp3 protein expression was 
measured by flow cytometry and reported as median fluorescence intensity (MFI). C) The 
percentage of Foxp3 promoter demethylation in CD4+ T cells for the different treatment 
conditions. Results were expressed as means ± SEM. p-values <0.05 were considered 
significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 4:  Treating naïve CD4+ T cells with TGF-β and tRA induced the highest level of 
Foxp3 mRNA expression. The level of Foxp3 mRNA expression in Tregs induced by 
different treatments measured by RT-PCR. Results were expressed as means ±SEM. p-values 
<0.05 were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 5: Foxp3 demethylation levels in Foxp3+ T cells induced by TGF-β or TGF-β 
and tRA. There was no significant difference between treatments on the level of Foxp3 
demethylation within the Foxp3+ T cell population. Results were expressed as means ±SEM. 
 
 
 
 
 
152 
 
A) 
B)
TGFβ+tRA TGFβ+tRA+VitD
0
20
40
60
80
*
%
 o
f 
C
D
4
+
C
D
2
5
+
F
O
X
P
3
+
 
TGFβ+tRA TGFβ+tRA+VitD
0
500
1000
1500
F
O
X
P
3
 M
F
I
 
C)  
    
TGFβ+tRA TGFβ+tRA+VitD
0
10
20
30
40
50
%
 o
f 
F
O
X
P
3
 d
e
m
e
th
y
la
ti
o
n
***
 
Figure 6: : 1α, 25-dihydroxyvitamin D3 significantly reduced the frequency of Foxp3+ T 
cells and the proportion of Foxp3 promoter demethylation A) Flow cytometric analysis of 
the percentage of Foxp3+ T cells induced by TGF-β + tRA in the presence or absence of 
VitD . B) Foxp3 protein expression was measured by flow cytometry and reported as median 
fluorescence intensity (MFI). C) The percentage of Foxp3 promoter demethylation in CD4+ 
T cells treated with TGF-β + tRA in the presence or absence of VitD. Results were expressed 
as means ±SEM. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, 
***p<0.001). 
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Figure 7: TGF-β plus tRA treatment enhanced the frequency of Foxp3+ memory T cells 
but not the proportion of Foxp3 promoter demethylation. A) Flow cytometric analysis of 
the percentage of Foxp3+ T cells induced by TGF-β + tRA treatment and control 
(Medium).B) The percentage of Foxp3 promoter demethylation in memory CD4+ T cells 
treated with TGF-β+ tRA. The values indicate the mean ± SEM of three separate 
experiments. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 8: Tregs induced by TGF-β plus tRA maintain their frequency and their Foxp3 
protein expression after restimulation. Naïve CD4+ T cells from two healthy donors were 
treated with TGF-β + tRA for five days. On day five, some wells were harvested and 
analysed by flow cytometry, the rest were restimulated with antiCD3/CD28 beads and IL-2 
(100 U/ml) for another five days. Cells were harvested on day ten of culture and analysed by 
flow cytometry for the frequency of Foxp3+ T cells and their Foxp3 expression. A) Flow 
cytometric analysis of the percentage of Foxp3+ T cells induced by TGF-β + tRA on day five 
and day ten of culture. B) Foxp3 protein expression was measured by flow cytometry and 
reported as median fluorescence intensity (MFI). 
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6.5   Discussion and Conclusions: 
Vitamin A and its metabolites are important anti-inflammatory molecules and play important 
roles in regulating different immune cells (315-318). The immune regulatory function of 
retinoids was clearly demonstrated in their abilities to induce and enhance Foxp3 expression 
in activated CD4+ T cells, particularly in the presence of TGF-β (319). This strategy of ex 
vivo generation of Foxp3+ Tregs showed promising results in mouse and human studies (56, 
74, 308, 313, 314). 
In this study, using flow cytometric analysis, semi-quantitative RT-PCR and Foxp3 promoter 
methylation assay, we clearly demonstrated that treating human naïve CD4+ T cells with 
TGF-β plus tRA significantly enhanced the frequency of Foxp3+ iTregs and the proportion of 
Foxp3 promoter demethylation. In addition, these iTregs displayed the highest levels of 
Foxp3 mRNA and protein expression. TGF-β plus tRA induced Tregs were also suppressive 
in vitro and maintained their Foxp3 protein expression for ten days after restimulation. 
Despite, increased Foxp3 promoter demethylation in TGF-β plus tRA induced Tregs, these 
human Foxp3+ iTregs displayed only partial demethylation. Furthermore, applying the same 
protocol to memory T cells did not improve the current protocol. Although TGF-β plus tRA 
co-treatment promoted Foxp3 expression in memory CD4+ T cells, the majority of these cells 
lack Foxp3 promoter demethylation. Furthermore, the addition of VitD reduced the frequency 
of Foxp3+ T cells and the proportion of Foxp3 promoter demethylation. 
We have shown that combining TGF-β and tRA induced and enhanced Foxp3 expression in 
naïve CD4+ T cells. This finding is in agreement with previous human studies (56, 306, 314, 
320). Kang et al. were the first to investigate the function of retinoids in the differentiation of 
human naïve CD4+ T cells (306).  These naïve CD4+ T cells were isolated from neonatal 
cord blood and activated in the presence and absence of tRA. In their study, tRA significantly 
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increased the numbers of Foxp3+ T cells and enhanced their Foxp3 protein and mRNA 
expression but, more importantly, it produced a synergistic effect on the induction of Foxp3 
when combined with TGF-β, and the TGF-β plus tRA treated T cells were even more 
suppressive in vitro than tRA treated or TGF-β treated T cells. Their study also indicated the 
conditions for optimal induction of Foxp3+ T cells by retinoids; these include the presence of 
IL-2 and activation of the co-stimulation receptor CD28 together with CD3 (306).  
These data were utilized by another study which investigated the effect of retinoids on adult 
peripheral blood naïve CD4+T cells with more emphasis on Tregs induced by TGF-β and 
tRA co-treatment (314).  According to the Wang et al study, combining TGF-β with tRA 
induced Foxp3+ Tregs with potent and stable suppressive activity, even after two weeks of 
culture (314).  Similarly, the TGF-β plus tRA induced Tregs from our study were suppressive 
and maintained their high level of Foxp3 protein expression after ten days of culture. 
However, these iTregs did not display a complete demethylation of the Foxp3 promoter. 
The Wang et al. study also evaluated the effect of retinoids on memory CD4+ T cells. In their 
study, memory T cells were resistant to Foxp3 induction by TGF-β, tRA or both and also 
failed to express significant suppressive activity. Furthermore, memory T cells inhibited 
Foxp3 expression and Treg conversion of naïve T cells treated with TGF-β and tRA, both in 
percentage and absolute number (314). The inhibitory effect of memory T cells on the 
induction of Tregs was also demonstrated in mouse studies (308, 313). In contrast, treating 
memory T cells with TGF-β plus tRA in our study significantly enhanced the frequency of 
Foxp3+ T cells, but more importantly, these cells were resistant to Foxp3 promoter 
demethylation. There are several possible explanations for this discrepancy.  First, the purity 
of the memory T cell population which raises the possibility of contamination with naïve 
CD4+ T cells. In their study, Flow sorting was used to isolate memory T cells while we used 
magnetic separation with >95% purity. This difference may suggest that their memory T cell 
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population is more pure.  Second, different timing of cell processing may contribute to this 
difference. Memory T cells from their study were analysed by flow cytometry on day ten of 
culture while memory T cells in our study were processed on day six. Although in both 
studies, memory CD4+ T cells were stimulated for five days with TGF-β and tRA, memory T 
cells in their study were rested in IL-2 for an additional 4-6 days before acquisition. This time 
difference could significantly affect Foxp3 expression and accordingly, the frequency of 
Foxp3+ T cells. However, a representative figure from their study showed that 16% of 
memory T cells treated with TGF-β plus tRA were CD25+Foxp3+ compared to 8% of 
memory T cells treated with medium. This indicates a positive response rather than resistance 
to Foxp3 induction. Despite, this discrepancy, both studies agree that naïve CD4+ T cells are 
more responsive to Foxp3 induction than memory T cells. The lack of suppression in their 
study and the resistance to Foxp3 promoter demethylation in our study, support the fact that 
memory T cells treated with TGF-β plus tRA are resistant to Treg conversion. 
The findings from the Wang et al. study were confirmed by a further study that evaluates the 
suppressive function of human TGF-β plus tRA iTregs in vivo (56). In the Lu et al. study, the 
combination of tRA and TGF-β markedly enhanced stable Foxp3 expression in human 
polyclonally stimulated naïve CD4+ T cells and produced Tregs with potent suppressive 
activity in vitro and in vivo. These iTregs displayed potent suppressive activity even at a ratio 
of only 3 per 100 responder T cells (1:32). 96% of responder T cells were suppressed at 1:4 
(Treg: responders) ratio and 67% were suppressed at 1:32. Furthermore, >80% of CD4+ T 
cells treated with TGF-β and tRA expressed Treg phenotype (CD4+CD25+CD127
lo
 Foxp3+). 
TGF-β plus tRA iTregs also produced low levels of proinflammatory cytokines and 
maintained the lymphoid homing receptors CD62L and CCR7. In their study, mice receiving 
human PBMCs with TGF-β plus tRA iTregs had delayed onset of xeno- graft-versus-host 
disease (GVHD) and better survival than those injected with PBMCs only. Furthermore, 
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these iTregs were resistant to the inhibitory effects of IL-6 and IL-1β in vivo. This protocol 
was utilised in our study to generate iTregs and our findings were in agreement with Lu et al. 
(56). However, the frequency of Foxp3+ T cells induced by TGF-β plus tRA in our study 
(mean ± SEM = 31% ± 6) was less than that obtained by the Lu et al. study.  Despite 
maintaining Foxp3 expression for ten days, these iTregs displayed only partial demethylation 
of the Foxp3 promoter and therefore, likely constitute an unstable Treg lineage. 
In vitro induction of Tregs by TGF-β plus tRA was recently evaluated in a group of lupus 
patients (320). In healthy controls, but not in lupus patients, TGF-β plus tRA treatment 
converted more than 30% of CD4+ T cells to suppressive Foxp3+ iTregs. Their study 
suggested that CD4+ T cells from lupus patients developed a defective response to the 
integrated signals from TGF-β and tRA (320). This defective response enhanced the 
production of non-suppressive CD25-Foxp3+ population rather than the functional 
CD25+Foxp3+ iTregs (320).  The results from their study indicate that CD4+ T cells state at 
the start of induction is affected by disease and can alter their response to different 
stimulations or protocols. 
Increasing evidence supports the immunomodulatory role of vitamin D, in particular its 
active metabolite VitD, which promote regulatory T cell populations (194). Activated T cells 
expressed vitamin D receptors (VDRs) and this suggests that VitD can act directly on 
activated T cells (321). Furthermore, treating human naïve CD4+ T cells with VitD induced 
Foxp3 expression and inhibited the production of proinflammatory cytokines (229). On the 
basis of these data, we studied the effect of combining VitD with TGF-β and tRA on Foxp3 
induction. The results were unexpected, as the addition of VitD significantly reduced the 
frequency of Foxp3+ T cells and the proportion of Foxp3 promoter demethylation. The effect 
of vitamin D receptor and retinoid receptor interactions on the regulation of gene expression 
has been evaluated in several reports (322-325). VitD inhibited the response to RA; this 
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inhibition is mediated by several, complex mechanisms. Vitamin D receptor (VDR) and 
retinoic acid (RA) receptors bind as heterodimers to retinoid X receptor (RXR). These 
heterodimers then bind to target DNA sequences and regulate gene expression. Subsequently, 
competition for binding to DNA may result in this inhibition (322). In addition, the binding 
of VDR/RXR heterodimers in a transcriptionally unproductive manner to certain RA 
response elements significantly contributes to this inhibitory response (324). Furthermore, 
VitD causes recruitment of co-repressors to a VDR target promoter and, therefore, inhibits 
gene transcription (325). These data indicate that combining VitD with tRA can inhibit 
increases in Foxp3 expression and demethylation as we observed. 
The molecular mechanisms underlying Foxp3 expression in Tregs induced by tRA or TGF-β 
plus tRA were investigated in human and murine studies (74, 306, 326). Histone modification 
and DNA methylation are two main epigenetic mechanisms that regulate gene expression by 
inducing changes in chromatin structure (17, 327). Kang et al. examined histone (H4) 
acetylation status of the Foxp3 promoter in tRA treated human naïve CD4+ T cells isolated 
from neonatal cord blood (306). In the Kang et al. study, tRA significantly enhanced histone 
acetylation of the Foxp3 promoter region and this promotes gene transcription. tRA also 
enhanced expression of  the retinoid nuclear receptor RARα in tRA treated cells (306). 
Similar findings were obtained in mouse Tregs induced by TGF-β plus tRA (326). RA 
stimulation of CD4+ T cells induced histone acetylation at the enhancer 1 region (CNS1) 
which contains a SMAD3 binding site, therefore, augmenting the TGF-β-dependent pathway 
by increasing the accessibility of phosphorylated SMAD3 to its binding site. Another murine 
study illustrated that tRA promotes TGF-β induced Tregs via histone methylation and 
acetylation in the promoter and conserved non-coding DNA sequence (CNS2) at the Foxp3 
locus (74). In the same study, evaluation of DNA methylation status  of CpG motifs in 
conserved non-coding DNA sequence (CNS3) of the Foxp3 locus revealed no significant 
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alteration after the addition of tRA (74). These data suggest that induction and maintenance 
of Foxp3 expression by tRA is controlled by histone modifications. However, these 
conclusions came mainly from murine studies and one human study that evaluated only 
histone acetylation in tRA treated naïve CD4+ T cells isolated from neonatal cord blood. In 
our study, human peripheral naïve CD4+ T cells were stimulated with TGF-β plus tRA then 
evaluated for Foxp3 promoter demethylation. TGF-β plus tRA treatment induced 
demethylation in a significant proportion of CD4+ T cells and these Foxp3+ iTregs displayed 
partial demethylation. This suggests that tRA also induced Foxp3 expression by enhancing 
Foxp3 promoter demethylation in addition to histone acetylation reported in previous studies. 
 In conclusion, we have demonstrated that treating human naïve CD4+ T cells with TGF-β 
plus tRA markedly enhanced Foxp3 expression, suppressive activity and Foxp3 promoter 
demethylation. These Foxp3+ Tregs maintained their Foxp3 expression in culture after 
restimulation but displayed only partial demethylation of the Foxp3 promoter indicating 
unstable Foxp3 expression. Accordingly, this protocol may not be suitable for Treg-based 
cellular therapy. However, more studies are required to confirm the methylation results 
obtained from this study and evaluating the methylation status of other regulatory regions 
(CNS) at the Foxp3 locus could provide an indication of the overall methylation changes 
induced by tRA.  
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Generation of human Foxp3+ iTregs with rapamycin. 
 
7.1   Summary: 
Background 
Rapamycin (Rapa) is an immunosuppressant drug with immunomodulatory properties. 
Several studies have revealed its positive effects on the number and function of regulatory T 
cells in vitro and in vivo. It has been successfully used to induce Foxp3 expression and 
suppressive function in CD4+ T cells. These Rapa-induced Tregs may present a suitable 
population for Treg-based cellular therapy. However, information regarding the methylation 
status of their Foxp3 promoter under Rapa treatment, which is essential for determining 
functional stability, is not available. 
Aim 
To evaluate the utility and stability of Foxp3+ Tregs induced by Rapa protocol using the 
Foxp3 methylation assay.  
Methods 
Human naïve CD4+ T cells from healthy donors were cultured with Rapa alone or in 
combination with TGF-β or tRA for five days in the presence of IL-2 and anti-CD3/CD28 
beads. The cells were then harvested and evaluated for Foxp3 protein expression and Foxp3 
promoter methylation. To evaluate the effect of combined treatments on de novo Foxp3 
expression, VitD was included. Memory CD4+ T cells were also treated with Rapa and 
evaluated for Foxp3 expression and methylation. 
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Results 
Treating human naïve CD4+ T cells with Rapa and TGF-β significantly enhanced the 
frequency of Foxp3+ iTregs when compared to control (p<0.05) and Rapa alone (p<0.05). 
These Foxp3+ iTregs also expressed high levels of Foxp3 protein (p<0.05). In addition, Rapa 
plus TGF-β treatment significantly enhanced the proportion of Foxp3 promoter 
demethylation (p<0.05), but these Foxp3+ iTregs exhibited < 50% demethylation of the 
Foxp3 promoter. In contrast, preliminary data showed that memory T cells treated with Rapa 
plus TGF-β failed to induce Foxp3 expression and promote Foxp3 promoter demethylation. 
The addition of VitD to Rapa also enhanced Foxp3 expression, but not the proportion of 
Foxp3 promoter demethylation. 
Conclusion 
Co-treatment with Rapa and TGF-β successfully enhanced Foxp3 expression and Foxp3 
promoter demethylation in naïve CD4+ T cells. However, these iTregs exhibited partial 
demethylation of the Foxp3 promoter presenting an unstable population for Treg 
immunotherapy.      
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7.2   Introduction: 
Rapa is a macrolide antibiotic that is produced by the bacterium Streptomyces hygroscopicus 
(328). It is also a potent immunosuppressant that has been widely used in the prevention of 
transplant rejection (329). Rapa functions as a kinase inhibitor, it binds to a highly conserved 
cytoplasmic receptor, FK506- binding protein-12 to form a complex that subsequently, 
inhibits a serine/threonine protein kinase, known as the mammalian target of Rapa (mTOR) 
(328, 330). The PIK3-AKT-mTOR signaling pathway regulates several immune functions, 
such as proliferation, activation and  effector functions of different immune-cells (331). Its 
inhibition impairs dendritic cell (DC) differentiation and function (331). In addition, it blocks 
proliferation, migration and cytokine production of conventional T cells. (331-333).  
In vitro and in vivo studies showed that Rapa inhibited the expression of costimulatory 
molecules, and production of IL-12 /TNF, and impaired antigen uptake by DCs (334-336). 
This effect promotes the development of tolerogenic DCs. For instance, injection of Rapa-
conditioned DCs pulsed with allo-antigen prior to transplantation, prolonged the survival of a 
heart allograft in mice (337). These Rapa induced tolerogenic DCs exhibited an immature 
phenotype and expressed low levels of T cell costimulatory molecules in both mice and 
humans (335). Furthermore, treating human DC cultures with Rapa promoted the 
development of tolerogenic DCs that had the capacity to expand and induce suppressive 
Foxp3+ Tregs in T cell culture (338). Rapa also had a profound effect on conventional T 
cells,  blocking cell-cycle progression during T cell activation, preventing the expression of 
homing receptors necessary for T cell migration to the target tissue and inducing T cell 
anergy by preventing the down-regulation of genes involved in the development of anergy 
(331).  
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However, regulatory T cells seem to respond differently to the effect of mTOR inhibition 
(339). Studies showed that Tregs maintained their function and viability in the presence of 
Rapa (339-341). Human Tregs, treated with Rapa continued to suppress T cell proliferation in 
vitro (340). Treating CD4+ T cell culture with Rapa induced expansion and promoted 
survival of Foxp3+ Tregs population (341, 342). Similarly, treating kidney transplant 
recipients with Rapa enhanced the frequency of Foxp3+ Tregs (343). The expansion effect 
induced by Rapa could also be explained by the increase in peripheral conversion of 
conventional T cells into Foxp3+ Tregs. In vitro stimulation of human circulating CD4+ T 
cells with Rapa produced a Foxp3+ T cell population with suppressive activity (344).  Recent 
reports found that Foxp3 expression is associated with induction of PIM kinases which 
mediate resistance to Rapa- inhibition and promote Treg survival and expansion (345, 
346).These data indicate that PIK3-AKT-mTOR signaling pathway is involved in regulating 
Foxp3 expression. This pathway also inhibits the activation of SMAD3 which binds to the 
Foxp3 enhancer region to induce Foxp3 expression after stimulation with TGF-β (347). 
Therefore, blocking this pathway with Rapa favours Foxp3 up-regulation. This information 
supports the immunomodulatory role of Rapa and provides a strong basis for it use in the 
generation of Foxp3+ Tregs in vitro.  
Rapa successfully converted murine naïve CD4+ T cells into Foxp3+ T cells that displayed 
suppressive activity and maintained their antigen specificity in vivo and in vitro (348, 349). 
Rapa also induced long term skin allograft survival and converted a significant portion of 
transferred naive T cells into Foxp3+ Tregs, which were enriched in the graft-draining lymph 
of recipient mice (349). Similarly, the ability of Rapa to induce Foxp3 expression and 
suppressive activity in human CD4+ T cells were demonstrated in several reports (57, 350-
352). Human polyclonal Foxp3+ iTregs with suppressive activity were effectively induced in 
vitro with Rapa and IL-2 (350). In a different study, adoptive transfer of human Foxp3+ 
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Tregs, induced by Rapa and TGF-β co-treatment, prolonged survival of a xenogeneic GVHD 
model (57). Furthermore, treating human natural Tregs with Rapa and tRA enhanced the 
percentage of Foxp3+ Tregs with TSDR demethylation (351). 
These human Rapa induced Tregs showed promising results and may have therapeutic 
potential for Treg-based cellular therapy. Here, we further evaluate the efficiency of Rapa in 
promoting the generation of stable Foxp3+ Tregs from peripheral naïve CD4+ T cells by 
measuring their Foxp3 methylation status. This will provide a better indication of Foxp3 
stability in these in vitro induced Tregs. 
7.3   Protocol: 
7.3.1   Protocol Summary: 
Human naïve CD4+ T cells were separated from peripheral blood and co-cultured with 
different combinations of TGF-β, tRA and Rapa for five days to generate Foxp3+ regulatory 
T cells. The cells were then harvested and evaluated by flow cytometric and genetic assays. 
7.3.2   Method: Generation of human Foxp3+ iTregs with Rapa. 
Purified naïve CD4+ T cells were isolated  and activated with anti-human CD3/CD28 beads  
10:1 (ten beads to 1 cell) in  TCM supplemented with IL-2 (100 U/ml).  After 48 hours, old 
media was replaced with fresh culture media supplemented with IL-2 (100 U/ml), TGF-β (5 
ng/ml), tRA (100 nM) and Rapa (100 nM) in different combinations. The cells were 
stimulated for five days in U-bottomed 96 well plates (BD Biosciences) in a final volume of 
200 µl of tissue culture medium. Fresh culture medium with the corresponding additives was 
replaced after 48hrs. The populations studied were naïve CD4+ T cells activated with IL-2 
(Medium), naïve CD4+ T cells activated with IL-2 and Rapa (Rapa),  naïve CD4+ T cells 
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activated with IL-2 , Rapa and TGF-β (TGFβ + Rapa)  and naïve CD4+ T cells activated with 
IL-2, Rapa and tRA (tRA + Rapa). VitD (2 nM) was added to Rapa in another experiment. 
For comparison purposes, purified human memory CD4+CD45RO+ T cells were cultured as 
naïve CD4+ T cells using the same protocol described above. 
7.3.3   Experiments: 
Five experiments from three healthy adult donors were performed using the Rapa protocol.  
To compare the effect of Rapa treatment, all results were combined and analysed against 
control (Medium). An additional experiment was performed to evaluate the effect of VitD in 
combination with Rapa. Due to the length and complexity of these experiments, a single 
experiment was performed to evaluate whether additional combination or changes to the 
original protocol are worth doing or investigating further. Although not suitable for statistical 
analysis, these additional experiments provide important information and therefore were 
included under supplementary results. 
7.4   Results: 
7.4.1   Frequency and methylation status of CD4+CD25+Foxp3+ iTregs: 
Results from all experiments revealed a significant increase in the frequency of Foxp3+ Tregs 
induced by the following treatments; Rapa (p<0.05), TGFβ + Rapa (p<0.05) and tRA + Rapa 
(p<0.05) when compared to control (Medium) (Figure 1A). In addition, the mean frequency 
of Foxp3+ Tregs generated with TGFβ + Rapa combined treatment (35% ± 7) was 
significantly higher (p<0.05) than that produced by Rapa treatment alone (15%  ± 2). Foxp3 
protein expression (MFI) was also significantly increased in Tregs induced by Rapa (p<0.05), 
TGFβ + Rapa (p<0.05 and tRA + Rapa (p<0.05) (Figure 1B). 
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However, the proportion of Foxp3 promoter demethylation was only significantly enhanced 
in naïve CD4+ T cells treated with TGFβ + Rapa (p<0.05) (Figure 1C). The mean percentage 
of Foxp3 demethylation was 30% ± 3 for TGFβ + Rapa co-treatment. Evaluation of the 
degree of demethylation in Foxp3+ T cell populations generated from TGF-β + Rapa or tRA+ 
Rapa treatments, revealed no significant difference. Both populations displayed less than 
50% demethylation of the Foxp3 promoter (Figure 2). The mean percentage of Foxp3 
demethylation was 32%  ±  8 in TGF-β + Rapa induced Foxp3+ Tregs and 33%  ±  9 in tRA 
+ Rapa induced Foxp3+ Tregs. 
 These data suggests that treating naïve CD4+ T cells with Rapa and TGF-β in vitro, 
significantly enhanced Foxp3 expression and Foxp3 promoter demethylation.  
7.4.2   Supplementary results: 
7.4.2.1   The effect of combining different agents on Foxp3 expression and methylation 
status: 
Naïve CD4+ T cells were treated with Rapa, tRA and TGF-β separately, or in combination, 
for five days as described in the method section. This preliminary experiment revealed the 
presence of a synergistic effect between Rapa and TGF-β or tRA. This effect was more 
pronounced on the frequency of Foxp3+ T cells generated after such treatment (Figure 3). 
Rapa treatment alone induced only 13% of CD4+ T cells to express a Treg phenotype, but in 
combination with TGF-β, 49% were Foxp3 positive and this figure increased to 59% when 
combined with tRA. Foxp3 protein expression was also enhanced, but to lesser extent. 
However, these combinations failed to enhance the proportion of Foxp3 promoter 
demethylation. 
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7.4.2.2   The effect of adding 1α, 25-dihydroxyvitamin D3: 
The effect of VitD was evaluated in a separate experiment. VitD (2 nM) was added to naïve 
CD4+ T cells on day two and day four of culture, alone or in combination with Rapa. VitD 
alone had no significant effect on Foxp3 expression or demethylation, but in combination 
with Rapa, it promoted Foxp3 protein expression and enhanced the frequency of Foxp3+ T 
cells (Figure 4). Similar to other combinations, adding VitD did not enhance the proportion of 
Foxp3 promoter demethylation. 
7.4.2.3   Memory CD4+CD45RO+ versus Naïve CD4+CD45RA+ T cells: 
Rapa was used to evaluate the ability of memory CD4+ T cells to up regulate Foxp3 
expression and generate iTregs. Preliminary results showed that treating memory CD4+ T 
cells with Rapa and tRA  produced a small increase (11%) in the percentage of Foxp3+ T 
cells when compared to control (Medium) (Figure 5). This is in contrast to naïve CD4+ T 
cells, where the same treatment produced a marked increase (54%) in the percentage of iTreg 
when compared to control (Medium). Interestingly, memory CD4+ T cells treated with 
different conditions had a higher percentage of Foxp3 promoter demethylation than naïve 
CD4+ T cells despite their poor response to Foxp3 induction. These findings indicate that 
memory T cells are more resistant to induction of Foxp3 expression and Foxp3 promoter 
demethylation than naïve CD4+ T cells. These preliminary data also suggest that not all 
induced Foxp3+ T cells (TGF-β + Rapa or tRA + Rapa) had demethylated Foxp3 promoter. 
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Figure 1: Co-treatment with Rapa and TGF-β produced a significant increase in the 
frequency of Foxp3+ T cells, their Foxp3 protein expression and the proportion of 
Foxp3 promoter demethylation. A)  The percentage of Foxp3+ induced Tregs generated 
from different treatment conditions measured by flow cytometry. B) Foxp3 protein 
expression was measured by flow cytometry and reported as median fluorescence intensity 
(MFI). C) The percentage of Foxp3 promoter demethylation in CD4+ T cells treated for all 
the different treatment conditions. Results were expressed as means ± SEM. p-values <0.05 
were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 2: Foxp3 demethylation levels in Foxp3+ Tregs induced by tRA plus Rapa and 
TGF-β plus Rapa. There was no significant difference between both treatments on the level 
of Foxp3 demethylation within the Foxp3+ T cell population. Results were expressed as 
mean ± SEM. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 3: Combining different agents has a positive effect on inducing Foxp3 protein 
expression, but not Foxp3 promoter demethylation. A)  The percentage of Foxp3+ 
induced Tregs generated from different treatment conditions measured by flow cytometry. B) 
Foxp3 protein expression was measured by flow cytometry and reported as median 
fluorescence intensity (MFI). C) The percentage of Foxp3 promoter demethylation in CD4+ 
T cells treated for all the different treatment conditions. 
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Figure 4:  Co-treatment with Rapa and 1α, 25-dihydroxyvitamin D3 enhanced Foxp3 
protein expression, but not the proportion of Foxp3 promoter demethylation. A)  The 
percentage of Foxp3+ induced Tregs generated from different treatment conditions measured 
by flow cytometry. B) Foxp3 protein expression was measured by flow cytometry and 
reported as median fluorescence intensity (MFI). C) The percentage of Foxp3 promoter 
demethylation in CD4+ T cells treated for all the different treatment conditions. 
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Figure 5: Memory CD4+ T cells are more resistant to Foxp3 induction and displayed 
higher proportion of Foxp3 promoter demethylation than naïve CD4+ T cells. A) Flow 
cytometric analysis of the percentage of Foxp3+ T cells in naïve and memory CD4+ T cells 
treated with Rapa, TGF-β and tRA in different combinations. B) The percentage of Foxp3 
promoter demethylation in naïve and memory CD4+ T cells treated for all the different 
treatment conditions. 
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7.5   Discussion and Conclusions: 
Ex vivo expansion of thymic (natural) Tregs or in vitro generation of Foxp3+ iTregs from 
conventional CD4+ T cells present the two main practical therapeutic options for a future 
Treg-based cellular therapy. Indeed, studies showed a significant impact of Rapa on both 
approaches: Rapa effectively expanded human thymus-derived Tregs ex vivo and successfully 
induced suppressive activity in human peripheral CD4+ T cells in vitro (57, 350, 351, 353, 
354).    
In this study, using flow cytometric analysis and a Foxp3 promoter methylation assay, we 
demonstrated that co-treatment with TGF-β and Rapa significantly enhanced the frequency of 
Foxp3+ iTregs and the proportion of Foxp3 promoter demethylation in treated human naïve 
CD4+ T cells. In addition, these iTregs displayed a significant increase in Foxp3 protein 
expression. However, Rapa plus TGF-β induced Tregs displayed only partial demethylation 
of the Foxp3 promoter (<50%).  Treating naïve CD4+ T cells with Rapa plus tRA also 
enhanced the frequency of Foxp3+ T cells and their Foxp3 protein expression, but the 
proportion of Foxp3 promoter demethylation did not differ significantly from that of control 
(Medium). Furthermore, applying the same protocol on memory T cells did not improve the 
current protocol. Co-treatment with Rapa and TGF-β failed to enhance the frequency of 
Foxp3+ memory T cells (iTregs). In addition, the proportion of Foxp3 promoter 
demethylation in treated memory T cells remained unchanged when compared to control 
(Medium). Although combining Rapa with VitDenhanced the frequency of Foxp3+ T cells, 
the proportion of Foxp3 promoter demethylation remained low. Taken together, these data 
indicate that only Rapa plus TGF-β treatment enhanced Foxp3 expression and Foxp3 
promoter demethylation in treated T cells, but these induced Tregs remained partially 
demethylated and thereby, their Foxp3 expression is transient. 
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Our results showed that Rapa plus TGF-β treatment significantly increased the proportion of 
Foxp3+ T cells (49%) when compared to Rapa (13%) or TGF-β (22%) separately. This 
finding is in agreement with previous reports (57, 355). The synergistic effect of Rapa and 
TGF-β was initially demonstrated in murine CD4+ T cells (355). This group used a mutant 
TGF-β1/Fc fusion protein and Rapa for the induction of Tregs. 30 % ± 5 of murine naïve 
CD4+ T cell stimulated with TGFβ1/ Fc and Rapa were Foxp3 positive  compared to 16% ± 
4 from TGF-β1/Fc only and 7% ± 2  form Rapa only (355). Similarly, this combination 
resulted in in vivo conversion of naive CD4+ T cells (25% ± 2) into Foxp3+ Tregs and 
permanent survival of pancreatic islet allograft in a mouse model (355). 
 A recent study also revealed that Rapa plus TGF-β induced stable Foxp3 expression and 
suppressive function in human naïve CD4+ T cells (57). In their study, Rapa alone did not 
enhance the frequency of CD25+Foxp3+ T cells (11% ± 1), but when combined with TGF-β, 
it produced a synergistic effect (56% ± 15 CD25+Foxp3+). Likewise, our results showed 
similar synergistic effect on the frequency of Foxp3+ T cells (35% ± 7) after combining Rapa 
with TGF-β. However, Rapa alone also enhanced the frequency of Foxp3+ T cells and their 
Foxp3 protein expression. This finding is consistent with study of Long et al. that showed 
significant increases in the frequency of Foxp3+ expressing cells and their suppressive 
activity after Rapa treatment (350).  In addition, human Rapa plus TGF-β iTregs potently 
suppressed T cell proliferation 79%  ± 6  at a 1:8 (iTreg: PBMCs) ratio in vitro and 
significantly prolonged survival in a xenogeneic GVHD model (57). Furthermore, repetitive 
stimulation of Rapa plus TGF-β iTregs showed only a small percentage of IFN-γ and IL-17 
secreting cells, suggesting a stable regulatory phenotype (57). These results indicate that co-
treatment with Rapa and TGF-β induced functional Foxp3+ Tregs with potent suppressive 
activities in vitro and in vivo. This is consistent with our findings as Rapa plus TGF-β 
treatment promoted the generation of Foxp3+ T cells with enhanced demethylation of the 
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Foxp3 promoter which was  shown to correlate with the suppressive abilities of regulatory T 
cells (122). However, the partially demethylated Foxp3 promoter in these iTregs suggests the 
presence of a functionally unstable regulatory T cell population despite being suppressive and 
expressing a Treg phenotype. The expansion capacity of Rapa plus TGF-β iTregs was also 
evaluated in the Hippen et al. study. This group generated 240 x10
9 
 Rapa plus TGF-β iTregs 
from CD4+ T cells  in less than two weeks using a single apheresis blood unit, thus providing 
a potentially therapeutic protocol(57). 
The molecular mechanism underlying the synergistic effect of Rapa and TGF-β on Foxp3 
expression may involve SMAD3 activation. Stimulation of CD4+ T cells with TGF-β 
induced activation of the transcription factor SMAD3 which binds to Foxp3 enhancer region 
and promotes Foxp3 transcription (131). Signaling through the AKT-mTOR pathway inhibits 
SMAD3 phosphorylation and prevents Foxp3 transcription. Therefore, blocking the mTOR 
pathway by Rapa removes this inhibition from SMAD3 favouring Foxp3 induction (347). 
Furthermore, the induction of Foxp3 by Rapa is also believed to be in part, TGF-β dependent, 
as mTOR inhibitors was shown to increase cellular responsiveness and sensitivity to the 
baseline levels of TGF-β present in the cultures and induce Foxp3 expression even in the 
absence of exogenous TGF-β supply (356). In addition, inhibition of the mTOR pathway 
induces phosphorylation of FOXO transcription factors which subsequently promote Foxp3 
expression (132). Rapa treatment also induced histone H3 lysine 4 (H3K4me2 and 3) 
methylation at the Foxp3 promoter, promoting Foxp3 transcription. This suggests that 
induction of Foxp3 by Rapa is likely to involve histone modifications rather than DNA 
demethylation (39). However, we clearly showed that in combination with TGF-β, Rapa 
enhanced demethylation of the Foxp3 promoter. 
Our preliminary data also demonstrated that memory CD4+ T cells were resistant to Foxp3 
induction and Foxp3 promoter demethylation even after treatment with Rapa plus TGF-β. 
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The resistance of memory T cells to Foxp3 induction has been reported previously and 
moreover, the presence of memory T cells in unfractionated CD4+ T cell culture was shown 
to  inhibit Foxp3 induction in naïve T cells (314). However, Hippen et al. found that 
induction of Foxp3 expression and suppressive function in naïve CD4+ T cells by Rapa plus 
TGF-β were not affected by the presence of memory CD4+ T cells (57). This group also 
found that there was no significant difference in the frequency of Foxp3+ T cells and 
suppressive activity induced by Rapa plus TGF-β treatment between CD4+ T cells and naïve 
CD4+ T cells. This observation was attributed to the inhibitory effect of Rapa on effector T 
cells which occurs through inhibiting IFN-γ secretion and preventing SMAD7 down-
regulation of TGF-β signaling (57). This immunomodulatory effect of Rapa on effector or 
memory T cells promotes Foxp3 induction in naïve CD4+ T cells and development of 
Foxp3+ iTregs.  The high proportion of Foxp3 promoter demethylation in memory T cells 
may indicate the presence of a small percentage of memory Foxp3+ regulatory T cells which 
is a subset of CD4+ memory T cells (357). 
VitD, the active metabolite of vitamin D plays an important role in modulating the immune 
system (358).  VitD directly regulates the expression of the Foxp3 gene in human CD4+ T 
cells and promotes Foxp3 expression and suppressive function in CD4+ T cells (224). Our 
preliminary results showed that adding VitD to Rapa enhanced the frequency of Foxp3+ T 
cells and promoted Foxp3 expression in naïve CD4+ T cells when compared to Rapa or VitD 
separately. This indicates that VitD and Rapa positively promote Foxp3 expression. These 
two agents may regulate Foxp3 expression by two separate mechanisms or integrate in one 
single mechanism. Further studies are required to determine the exact molecular mechanism. 
The lack of significant changes in Foxp3 promoter demethylation of Rapa plus VitD iTregs 
suggests that Foxp3 expression is transient and is induced through a mechanism that does not 
involved Foxp3 demethylation. 
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In conclusion, we have demonstrated that Rapa alone, and in combination with TGF-β or tRA 
can promote the expression of Foxp3 in naïve CD4+ T cells. However, only in combination 
with TGF-β, Rapa did enhance Foxp3 promoter demethylation in a significant proportion of 
cells, yet these cells were only partially demethylated. Therefore, these iTregs remain 
functionally unstable and not yet suitable for clinical use in Treg immunotherapy. However, 
more studies are needed to confirm these findings and to evaluate the methylation status of 
other conserved region in the Foxp3 gene, particularly the TSDR. In addition, exploring the 
molecular mechanisms underlying Foxp3 induction by Rapa plus VitD and Rapa plus tRA 
would enhance our understanding and improve future Foxp3+ Treg generation strategies. 
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Generation of human Foxp3+ iTregs using 5-Aza 2’ deoxycytidine (5Aza). 
 
8.1   Summary: 
Background 
Epigenetic mechanisms play an important role in regulating Foxp3 gene expression. 
Demethylation of regulatory elements in the Foxp3 locus is one suggested mechanism, 
proposed to control the stability of Foxp3 expression. Therefore, inhibiting DNA methylation 
by a hypomethylating agent such as 5-Aza 2’ deoxycytidine (5Aza) may provide a feasible 
method for generating stable Tregs in vitro. This demethylating agent was evaluated in 
several studies that claimed its effectiveness in stabilising Foxp3 expression. However, the 
level of Foxp3 demethylation induced by this drug was not clearly identified in murine 
studies and was not reported in previous human studies. 
Aim 
Here we assess the capacity of 5Aza to induce complete demethylation of the Foxp3 
promoter and produce stable Foxp3+Tregs in vitro. 
Methods 
Human naïve CD4+ T cells from healthy donors were cultured with 5Aza and stimulated for 
5 days in the presence of IL-2 and anti-CD3/CD28 beads. To evaluate the effect of combined 
treatments on de novo Foxp3 expression, TGF-β or tRA were included. The cells were 
harvested and evaluated for Foxp3 protein expression and Foxp3 promoter demethylation. 
Results 
5Aza alone, or in combination with TGF-β or tRA, produced significant increases in the 
frequency of Foxp3+iTregs: (p<0.001), (p<0.001), (p<0.01) respectively. These iTregs also 
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displayed high levels of Foxp3 protein expression (p<0.05) and Foxp3 mRNA expression 
(p<0.05). However, only T cells treated with 5Aza alone or 5Aza plus tRA induced a 
significant increase in Foxp3 promoter demethylation: (p<0.01), (p<0.05) respectively when 
compared to control. These 5Aza-induced Tregs exhibited less than 50% demethylation of 
the Foxp3 promoter. 
Conclusion 
5Aza successfully enhanced Foxp3 expression in naïve CD4+ T cells, but the Foxp3 
promoter was not fully demethylated in the induced Tregs. Further investigation of the use of 
this agent is warranted. 
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8.2   Introduction:  
Regulation of Foxp3 expression involves several molecular mechanisms including epigenetic 
modifications. DNA methylation is one major epigenetic control mechanism, particularly 
involved in regulating the transcriptional activity of the Foxp3 gene. The human Foxp3 gene 
region contains conserved non coding sequence regions that are rich in CpG motifs. The 
methylation status of these regions proved to be crucial for Foxp3 transcriptional activity (41, 
44). Demethylation of CpG motifs in the Foxp3 promoter and Treg specific demethylated 
region (TSDR) promotes gene activation and transcription. This epigenetic imprinting was 
proposed to be the key regulator for inducing stable Foxp3 expression. Therefore, 
manipulating these conserved non-coding regions in the Foxp3 gene using hypomethylating 
agents or drugs such as 5Azacould present a smart method to generate and establish a 
permanent Tregs lineage in vitro.  
5Aza is a cytotoxic drug also known as decitabine. It is an analogue of cytosine. This drug is 
converted into nucleotide triphosphates which are then incorporated into replicating DNA, 
resulting in replication-dependent global demethylation (17). It acts by inhibiting DNA 
methylation allowing expression of methylated genes (359). It interferes with de novo DNA 
methylation during cellular replication by disturbing the function of DNA methyltransferase 
1 (DNMT1). Inhibition of DNMT1 activity induces passive demethylation which remodels 
and opens chromatin structure allowing transcription factors to bind to the gene promoter 
region promoting gene expression (360, 361). It demethylates the upstream enhancer of the 
Foxp3 gene, which then facilitates the binding of positive transcription factors leading to 
active transcription of Foxp3 protein. These data indicate that 5Aza is more effective when it 
is used in low doses and during DNA replication. 
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 5Aza has been claimed to induce stable Foxp3 expression in several studies (41, 150, 151, 
362). In vitro stimulation of murine naïve CD4+ T cells with 5Aza successfully induced and 
stabilized Foxp3 expression. This was supported by efficient TSDR demethylation in Foxp3+ 
Tregs generated with 5Aza (41). In addition, restimulation of 5Aza induced Foxp3+ Tregs 
promoted Foxp3 expression in 87% of the cells compared to 17% in TGF-β induced Foxp3+ 
Tregs (41). This indicates that Foxp3 expression is more stable in 5Aza-induced Tregs. 
Similar findings were reported in another murine study which showed complete 
demethylation of the upstream Foxp3 enhancer in naïve CD4+ T cells treated with 5Aza 
(151). Furthermore, naïve CD4+ T cells treated with 5Aza expressed suppressive activity in 
vitro and produced a high level of Foxp3 protein expression (362). Treating human activated 
CD4+ T cells with 5Aza also produced a stable population of Foxp3+CD4+ T cells and  
induced significant expression of Foxp3 protein (150). These findings support a role for 5Aza 
intervention in the induction and maintenance of Foxp3 gene expression.  
However, in human studies, 5Aza-induced Tregs were not evaluated by Foxp3 methylation 
assay and there is no current application of this drug in Treg based cellular therapies (150, 
151).  Hence, this study aims to investigate the ability of this drug to generate a stable 
Foxp3+ Treg population with complete demethylation of the Foxp3 promoter from human 
naïve CD4+ T cells. 
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8.3   Protocol: 
8.3.1   Protocol summary: 
Human naïve CD4+ T cells were separated from peripheral blood and co-cultured with 
different combinations of IL-2, TGF-β , tRA and 5Aza for 5 days to generate Foxp3+ 
regulatory T cells. The cells were then harvested and evaluated by flow cytometric and 
genetic assays. 
8.3.2   Method: Generation of human Foxp3+ iTregs with 5-Aza 2’ deoxycytidine.  
Purified naïve T cells were cultured with anti-human CD3/ CD28 beads at 1:1 ( one bead  to 
one cell) ratio in  TCM supplemented with IL-2 (100 U/ml) , TGF-β (5 ng/ml) , tRA (100 
nM) and 5-Aza (5 µM) in different combinations. 5Aza was removed after 24 hours of 
culture and the cells were cultured for another 4 days in the presence of IL-2, anti-CD3/CD28 
beads, tRA and TGF-β. Fresh tissue culture medium with the corresponding supplements was 
replaced after 48 hours of culture. The cells were cultured in U-bottomed 96 well plates in a 
final volume of 200 µl of tissue culture medium. The populations studies were naïve CD4+ T  
cells activated with IL-2 (Medium), naïve CD4+ T cells activated with IL-2 and 5Aza( 5Aza ) 
, naïve CD4+ T cells activated with IL-2, TGF-β and  5Aza (TGF-β + 5Aza ),  naïve CD4+ T 
cells activated with IL-2 and TGF-β (TGFβ) and naïve CD4+ T cells activated with IL-2 , 
5Aza and tRA (tRA+ 5Aza).  
Some experiments had minor changes to the above protocol for instance, 5Aza was added on 
day 0 and day 2. In another experiment, T cell depleted irradiated PBMCs were used as 
antigen presenting cells (APCs). These APCs were prepared from PBMCs using an EasySep 
Human CD3+ T cell kit (positive selection-STEMCELL Technologies, VIC, Australia). T 
cell depleted PBMCs were gamma irradiated (4000 Rad) and then added to the T cells 
culture.   
186 
 
For comparison purposes, purified human memory CD4+CD45RO+ T cells were cultured 
with 5Aza using the same protocol described for naïve CD4+ T cells. Cells from all culture 
conditions were harvested and evaluated by flow cytometric and genetic assays 
8.3.3   Experiments: 
A total of seven experiments from five healthy adult donors was performed using a 5Aza 
protocol. To compare the effect of 5Aza treatment, all results were combined and analysed 
against control (Medium). Due to the length and complexity of these experiments, a single 
experiment was performed to evaluate whether additional combination or changes to the 
original protocol might increase Foxp3 promoter demethylation or protein production. 
Although not suitable for statistical analysis, these additional experiments provide important 
information and therefore were included under supplementary results 
8.4   Results: 
8.4.1   Frequency and methylation status of Foxp3+ Tregs induced by 5Aza treatment: 
Naïve CD4+ T cells were treated with a range of concentrations from 0.25 to 10 µM of 5Aza. 
Results indicated that treating naïve CD4+ T cells with 5 µM of 5Aza produced the highest 
level of Foxp3+ expressing cells (30%) with the maximum median fluorescence intensity 
(MFI) as determined by flow cytometric analysis (Figure 1). An initial experiment was 
performed to compare the effect of treating naïve T cells with 5Aza alone versus combining it 
with other reagents such as tRA or TGF-β on the level of Foxp3 expression and gene 
demethylation. These initial results suggested that combining 5Aza with TGF-β produced the 
highest frequency of Foxp3+ iTregs that expressed the highest level of Foxp3 mRNA 
transcripts but the lowest proportion of Foxp3 promoter demethylation (Figure 2).  
 Results from all experiments revealed a significant increase in the mean frequency of 
Foxp3+ Tregs induced by 5Aza treatment (p<0.001), TGF-β + 5Aza co-treatment (p<0.001), 
TGF-β (p<0.05) and tRA + 5Aza co-treatment (p<0.01) when compared to control (Medium) 
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(Figure 3-A). Furthermore, treating naive CD4+ T cells with a combination of TGF-β and 
5Aza produced a significantly higher frequency (p<0.01) of Foxp3+ iTregs than that 
produced by 5Aza treatment alone. Similarly, Foxp3 protein expression (MFI) was 
significantly enhanced in Tregs induced by 5Aza (p<0.01), TGF-β + 5Aza co-treatment 
(p<0.05), TGF-β (p<0.05) and tRA + 5Aza co-treatment (p<0.05) (Figure 3-B). Tregs 
induced by 5Aza and TGF-β displayed higher level of Foxp3 protein expression (p<0.05) 
than Tregs induced by 5Aza alone. This combination produced an enhancing effect on the 
level of Foxp3 protein expression, but failed to induce statistically significant changes in the 
level of Foxp3 promoter demethylation. This is in contrast to 5Aza treatment, which 
significantly enhanced the proportion of Foxp3 promoter demethylation (p<0.01) and their 
Foxp3 protein expression (p<0.01) (Figure 3-C). 
Similar changes were seen with 5Aza plus tRA co-treatment of naïve CD4+ T cells. This 
combination produced significant increases in the frequency of Foxp3+ iTregs (p<0.01), the 
proportion of Foxp3 promoter demethylation (p<0.05) and the level of Foxp3 protein 
expression (p<0.05) (Figure 3). However, there was no evidence that tRA plus 5Aza co-
treatment is better than 5Aza treatment alone. Evaluation of the levels of demethylation in the 
Foxp3+ T cells populations generated with 5Aza or 5Aza and tRA co-treatment, showed no 
significant difference (Figure 4). Both populations displayed less than 50% demethylation of 
the Foxp3 promoter. The mean percentage of Foxp3 demethylation was 38% ± 2 for 5Aza 
induced Foxp3+ T cell and 36% ± 1 for 5Aza+tRA induced Foxp3+ T cells. 
8.4.2   Foxp3 mRNA expression of CD4+CD25+Foxp3+ iTregs: 
Foxp3 mRNA expression for each treatment conditions was measured by reverse 
transcriptase polymerase chain reaction (RT-PCR).  Results showed that Foxp3+ iTregs 
generated from treating naïve CD4+ T cells with 5Aza and TGF-β expressed the highest level 
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of Foxp3 mRNA transcripts (Figure 5). In addition, the Foxp3 mRNA level was significantly 
higher than that produced by 5Aza treatment alone (p<0.05). However, all other treatments 
induced significant increases in the level of Foxp3 mRNA expression (p<0.05) when 
compared to control (Medium). These induced Tregs displayed a similar increase in the level 
of Foxp3 protein expression as measured by flow cytometric method which correlates well 
with the increase seen at the mRNA level. 
8.4.3   Supplementary results:  
8.4.3.1   Antigen presenting cells in T cell culture: 
The effect of adding T cell depleted irradiated PBMCs as antigen presenting cells (APCs) to 
naïve CD4+ T cells treated with 5Aza was evaluated in one experiment. The presence of 
these antigen presenting cells did not seem to improve or enhance the generation of Foxp3+ 
iTregs. In fact the percentage of Foxp3+ iTregs generated by 5Aza treatment dropped in the 
presence of T cell depleted irradiated PBMCs (Figure 6). Similarly, the proportion of Foxp3 
promoter demethylation was lower in T cells treated by 5Aza treatment in the presence of T 
cell depleted irradiated PBMCs (Figure 7). 
8.4.3.2   Memory CD4+CD45RO+ versus Naïve CD4+CD45RA+ T cells: 
The ability of memory CD4+CD45RO+ T cells to up regulate Foxp3 expression and generate 
Foxp3+ iTregs in response to 5Aza treatment was examined. Treating memory CD4+ T cells 
with 5Aza + TGF-β resulted in a very small increase in the percentage of Foxp3+ iTregs 
(Figure 8). Similar changes were observed in the level of Foxp3 mRNA expression. Treating 
memory T cells with 5Aza alone had no effect on the level of Foxp3 expression and Foxp3 
promoter demethylation when compared to naïve CD4+ T cells receiving similar treatment 
conditions. The proportion of Foxp3 promoter demethylation in memory T cell population 
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was the least affected by 5Aza treatment and remained similar to that of control cells 
(Medium). The level of Foxp3 promoter demethylation in control wells was much higher in 
memory T cells (28%) than that of naïve T cells (8%). The low level of Foxp3 promoter 
demethylation in naïve CD4+ T cells seems to permit further changes in demethylation after 
additional treatments when compared to memory T cells. 
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Figure 1. Optimisation of 5-Aza 2’ deoxycytidine concentration. Naïve CD4+ T cells 
were treated with different concentrations of 5Aza (0.25 to 10 µM) and then analysed by flow 
cytometry. The frequencies of CD4+CD25+Foxp3+ iTregs and Foxp3 median fluorescence 
intensity (MFI) induced by each concentration were compared. The optimal concentration of 
5Aza was 5 µM. 
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Figure 2. Co-treatment with TGF-β and 5-Aza 2’ deoxycytidine enhanced Foxp3 
expression, but reduced Foxp3 promoter demethylation when compared to control. 
Naïve CD4+ T cells were treated with 5Aza, TGF-β and tRA in different combination for 5 
days. A) The percentage of Foxp3+ induced Tregs generated from different treatment 
conditions measured by flow cytometry. B) The expression level of Foxp3 mRNA in Tregs 
induced by different treatment conditions measured by RT-PCR. C) The percentage of Foxp3 
promoter demethylation in CD4+ T cells treated for the all different conditions.  
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Figure 3. Treating naïve T cells with 5-Aza 2’ deoxycytidine alone or in combination 
with tRA significantly enhanced Foxp3 expression and Foxp3 promoter demethylation. 
A) The percentage of Foxp3+ induced Tregs generated from different treatment conditions 
measured by flow cytometry. B) Foxp3 protein expression was measured by flow cytometry 
and reported as median fluorescence intensity (MFI). C) The percentage of Foxp3 promoter 
demethylation in CD4+ T cells treated for the all different conditions. P-values <0.05 were 
considered significant (*p<0.05, **p< 0.01, ***p<0.001). The values indicate the mean ± 
SEM of 7 separate experiments. 
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Figure 4: Foxp3 demethylation levels in Foxp3+ Tregs induced by 5-Aza 2’ 
deoxycytidine and 5-Aza 2’ deoxycytidine plus tRA. Foxp3+ Tregs induced by both 
treatments displayed similar levels of Foxp3 promoter demethylation (<50%). The values 
indicate the mean ± SEM of 4 separate experiments. 
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Figure 5:  Treating naïve T cells with 5-Aza 2’ deoxycytidine plus TGF-β produced the 
highest level of Foxp3 mRNA expression. The level of Foxp3 mRNA expression in Tregs 
induced by different treatments measured by RT-PCR. P-values <0.05 were considered 
significant (*p<0.05, **p< 0.01, ***p<0.001). The values indicate the mean ± SEM of 5 
separate experiments. 
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Figure 6: The use of T cell depleted irradiated PBMCs reduced the frequency of Foxp3+ 
Tregs induced by 5-Aza 2’ deoxycytidine treatment. Naïve CD4+ T cells were treated with 
5Aza, TGF-β and tRA in different combination for 5 days in the presence, or absence, of T 
cell depleted irradiated PBMCs. 
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Figure 7: The use of T cell depleted irradiated PBMC reduced the proportion of Foxp3 
promoter demethylation DNA induced by 5-Aza 2’ deoxycytidine treatment. Naïve 
CD4+ T cells were treated with 5Aza, TGF-β and tRA in different combination for 5 days in 
the presence or absence of T cell depleted irradiated PBMCs. 
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Figure 8: Memory T cells are less responsive to Foxp3 induction by 5-Aza 2’ 
deoxycytidine than naïve T cells. Memory and naïve CD4+ T cells were treated with 5Aza 
or TGF-β + 5Aza for 5 days then the cells were harvested for analysis. A) The percentage of 
Foxp3+ induced Tregs generated from different treatment conditions measured by flow 
cytometry. B) The expression level of Foxp3 mRNA in Tregs induced by different treatment 
conditions measured by RT-PCR. C) The percentage of Foxp3 promoter demethylation in 
CD4+ T cells treated for all the different conditions.   
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8.5   Discussion and Conclusions: 
Currently, increasing evidence exists for the critical role of epigenetic mechanisms in 
regulating Foxp3 gene expression, particularly DNA methylation. Nucleoside based DNA 
methyltransferase inhibitors such as 5Aza and 5-azacytidine were evaluated in several studies 
and were claimed to induce demethylation of the Foxp3 gene, promoting stable Foxp3 
expression in conventional T cells (41, 150, 151). 
In this study, using flow cytometric analysis, RT-PCR and Foxp3 methylation assays, we 
demonstrated that treating human naïve CD4+ T cells with 5Aza  increased Foxp3 expression 
and demethylation of the Foxp3 promoter. Adding tRA to 5Aza produced similar increases 
on treated naïve CD4+ T cells. However, both types of Foxp3+ iTregs displayed only partial 
demethylation of the Foxp3 promoter (<50%). Despite the impressive increase in the levels 
of Foxp3 mRNA and protein expression induced by TGF-β plus 5Aza co-treatment, this 
combination failed to enhance the proportion of Foxp3 promoter demethylation when 
compared to control. Furthermore, applying the same protocol on CD45RO+ memory T cells 
did not enhance Foxp3 promoter demethylation. The memory T cells in control wells had a 
high level of Foxp3 promoter demethylation when compared to naïve T cells and failed to up 
regulate Foxp3 expression after treatment with 5Aza or TGF-β + 5Aza. 
The ability of 5Aza to induce strong Foxp3 expression has been reported in several studies 
(17, 41, 150, 151, 362-365). The effect of 5Aza on Foxp3 expression was initially studied in 
mice. In vitro studies showed that 5Aza induced and stabilised Foxp3 expression in mouse 
naïve CD4+ T cells (1, 8). 5Aza was found to induce Foxp3 protein and mRNA expression in 
all studies (41, 150, 362, 363, 365). Restimulation studies of murine Foxp3+ T cells induced 
by 5Aza showed that 87% of these cells maintained their Foxp3 expression at day five of 
culture and displayed less methylation when compared to Foxp3+ T cells treated with TGF-β 
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(1). Treating naïve CD4+CD25- T cells with 5Aza also induced complete demethylation of 
the Foxp3 CpG sites (151). Furthermore, in vivo studies demonstrated the effectiveness of 
5Aza in preventing autoimmune disorders. Treating NOD mice with 5Aza intraperitoneally at 
low dose for five weeks prevents the occurrence of diabetes. 5Aza treatment induced Foxp3 
demethylation and enhanced Foxp3 expression in immature thymic CD4+CD25+Foxp3- T 
cells, it increased the number and percentage of thymic Foxp3+ T cells in mice (365). Tregs 
induced by 5Aza and TGF-β showed similar potency to 5Aza induced Tregs. These cells 
exhibited suppressive activity in vitro and in vivo. Adoptive transfer of these cells prevented 
autoimmune colitis and prolonged pancreatic islet allograft survival in mouse models (151) 
.In a GVHD mouse model, administration of 5Aza improved survival and increased the 
percentage of Foxp3+Tregs in bone marrow, spleen and peripheral blood (366). The data 
from these animal studies are consistent and clearly demonstrate the impact of 5Aza in the 
process of Foxp3 induction and demethylation. 
5Aza successfully induced Foxp3 expression in human natural killer (NK) cells (CD3-
CD56+) and restored the IL-2 signaling pathway after 72 hours of in vitro stimulation with 
5Aza. In addition, human naïve CD4+ T cells treated with 5Aza (1 µM) for 24 hours under 
TGF-β induced Treg conditions produced strong Foxp3 expression and suppressive function 
(363). This protocol was evaluated and optimised in the present study. Our findings are in 
agreement with the results of  Lal et al. (151) Tregs induced by TGF-β plus 5Aza produced 
the highest level of Foxp3 protein and mRNA expression. These levels were significantly 
higher than that induced by 5Aza treatment alone. In another study, treating recently 
activated human CD4+CD25- T cells with 5Aza (5 µM) for 5 days significantly increased the 
percentage of Foxp3+ T cells and the levels of Foxp3 protein expression (150). In this study, 
the level of Foxp3 expression induced in 5Aza-treated T cells was comparable to that 
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detected in natural Tregs (150). Similarly, our data show enhanced Foxp3 protein and mRNA 
expression in activated CD4+ T cells treated with 5Aza (5 µM).  
Most studies have shown that epigenetic modification by demethylating drugs like 5Aza 
promotes stable Foxp3 gene expression in naïve CD4+ T cells. However, the level of Foxp3 
demethylation induced by this drug was not clearly identified in murine studies and was not 
reported in previous human studies. This issue is very important as studies found that only 
completely demethylated CpG at the Foxp3 locus is consistent with stable Foxp3 expression 
(17, 145). Murine studies evaluated the stability of Foxp3 expression in 5Aza-induced Tregs 
by restimulation experiments with or without Foxp3 methylation assay. These studies showed 
that 5Aza induced significant demethylation in the conserved non coding regions of the 
Foxp3 gene and 5Aza induced Tregs maintained their Foxp3 expression after restimulation 
(41, 151).  
This analysis was based on analysing the methylation status of all CpG motifs in different 
conserved regions. In this study we used the Foxp3 methylation assay to evaluate all culture 
conditions and analysed the results on the basis of  the most discriminating CpG position (-
77) in the Foxp3 promoter region (122). Our results indicated that only T cells treated by 
5Aza or 5Aza + tRA induced a significant increase of Foxp3 promoter demethylation. 
Although TGF-β + 5Aza induced Tregs exhibited a high level of Foxp3 expression in vitro, 
the lack of significant level of Foxp3 demethylation indicates unstable Foxp3 expression and 
suppressive function. Further analysis of the Foxp3+ T cells showed that both 5Aza and tRA 
plus 5Aza treatments induced partial (<50%), but not complete, demethylation of the Foxp3 
promoter. Therefore, in humans, 5Aza treatment induced transient Foxp3 expression and 
produced Foxp3+ Treg lineage with unstable suppressive function. Similar results were 
obtained in a recent study that used 5Aza as a positive control (367). In this study, 5Aza 
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iTregs had a high level of Foxp3 expression and suppressive function but exhibited partial 
demethylation of the CpG sites located in the proximal promoter region. 
The failure of 5Aza to induce Foxp3 expression and demethylation in memory T cells was 
unexpected, given that even in NK cells 5Aza could induce Foxp3 expression (363). In 
contrast to naïve T cells, the memory T cell population has been reported to repress the 
activation-dependent expression of Foxp3 with only 6% of memory CD45RO+ T cells 
upregulating Foxp3 following TCR activation (150). This is consistent with our results as 
only a small percentage (3%) of memory T cells expressed Foxp3 after activation. However, 
this repression is expected to be abolished after adding 5Aza treatment, which acts by 
inducing global DNA demethylation. Failure to induce Foxp3 expression in memory T cells 
treated with 5Aza may be due to the presence of suboptimal conditions. 5Aza requires active 
DNA replication to exert its optimal demethylation and possibly reduced number of 
replication cycles in  the memory T cell population following TCR activation reduced its 
efficacy. Interestingly, memory T cells treated with medium only displayed a higher level of 
Foxp3 demethylation than that of naïve T cells treated with the same condition. This high 
level may be explained by the presence of endogenous memory Foxp3+ Tregs which are not 
affected by 5Aza or TGF-β treatment. More experiments on memory T cells are needed to 
confirm these findings. 
5Aza acts by inducing global and random demethylation of the genome (368). Therefore, it 
can reprogram any type of cells by altering expression of several genes which may produce a 
different cellular phenotype. In this study, 5Aza induced Foxp3 expression in activated T 
cells by promoting demethylation of the Foxp3 gene, but the methylation status of other T 
cell genes such as proinflammatory cytokines was not evaluated. The hypomethylating effect 
of 5Aza on the function of human T cells was investigated by Luis et al (366). This group 
found that 5Aza at low doses produced immunomodulatory effects on T cells. 5Aza was 
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shown to significantly reduced the production of proinflammatory cytokines (TNF-α & IFN-
γ) in activated T cells. In addition, gene expression assays showed down-regulation of several 
genes involved in T cell proliferation and activation (MAP3K5, IFNAR2, CD58, IFN and 
MTCP1). At the same time, 5Aza induced up-regulation of genes involved in promoting cell 
growth and inhibiting cell cycle (p53, p73& U2AF2). Similarly, Foxp3 and FOXOa genes 
were up-regulated by 5Aza. These findings confirm the immunomodulatory effect of 5Aza 
and support its role in promoting the generation of Foxp3+ Tregs 
The current study clearly demonstrates that 5Aza treatment of naïve CD4+ T cells increases 
Foxp3 protein expression and Foxp3 promoter demethylation, supporting its capacity to 
generate Foxp3+ Tregs in vitro. However, Tregs induced by 5Aza using this protocol 
displayed only partial demethylation of the Foxp3 promoter suggesting a transient 
suppressive phenotype. Performing restimulation experiments with 5Aza-induced Tregs 
would provide more information about the stability of the Tregs induced in this study. In 
addition, performing Foxp3 methylation assay on flow sorted Foxp3+ and Foxp3- 5Aza-
treated T cells may give more accurate estimation of the level of Foxp3 demethylation in the 
Foxp3+ population. Although the results from the Foxp3 methylation assay indicate that 
5Aza can’t produce a stable Treg population from human naïve T cells, further manipulation 
of this protocol by including other agents that increase T cell proliferation may enhance the 
efficacy of 5Aza in promoting Foxp3 demethylating and facilitate the generation of a 
functionally stable Treg population. 
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Generation of human Foxp3+ iTregs using azathioprine (AZA) 
9.1   Summary 
Background 
Azathioprine (AZA) is a thiopurine drug which is well known for its immunosuppressive and 
anti-inflammatory properties. This drug has been evaluated by several in vitro studies which 
investigated its various effects on the function and number of different immune cells. 
However, most of these studies were performed in the 1970s and 1980s when Foxp3+ 
regulatory T cells had not been identified and characterised. 
Aim 
To investigate whether AZA can induce Foxp3+ Tregs from naïve CD4+ T cells in vitro 
which may contribute to its therapeutic role in vivo and present a new method for generating 
Foxp3+ Tregs in vitro. 
Methods: 
Human naïve CD4+ T cells from healthy donors were treated with AZA and cultured for five 
days in the presence of IL-2 and anti-CD3/CD28 beads. TGF-β or tRA were also combined 
with AZA for comparison. The cells were then harvested and evaluated for Foxp3 protein 
expression and Foxp3 promoter demethylation. 
Results:  
AZA alone or in combination with TGF-β significantly enhanced the frequency of Foxp3+ 
iTregs (p<0.05), the level of Foxp3 protein expression (p<0.05) and the proportion of Foxp3 
promoter demethylation (p<0.05) in treated T cells when compared to control. These iTregs 
also displayed high levels of Foxp3 mRNA expression (p<0.05) and Foxp3 promoter 
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demethylation (>50%). However, the proportion of Foxp3 promoter demethylation did not 
increase after adding VitD or Rapa to AZA treated T cells. In addition, all AZA-induced 
Tregs exhibited partial demethylation of the Foxp3 promoter. 
Conclusion: 
At low concentration AZA is capable of converting naïve CD4+ T cells into Foxp3+ iTregs 
in vitro. These findings reveal a potential therapeutic mechanism for AZA and provide an 
alternate method for generating Foxp3+ Tregs in vitro. However, the Foxp3 promoter in 
AZA-induced Tregs remained partially demethylated, indicating unstable Foxp3 expression. 
Therefore, this protocol is similar to other protocols used to generate Foxp3+ Tregs in vitro 
and is currently not suitable for Treg-based cellular therapy. Further studies are needed to 
confirm these findings and to explore the molecular mechanisms underlying Foxp3 induction 
and expression by AZA. 
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9.2   Introduction: 
AZA is an immunosuppressive and anti-inflammatory drug with many therapeutic 
applications. It is commonly used to treat autoimmune and chronic inflammatory conditions, 
such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and  
inflammatory bowel diseases (369-372). It has also an important therapeutic role in kidney, 
liver and heart transplantation (373-376).  This drug has been evaluated by several in vitro 
studies which investigated its various effects on the function and number of different immune 
cells (377-379). However, most of these studies were performed in the 1970s and 1980s when 
Foxp3+ regulatory T cells had not been identified and characterised. In addition, the exact 
mechanism of action for this drug is still undefined.  
AZA is nonenzymatically broken down to 6-mercaptopurine (6-MP) and 
methylnitroimidazole (380). This conversion is facilitated by a glutathione-dependent 
reaction which occurs both in vitro and in vivo (381-383). The 6-MP readily crosses cell 
membranes and is metabolised intracellularly to 6-thioguanine nucleotides (6-TGNs) by the 
hypoxanthine phosphoribosyl-transferase pathway (384). The thioguanine nucleotides share 
structural similarity to the endogenous purine nucleotides and seem to be the most active 
metabolites of thiopurine drugs. Consequently, these purine thioanalogues inhibit the 
synthesis and utilisation of endogenous  purine nucleotides (385). The lack of these essential 
nucleotides impairs critical cellular mechanisms, such as DNA synthesis, RNA synthesis, 
phosphorylation and glycosylation (377). In addition, the incorporation of purine 
thioanalogues into DNA of leucocytes results in strand breakage (386). DNA 6-TGNs 
containing cells are also more susceptible to oxidative damage (387). Moreover, one of the 
thioguanine nucleotides, 6- thioguanine-triphosphate (6-TGTP), was found to bind and inhibit 
Rac1 (apoptosis inhibitor) leading to T cell apoptosis (373). The 6-MP is also enzymatically 
inactivated by xanthine oxidase and thiopurine methyltransferase (384). The precise role of 
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the second component (methylnitroimidazole) is still not clear though it was proposed to 
exhibit immunosuppressive properties similar to 6-MP in the murine model (388).  In 
addition, in vitro studies showed that in contrast to 6MP, AZA inhibits T cell proliferation by 
a mechanism independent of purine ribonucleotide depletion (389).  
All these data indicate that AZA’s immunosuppression is a consequence of multiple, complex 
mechanisms. The immunomodulatory effect of this drug may also suggest the involvement of 
Foxp3+ regulatory T cells in the therapeutic process. As discussed in Chapter One, Foxp3+ 
regulatory T cells are the main immune suppressor cells that play a critical role in controlling 
inflammatory responses and functional or quantitative deficits of regulatory T cells have been 
reported in several inflammatory and autoimmune disorders. These deficits were corrected or 
modulated by immunosuppressive drugs such as corticosteroids, mycophenolate and Rapa 
(390-394). AZA may also act through modulating regulatory T cell number or function. 
Therefore, studying the in vitro effect of AZA on Foxp3 expression and Treg generation 
could clarify part of its mechanism of action and introduce a new method for generating 
Foxp3+ Tregs in vitro. 
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9.3   Protocol: 
9.3.1   Protocol Summary: 
Human naïve CD4+ T cells were separated from peripheral blood and co-cultured with 
different combinations of IL-2, TGF-β, tRA and AZA for five to six days to generate Foxp3+ 
regulatory T cells. The cells were then harvested and evaluated by flow cytometry, RT-PCR 
and Foxp3 methylation assay.  
9.3.2   Method: Generation of human iTregs with AZA. 
Purified naïve T cells were cultured with anti-CD3/CD28 beads at a ratio of  10:1 (ten beads 
to 1 cell) in  TCM supplemented with IL-2 (100 U/ml) and TGF-β (5 ng/ml), tRA (100 nM) 
and AZA (1 µM) in different combination. AZA was removed with the old medium after 24 
hours of culture and the cells were resuspended in a fresh TCM without AZA. The cells were 
cultured for another five days in U-bottomed 96 well plates in a final volume of 200 µl of 
TCM and in the presence of  IL-2, anti-CD3/CD28 beads, tRA and TGFβ. Tissue culture 
medium with the corresponding supplements was replaced every 48 hours. 
 The populations studied were naïve CD4+ T cells activated with IL-2 (Medium), naïve 
CD4+ T  cells activated with IL-2 and AZA (AZA), naïve CD4+ T cells activated with IL-2, 
tRA and AZA (tRA + AZA)  and naïve CD4 + T cells activated with IL-2, TGF-β and  AZA 
(TGF-β + AZA ). In some experiments, minor changes were made to the above protocol such 
as, adding AZA on different days of culture. T cell depleted irradiated PBMCs were used in 
one experiment and were prepared from PBMCs using EasySep Human CD3+ T cell kit 
(positive selection – Stem Cell Technologies, VIC, Australia). T cell depleted PBMC were 
then gamma irradiated (3000 Rad) and used as antigen presenting cells (APCs). VitD and 
Rapa were included in some experiments.  
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9.3.3   Experiments: 
A total of eight experiments from four healthy adult donors was performed using this 
protocol. To evaluate the effect of AZA, all results were combined and then analysed against 
control (Medium). Due to the length and complexity of these experiments, a single 
experiment was performed to evaluate whether additional combination or changes to the 
original protocol are worth doing or investigating further. Although not suitable for statistical 
analysis, these additional experiments provide important information and therefore were 
included under supplementary results.  
 
9.4   Results: 
 
9.4.1   Frequency and methylation status of CD4+CD25+Foxp3+ iTregs: 
Naïve CD4+ T cells were treated with a range of concentrations (0.5 to 100 µM) of AZA. 
Results indicated that treating naïve CD4+ T cells with 1 µM of AZA produced the highest 
percentage of Foxp3+ expressing cells (21%) with the maximum median fluorescence 
intensity (MFI=336) as determined by flow cytometric analysis (Figure 1). An initial 
experiment was performed to compare the effect of single (AZA) versus combined treatment 
(AZA + TGFβ or AZA + tRA) on the level of Foxp3 expression and methylation. The 
percentage of Foxp3+ iTregs was slightly increased (6% to 8%) after combining AZA with 
TGFβ, but this combination did not enhance the proportion of Foxp3 promoter 
demethylation. Similar changes were seen after combining AZA with tRA (Figure 2). 
 Results from all experiments revealed a significant increase in the frequency of Foxp3+ 
Tregs induced by the following treatments: AZA (p<0.05), TGFβ+AZA (p<0.05) and tRA 
+AZA (p<0.05) when compared to control (Medium) (Figure 3A). The mean frequencies of 
Foxp3+ iTregs treated with AZA + TGFβ (26% ± 6) or AZA + tRA (29% ± 6) were higher 
than that produced by AZA treatment alone (18% ± 3), but these differences were not 
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statistically significant. Foxp3 protein expression (MFI) was also significantly increased in 
Tregs induced by AZA (p<0.05) and AZA + TGFβ treatment (p<0.05) (Figure 3B).  
Likewise the proportion of Foxp3 promoter demethylation was significantly enhanced in T 
cells treated with AZA (p<0.05) alone or in combination with TGFβ (p<0.05) (Figure 3C). 
The mean frequency of Foxp3 promoter demethylation was 23%  ± 2 for AZA treatment and 
24% ± 3 for TGFβ + AZA co-treatment. Despite the increase in the frequency of Foxp3+ T 
cells induced by tRA + AZA co-treatment, the proportion of Foxp3 promoter demethylation 
in CD4+ T cells was similar to that produced by control (Medium). Foxp3+ Tregs induced by 
AZA or AZA and TGFβ co-treatment also displayed high level of Foxp3 promoter 
demethylation (≥ 50%) (Figure 4). The mean percentage of Foxp3 demethylation was 64% ± 
6 for AZA induced Foxp3+ Tregs and 50% ± 11 for AZA + TGF-β induced Foxp3+ Tregs. 
Despite this high demethylation levels, these induced Tregs are still partially demethylated 
and therefore, functionally unstable. 
These data provide clear evidence of the effectiveness of AZA in the induction of Foxp3+ 
iTregs in vitro and demonstrates its ability to modulate Foxp3 expression at protein and 
molecular levels. 
9.4.2   Foxp3 mRNA expression of CD4+CD25+Foxp3+ iTregs: 
Foxp3 mRNA expression for each treatment condition was measured by RT-PCR. Tregs 
induced by AZA alone, or in combination with TGFβ, produced high levels of Foxp3 mRNA 
expression (p<0.05). Moreover, combining TGFβ with AZA was more effective in induction 
of Foxp3 mRNA expression than AZA treatment alone (p<0.05). These results further 
support the role of AZA in the induction of Foxp3 expression and subsequently generation of 
Foxp3+ Tregs (Figure 5). 
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9.4.3   Supplementary results: 
9.4.3.1   The effect of 1α, 25-dihydroxyvitamin D3or rapamycin treatment: 
The effect of VitD treatment was evaluated in a single experiment. Naïve CD4+ T cells were 
treated with AZA, TGFβ + AZA and tRA + AZA according to the previously described 
protocol and VitD (2 nM) was added on day two of culture.  
Inclusion of VitD in the AZA protocol had minimal effect on the production of Foxp3+ 
iTreg. The frequency of Foxp3+ iTregs did not change remarkably after adding VitD to wells 
treated with TGFβ + AZA or tRA + AZA (Figure 6). However, combining VitD with AZA 
resulted in a two fold increase in the frequency of Foxp3+ expressing cells (Figure 7). 
Although there was an increase in the frequency of Foxp3+ T cells after adding VitD,, the 
proportion of Foxp3 promoter demethylation remained low. In fact, this combination 
produced less demethylation of the Foxp3 promoter than that produced by AZA treatment 
alone (Figure 7). Therefore, it seems that VitD, in the presence of an appropriate combination 
can induce Foxp3 protein expression in many cells without affecting the methylation status of 
the Foxp3 promoter.  
In another experiment, we investigated the effect of Rapa treatment. Rapa is another 
immunosuppressant drug, but more importantly it has immunomodulatory properties, 
particularly on Foxp3+ regulatory T cells (331). Studies showed that Rapa selectively 
expanded Foxp3+ thymic Treg population in T cell culture and induced Foxp3 expression as 
well as suppressive function in CD4+ T cells (340, 350). In this experiment, naïve CD4+ T 
cells were treated with AZA, Rapa and Rapa + AZA for five days. Rapa (100 nM) was added 
on day two of culture. In this experiment, combining AZA and Rapa failed to enhance the 
frequency of Foxp3+ T cells and the proportion of Foxp3 promoter demethylation when 
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compared to each drug separately (Figure 8). Indeed, this combination reduced the proportion 
of Foxp3 promoter demethylation. 
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Figure 1: Optimizing Azathioprine concentration. Naïve CD4+ T cells were treated with a 
range of concentration of AZA (0.5 to 100 µM) and then analysed by flow cytometry. The 
frequency of CD4+CD25+Foxp3+ T cells and Foxp3 median fluorescence intensity (MFI) 
induced by each concentration were compared.  
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Figure 2: Azathioprine alone or in combination with TGFβ or tRA enhanced the 
frequency of Foxp3+ T cells and the proportion of Foxp3 promoter demethylation when 
compared to control (Medium). Naïve CD4+ T cells were treated with AZA, TGF-β and 
tRA in different combination for five days. (A) The percentage of Foxp3+ induced Tregs 
generated from different treatment conditions measured by flow cytometry. B) The 
percentage of Foxp3 promoter demethylation in CD4+ T cells treated for the all different 
conditions.  
 
 
213 
 
 
A) 
Medium AZA TGFβ+AZA tRA+AZA
0
10
20
30
40 *
*
*
%
 o
f 
C
D
4
+
C
D
2
5
+
F
o
x
p
3
+
 
B) 
Medium AZA TGFβ+AZA tRA+AZA
0
100
200
300
 *
*
F
O
X
P
3
 M
F
I
 
C) 
Medium AZA TGFβ+AZA tRA+AZA
0
10
20
30
*
*
%
 o
f 
F
o
x
p
3
 d
e
m
e
th
y
la
ti
o
n
 
Figure 3: Azathioprine alone or in combination with TGF-β produced significant 
increase in the frequency of Foxp3+ T cells, their Foxp3 expression and the proportion 
of Foxp3 promoter demethylation when compared to control (Medium). Results were 
obtained from 8 independent experiments. A)  The percentage of Foxp3+ induced Tregs 
generated from different treatment conditions measured by flow cytometry. B) Foxp3 protein 
expression was measured by flow cytometry and reported as median fluorescence intensity 
(MFI). C) The percentage of Foxp3 promoter demethylation induced by different treatment 
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conditions. Results were expressed as means ± SEM. p-values <0.05 were considered 
significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 4: Foxp3 demethylation levels in Foxp3+ T cells treated with azathioprine or 
azathioprine plus TGF-β . Foxp3+ Tregs induced by both treatments displayed partial 
demethylation of the Foxp3 promoter (≥50%). Results were expressed as means ± SEM. 
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Figure 5: Azathioprine alone or in combination with TGF-β, significantly enhanced 
Foxp3 mRNA expression in iTregs. Results were derived from 3 independent experiments. 
The level of Foxp3 mRNA expression was measured by RT-PCR. p-values <0.05 were 
considered significant (*P<0.05, **P< 0.01, ***P<0.001). 
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Figure 6: The addition of 1α, 25-dihydroxyvitamin D3 did not enhance the frequency of 
Foxp3+ T cells induced by TGFβ+AZA or tRA+AZA. VitD was added on day two of 
culture at a final concentration of 2 nM. 
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Figure 7:Co-treatment of 1α, 25-dihydroxyvitamin D3and azathioprine enhanced the 
frequency of Foxp3+ T cells, but not the proportion of Foxp3 promoter demethylation 
when compared to azathioprine only. VitD was added on day two of culture to AZA-
treated T cells at a final concentration of 2 nM. 
 
 
216 
 
M
ed
ia
A
ZA
R
ap
a
R
ap
a 
+A
ZA
M
ed
ia
A
ZA
R
ap
a
R
ap
a 
+A
ZA
0
5
10
15
20
25
% CD4+CD25+FOXP3+
% FOXP3 demethylation
P
e
rc
e
n
ta
g
e
 
Figure 8: Co-treatment of rapamycin and azathioprine did not enhance the frequency of 
Foxp3+ T cells but reduced the proportion of Foxp3 promoter demethylation when 
compared to single treatment. Rapa was added on day two of culture to naïve CD4+ T cells 
treated with or without AZA at a final concentration of 100 nM. 
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9.5   Discussion and Conclusions: 
In this in vitro study, it was demonstrated that AZA was capable of converting peripheral 
naïve CD4+ T cells into Foxp3+ regulatory T cells.  AZA successfully induced Foxp3 
expression in naïve CD4+ T cells at the mRNA and protein levels. In addition, it produced 
significant demethylation of the Foxp3 promoter, which is an important measure of Treg 
stability and function. 
Several in vitro studies have investigated the effect of this drug on the function and number 
of different immune cells in the 1970s and 1980s (377-379, 395). In vitro evaluation of AZA 
immunosuppressive activities showed that the inhibitory effect of AZA on lymphocyte 
suspensions is not immediate and is generated at least after 60 minutes, indicating the need of 
metabolic alteration (396). Furthermore, AZA inhibited PHA lympho-proliferative responses, 
mixed lymphocyte culture responses and had various inhibitory effect on B lymphocytes 
(397). Later studies evaluated the number and function of peripheral Tregs in AZA-treated 
patients, but not the in vitro effect of AZA. For instance, in patients with inflammatory bowel 
disease (IBD) AZA treatment was associated with low peripheral numbers of Tregs, but Treg 
numbers were higher in the lamina propria from these patients than those in normal controls 
(398, 399). Similar changes in Treg distribution between peripheral and mucosal tissues were 
seen in patients with ulcerative colitis treated with conventional treatment including AZA 
(400, 401). Therefore, this may represent a redistribution of Tregs to inflammatory sites 
rather than true deficit caused by AZA treatment. 
The ability of AZA to enhance Foxp3+ Tregs was described by a recent study of colon 
biopsies taken from patients with IBD who were on AZA (402). The results from this study 
showed significant increases in the percent of mucosal Foxp3+ T cells. In vitro cultures from 
this study also demonstrated selective enrichments of Foxp3+ induced Tregs by 6-TGN 
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(active metabolite of AZA). To our knowledge, no other studies have investigated this 
property of AZA. It is important to mention that the concentration of AZA and the cell 
exposure time to AZA in culture can significantly affect lymphocytes response. Low 
concentration and short exposure seem to facilitate the induction of Foxp3+ Tregs while high 
concentration and prolonged exposure are cytotoxic and induce cell death. 
Studies found that the therapeutic efficacy of AZA is correlated with thiopurine nucleotide 
concentrations in tissues rather than blood concentrations (403, 404). In the Tiede et al. study, 
AZA induced T cell apoptosis at a concentration of 5 µM in vitro which resulted in 
intracellular 6-TGTP level of 168 pmol/mg DNA (373). This level was comparable to 6-
TGTP concentration in leukocytes derived for AZA treated patients (100–2,305 pmol/mg 
DNA)  hence,  this in vitro concentration is relevant to the therapeutic concentration of AZA 
in vivo (405) . In this study, 1 µM of AZA was used to induce Foxp3 expression in activated 
T cells which is equivalent to 34 pmol/mg DNA. This value is lower than the therapeutic 
range used in the Tiede et al. study. This suggests that lower therapeutics concentrations of 
AZA are needed to promote Treg generation and reduce T cell apoptosis in vivo. 
Previous studies have shown that AZA is converted to 6-MP and methylnitro imidazole by a 
glutathione-dependent reaction in vitro (381, 383). The high intracellular level of glutathione 
in lymphocytes, particularly CD4+ T cells may facilitate AZA conversion into its main 
components in vitro (406). Administration of AZA or 6-MP  was found to prevent anti-BSA 
antibody response in rabbits and promote long-term antigen specific tolerance, supporting the 
immunomodulatory effects of thiopurine drugs (382). However, it is important to emphasize 
that AZA is not equal to 6-MP. In vitro studies have found that AZA has more inhibitory 
effect on T cell activation and proliferation than 6-MP, and its effect can’t be antagonised by 
exogenous purine administration (389, 407, 408). In addition, anti-bacterial properties were 
demonstrated in vitro for AZA, which may reflect the potential immunomodulation effect of 
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imidazole (409). Furthermore, in one murine study, methylnitroimidazole displayed similar 
immunosuppressive properties to 6-MP (388). This information suggests that the Foxp3 
induction observed in this study can be attributed to 6-MP or methylnitroimidazole. 
In the last decade, studies have described additional molecular mechanisms for the 
immunosuppressive properties of AZA. Poppe et al. found that AZA interferes with CD28 
signaling pathway which subsequently blocks T cell-antigen presenting cell conjugation 
(410). Tiede et al. also reported that the AZA metabolite 6-TGTP (6-Thio-guanosine-5′-
triphosphate) induced T cell apoptosis by blocking the function of a small GTP-binding 
protein, Rac1 during CD28 activation (373). However, CD28 signaling also promotes 
recruitment of PI3K and downstream activation of PKB (411). These protein kinases interfere 
with Foxp3 induction by sequestering Foxo proteins (132). Therefore, inactivation of PI3K or 
Atk by inhibiting or attenuating CD28 activation with AZA may promote Foxp3 expression 
in activated T cells and provide a potential explanation for AZA ability to induce Foxp3 
expression. These studies also suggest that 6-MP rather than imidazole is likely to be 
involved in the induction of Foxp3+ Tregs in vitro, but this requires further investigations  
TGF-β is well known for its ability to induce Foxp3 expression (109). In our study, TGF-β 
induction of Foxp3 expression was enhanced by AZA. tRA is another agent recently used to 
generate Foxp3+ iTregs (412), combining it with AZA significantly enhanced Foxp3 
expression but has no significant effect on the level of Foxp3 promoter demethylation. VitD 
is an important immune-modulator, it directly regulates the expression of the Foxp3 gene and 
promotes Foxp3 expression and suppressive function in CD4+ T cells (224, 413). Preliminary 
data from this study showed that combining VitD with AZA enhanced the percentage of 
Foxp3 expressing T cells, but failed to promote Foxp3 promoter demethylation in these cells. 
Rapa, is another immunosuppressant drug claimed to possess positive effects on human Treg 
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frequency and function (342, 392). In this study, combining Rapa with AZA produced less 
demethylation of the Foxp3 promoter than that produced by each drug separately. 
These results demonstrate the complexity of the molecular processes regulating the induction 
and maintenance of Foxp3 expression. Some agents induce Foxp3 protein expression but 
have no effect on the methylation status of Foxp3 gene while others affect both in similar or 
opposite directions. Therefore, understanding the molecular mechanism and the signaling 
pathway utilised by each agent would facilitate the generation of stable Foxp3+ Tregs and 
optimisation of culture conditions. The findings from this study reveal a potentially important 
role of AZA in the process of Foxp3 induction and provide alternate method for generating 
Foxp3+ Tregs in vitro. Evaluating the suppressive function of AZA induced-Tregs by in vitro 
suppression assay and in vivo mouse models will further support the findings from this study. 
In addition, examining the methylation status of the Foxp3 enhancer region and evaluating 
other epigenetic mechanisms such as histone acetylation or methylation will provide better 
understanding of the molecular mechanisms involved in Foxp3 induction by AZA. 
Furthermore, using 6-MP, imidazole and other AZA metabolites to generate Foxp3+ Tregs in 
vitro and in vivo, will facilitate the identification of the underlying molecular mechanism and 
related signaling pathways. 
In conclusion, AZA induces and enhances the generation of Foxp3+ Tregs in vitro, this may 
explain part of the anti-inflammatory property of this drug in vivo, but further studies are 
needed to confirm these findings. In addition, these data provide scientific basis for 
researchers to investigate the molecular mechanisms underlying Foxp3 induction and 
expression by AZA which will facilitate the development of more specific drug and improve 
strategies for generating stable Foxp3+ Tregs. 
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CHAPTER TEN:  COMPARISON OF ALL PROTOCOLS 
 
10.1   Introduction: 
In this chapter the results derived from all protocols are compared on the basis of three major 
variables: the frequency of cells expressing the Treg phenotype (CD4+CD25+Foxp3+), the 
level of Foxp3 protein expression and the percent of Foxp3 promoter demethylation. The 
percent of Foxp3 promoter demethylation was calculated relative to all CD4+ T cells and 
relative to just Foxp3+ T cells. All materials and methods have been described in detail in 
Chapter Two (Material & Methods) and in the relevant chapter for a particular protocol.  
The analysis includes all treatment conditions that produced statistically significant results 
when compared to the control (Medium) in each protocol. It is important to mention that the 
control conditions from different protocols were not comparable, as there was a variation in 
the concentrations used for IL-2 and CD3/CD28 beads. This variation can produce different 
values for control conditions of the same donor. Therefore, comparison with control 
condition was not used for the final analysis.  
 The results for each significant treatment condition were obtained from the relevant chapter. 
Kruskal–Wallis one-way analysis of variance was used to compare all different treatment 
conditions for any significant difference and the Mann-Whitney test was then used to identify 
which specific pairs are significantly different. The treatment conditions that produce 
significantly low results were excluded and the remaining conditions were presented in 
separate figures for the final comparison. Correlation analysis was also performed using 
Spearman correlation to determine the strength of the linear relationship between Foxp3 
promoter demethylation and other measured variables (Foxp3 mRNA expression, Foxp3 
protein expression and frequency of CD4+CD25+Foxp3+ T cells). As cell-based therapy 
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mainly depends on the total cell number, the actual number of iTregs was determined for the 
most promising protocol. The average Treg number was obtained from three independent 
experiments of three healthy adult donors. 
10.2   Results: 
A total of seven protocols and 24 different culture conditions were analysed for the frequency 
of Foxp3+ iTregs, the level of Foxp3 protein expression (MFI) and the percent of Foxp3 
promoter demethylation. Summary of results is included in Table I. 
10.2.1   Frequency of CD4+CD25+Foxp3+ iTregs: 
The frequency of Foxp3+  iTregs was expressed as the percentage of CD4+CD127
lo
CD25
hi
 
compared to all CD4+ T cells using flow cytometric analysis and the gating strategy 
described in chapter two (Materials & Methods). 16 treatment conditions from seven 
protocols were compared for their capacity to induce a Treg phenotype in naïve or memory 
CD4+ T cells. There was a statistically significant difference between all treatment groups in 
the frequency of induced Tregs (p<0.01) (Figure 1). This difference was demonstrated in four 
treatment conditions: IFN-β (p<0.05), Rapa (p<0.05), 5Aza (p<0.01) and AZA (p<0.01).  
These treatment conditions based on the use of a single agent produced less than 20% of 
Foxp3 expressing T cells or iTregs. TGFβ + VitD treatment produced the highest mean 
frequency of iTregs (37% ± 4) and IFN-β treatment produced the lowest mean frequency of 
iTregs (14.4% ± 2). In total, only five treatment conditions produced a mean frequency of 
greater than 30%. These include: TGFβ + VitD, TGFβ + Rapa, TGFβ + tRA, tRA + Rapa and 
vitamin D3 treated memory T cells (VitD M). 
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 10.2.2   Foxp3 protein expression in CD4+CD25+Foxp3+ iTregs: 
Intracellular Foxp3 protein expression was reported as median fluorescence intensity (MFI) 
and was measured by flow cytometry. The comparison analysis of all the 16 treatment 
conditions showed the presence of a statistically significant difference between the different 
treatment conditions (p<0.0001) (Figure 2). TGFβ+tRA treatment induced the highest Foxp3 
expression (543 ± 41) and 5Aza treatment induced the lowest Foxp3 expression (154 ± 9).  
Foxp3 protein expression induced by TGFβ + tRA treatment was significantly higher than 
that induced by 12 treatment conditions including: Rapa (p<0.01), tRA + Rapa (p<0.01), 
TGFβ + Rapa (p<0.01), 5Aza (p<0.001), TGFβ + 5Aza (p<0.001), tRA + 5Aza (p<0.01), 
AZA (p<0.001), TGFβ + AZA (p<0.001), TGFβ (p<0.001), memory T cells treated with 
TGFβ+tRA (TGFβ + tRA M) (p<0.05), memory T cells treated with vitamin D3 (VitD M) 
(p<0.05) and T cells treated with vitamin D3 dendritic cells plus beads (VitD-Dc+) (p<0.05). 
10.2.3   Foxp3 promoter demethylation: 
The methylation status of the Foxp3 promoter in Tregs generated with different treatments 
was expressed as percent demethylation of the Foxp3 promoter at -77 position using bisulfite 
sequencing. The percentage of Foxp3 demethylation was determined relative to all CD4+ T 
cells,  and then relative to just the Foxp3+ T cell in the well using a specific calculation as 
described in Chapter Two (Materials & Methods).  
This analysis only includes treatment conditions that were significantly different form their 
matched control (Medium). Analysis of all seven treatment conditions revealed the presence 
of a significant difference in the proportion of Foxp3 promoter demethylation (relative to  
CD4+ T cells) induced by different treatment conditions (p =0.01) (Figure 3). TGFβ + tRA 
treatment induced the highest proportion of Foxp3 promoter demethylation, 36% ± 3 of the 
total DNA was demethylated, while 5Aza treatment produced the lowest proportion of Foxp3 
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promoter demethylation (20% ± 2). The proportion of Foxp3 promoter demethylation 
induced by TGFβ + tRA treatment was significantly higher than that induced by four 
different treatment conditions including: AZA (p<0.01), TGFβ + AZA (p<0.05), 5Aza 
(p<0.01) and VitD (p<0.05).  
Evaluation of the proportion of Foxp3 promoter demethylation in Foxp3+ T cells also 
showed that these treatment conditions significantly differed from each other (p=0.04) 
(Figure 4). The highest proportion of Foxp3 promoter demethylation was induced by AZA 
treatment (64% ± 6) followed by TGFβ+tRA treatment (54% ± 10). VitD treatment produced 
the lowest proportion of Foxp3 promoter demethylation (28% ± 1). Foxp3 demethylation 
induced by AZA treatment was significantly higher than that induced by VitD (p<0.05), 
TGFβ + Rapa (p<0.05), 5Aza (p<0.01) and tRA + 5Aza (p<0.01). 
  10.2.4   Overall comparison:  
Treatment conditions that produced significantly lower results were excluded and only 
treatment conditions with comparable results were graphed again for the final comparison. 
The comparison includes all previously measured variables (Frequency of 
CD4+CD25+Foxp3+, Foxp3 protein expression, percent of Foxp3 promoter demethylation 
relative to CD4+ T cells and percent of Foxp3 promoter demethylation relative to Foxp3+ T 
cells). The treatment conditions were presented in descending order for each variable (Figure 
5).   A total of 12 treatment conditions produced comparable frequencies of Foxp3 expressing 
T cells but only four treatment conditions produced similar levels of Foxp3 protein 
expression. For Foxp3 promoter demethylation (relative to CD4+ T cells), three treatment 
conditions were comparable and for Foxp3 promoter demethylation (relative to Foxp3 + T 
cells), three treatment conditions also induced similar changes in demethylation. These 
results indicate that each treatment condition produced variable effects on each aspect of 
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Foxp3 analysis. However, only TGFβ + tRA treatment produced consistent results with 
positive effects in all Foxp3 variables. This treatment consistently enhanced the frequency of 
Foxp3 expressing T cells, Foxp3 protein expression and Foxp3 promoter demethylation.  The 
TGFβ + tRA protocol can convert 38% ± 4.2 of naïve CD4+ T cells to Foxp3 expressing T 
cells. These iTregs displayed a high level of Foxp3 expression (543 ± 41) and an enhanced 
Foxp3 promoter demethylation (54% ± 10). However, when Tregs induced by the TGFβ + 
tRA protocol were compared with peripheral blood derived thymic or natural Tregs, these 
iTregs still displayed partial demethylation of the Foxp3 promoter (Figure 6). 
10.2.5   Correlation analysis:  
The previous analysis indicated that each treatment condition induced a variable degree of 
Foxp3 expression and demethylation. Therefore, it is important to understand the relationship 
between Foxp3 gene demethylation and Foxp3 expression, and whether one variable is 
dependent on the other. Correlation analysis was performed to study the relationship between 
the percent of Foxp3 promoter demethylation and other variables. Results showed that Foxp3 
promoter demethylation was positively correlated (p<0.0001, r =0.55) with the frequency of 
iTregs (CD4+CD25+Foxp3+) (Figure 7). Similarly, a positive correlation (p<0.0001, r = 
0.63) was observed between Foxp3 promoter demethylation and Foxp3 mRNA expression 
(Figure 8).  Although Foxp3 promoter demethylation was also positively correlated with 
Foxp3 protein expression, this correlation was weak (p<0.0001, r = 0.31) (Figure 9).  These 
results indicate that Foxp3 promoter demethylation is associated with enhanced Foxp3 
mRNA and protein expression. 
10.2.6   Quantification experiments: 
Although the frequency of induced Foxp3 + T cells is considered an important factor for 
evaluating the efficiency of different protocols used to generate therapeutic Tregs, the actual 
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cell number of iTregs is more important for the clinical application of cell-based therapy. The 
actual cell number of iTregs was estimated using TGFβ + tRA treatment, which presents the 
most promising method for generating iTregs in our study. Naïve CD4+ T cells were 
stimulated with TGFβ + tRA in the presence of IL-2 supply and anti-CD3/CD28 beads for 5 
days as described in the TGFβ + tRA protocol. Each well received around 10
5
 cells. The total 
cell number was counted on day zero and day six. The number of Foxp3 expressing cells was 
calculated using flow cytometry data analysis. Results showed that the total number of CD4+ 
T cells significantly increased (p<0.05) after five days of culture, producing a mean-fold 
increase of 2.8 ± 0.3 (Figure 10). In addition, Foxp3 expressing T cells represent 43% ± 7 of 
the total CD4+ T cells, producing an average of 1.14x 10
5 
± 0.2 cells or iTregs. This number 
of Foxp3 expressing is almost equal to the number of CD4+ T cells on day zero (before 
treatment).  
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Table I: Summary of results from all protocols. 
 
This table documents the percent of Foxp3+ induced Tregs, Foxp3 protein expression (MFI) 
and the percent of Foxp3 promoter demethylation generated from all different culture 
conditions in comparison with control condition of each protocol. Results were expressed as 
mean ± SEM. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
The statistical significance is relative to medium (control condition). Normalized Foxp3 
demethylation data (using prism) were also included to facilitate comparison. 
Protocol Culture 
conditions 
%  Foxp3+ 
iTregs 
Foxp3 
MFI 
% Foxp3 
demethyl
ation 
Normalized  
Foxp3 
demethylation 
Vitamin D3 tolerogenic 
dendritic cells. 
VitD-Dc+ 30±4
** 
272±27
* 
12±3 11 
 VitD-Dc 5± 1 215±27 9±1 0 
      
Vitamin D3 or Interferons. VitD 26±4
** 
399±74
* 
20±2
* 
41 
 IFNβ 15±2
** 
406±58
* 
11±4 7 
 IFNγ 10±3 343±81 17±5 30 
 VitD M 32±5
* 
327±72
* 
13±0.3 15 
 IFNβ M 15±4 292±56
* 
13±0.4 15 
 IFNγ M 14±1 240±94 11±0.3 7 
      
Vitamin D3 and TGF-β TGFβ+VitD 38±4
*** 
394±100
* 
17±2 30 
 TGFβ 20±0.7
* 
327±102 20±7 41 
      
      
TGF-β and All-trans retinoic 
acid. 
TGFβ 19±3
* 
443±80 24±11 56 
 tRA 9±3 336±18 22±4 48 
 TGFβ+tRA 31±6
** 
543±41
** 
36±3
* 
100 
 TGFβ+tRA 
M 
25±2
* 
396±38
* 
16±2 26 
      
Rapamycin Rapa 15±2
* 
210±31
* 
28±5 70 
 TGFβ+Rapa 35±7
* 
245±21
* 
30±3
* 
78 
 tRA+ Rapa 33±7
* 
282±33
* 
27±2 67 
      
5-Aza 2’ deoxycytidine 5Aza 18±2
*** 
159±9
** 
20±2
** 
41 
 TGFβ 25±5
* 
198±17
* 
16±1 26 
 TGFβ+5Aza 28±2
*** 
178±14
* 
24±6 56 
 tRA +5Aza 25±1
** 
163±14
* 
27±2
* 
67 
      
Azathioprine AZA 18±3
* 
215±29
* 
23±2
* 
52 
 TGFβ+AZA 26±6
* 
243±20
* 
24±3
* 
56 
 tRA + AZA 29±6
* 
210±26 20±2 41 
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Figure 1: The frequency of Foxp3+ iTregs generated from all protocols. There is a 
statistically significant difference between the 16 different treatment groups on the frequency 
of induced Foxp3 + Tregs (p<0.01). This was determined by a Kruskal–Wallis H test (H 
(15)=36, p=0.002) and the Mann-Whitney test. Results were expressed as mean ± SEM. p-
values <0.05 were considered significant (*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 2: The levels of Foxp3 protein expression generated by all protocols. There is a 
statistically significant difference between the 16 different treatment groups on the level of 
Foxp3 protein expression (Median fluorescence intensity). This was determined by a 
Kruskal–Wallis H test (H (15)=57, p=<0.0001) and  the Mann-Whitney test. Results were 
expressed as mean ± SEM. p-values <0.05 were considered significant (*p<0.05, **p< 0.01, 
***p<0.001). 
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Figure 3: The proportion of Foxp3 promoter demethylation (relative to CD4+ T cells) 
generated from all protocols. There is a statistically significant difference between the 7 
different treatment groups in the proportion of Foxp3 promoter demethylation. This was 
determined by a Kruskal–Wallis H test (H (6)=16, p=0.01) and the Mann-Whitney test. 
Results were expressed as mean ± SEM. p-values <0.05 were considered significant 
(*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 4: The proportion of Foxp3 promoter demethylation (relative to Foxp3+ T cells) 
generated from all protocols. There is a statistically significant difference between the 7 
different treatment groups on the proportion of Foxp3 promoter demethylation. This was 
determined by a Kruskal–Wallis H test (H (6)=13, p=0.04) and the Mann-Whitney test. 
Results were expressed as mean ± SEM. p-values <0.05 were considered significant 
(*p<0.05, **p< 0.01, ***p<0.001). 
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Figure 5:  A protocol using TGFβ+tRA consistently enhanced Foxp3 expression and 
Foxp3 gene demethylation. Treatment conditions that produced significantly low results 
were excluded from each evaluation variable. The remaining treatment conditions were 
graphed and organised in descending order. A) The percentage of Foxp3+ induced Tregs 
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generated from different treatment conditions measured by flow cytometry. B) Foxp3 protein 
expression was measured by flow cytometry and reported as median fluorescence intensity 
(MFI). C) The percentage of Foxp3 promoter demethylation relative to CD4+ T cells treated 
for the all different conditions. D)  The percentage of Foxp3 promoter demethylation relative 
Foxp3+ T cells for the all different treatment conditions. Results were expressed as mean ± 
SEM. 
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Figure 6: Tregs induced by TGFβ+tRA are partially demethylated when compared to ex 
vivo isolated natural or thymic regulatory T cells (tTregs). Results were expressed as 
mean ± SEM. 
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Figure 7: There is a moderate positive correlation between the frequency of Foxp3 
expressing T cells and Foxp3 promoter demethylation. p<0.0001, r =0.55 using Spearman 
correlation. 
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Figure 8: There is a moderate positive correlation between the proportion of Foxp3 
promoter demethylation and Foxp3 mRNA expression. p<0.0001, r =0.63 using Spearman 
correlation. 
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Figure 9: There is a weak positive correlation between the proportion of Foxp3 
promoter demethylation and Foxp3 protein expression (Median Fluorescence Intensity). 
p<0.0001, r =0.31 using Spearman correlation. 
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Figure 10: There is a significant increase in the number of CD4+ T cells treated with 
TGF-β+tRA after 5 days of culture, which includes a significant proportion of Foxp3 
expressing T cells. The mean-fold increase = 2.8±0.3 and an average of 43.3%±6.8 were 
expressing the Treg phenotype (CD4+CD25+ CD127
lo
 Foxp3+). 
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10.3   Summary:  
In this study, the comparison of seven different protocols and 16 different treatment 
conditions revealed the presence of wide variations in the capacity of each treatment 
condition to induce Foxp3 expression and demethylation in CD4+ T cells. Some protocols 
significantly enhanced the frequency of Foxp3-expressing T cells but induced small changes 
in Foxp3 demethylation, while other protocols increased Foxp3 demethylation, but produced 
a low frequency of Foxp3- expressing T cells.  
 The only protocol that produced consistent increases in promoting Foxp3 expression and 
demethylation was TGFβ + tRA. Naïve CD4+ T cells, treated with TGFβ + tRA, showed 
significant increases in Foxp3 expression and demethylation, when compared to other 
protocols. In addition, this protocol produced a 2.8 fold increase in total cell number after five 
days of culture and, of those 43% were Foxp3 positive T cells. These results support its 
potential use for cell-based therapy. Despite this, these iTregs are partially demethylated 
when compared to thymic Tregs, which keeps their functional stability in question. Of 
importance, Foxp3 promoter demethylation showed positive correlations with the frequency 
of Foxp3 positive T cells, Foxp3 mRNA expression and Foxp3 protein expression, 
supporting the role of epigenetic modification in regulation of gene expression. 
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CHAPTER ELEVEN: OVERALL DISCUSSION &CONCLUSIONS 
11.1   Treg immunotherapy: importance and challenges. 
This study provides a comprehensive review of different types of in vitro induced Tregs and 
uses specific criteria to compare all induced Tregs in one study. To our knowledge, no such 
comparison studies exist.  The strengths of this study also lie in the use of the Foxp3 
demethylation assay to compare the functional stability of different iTregs, an essential 
criterion for successful Treg immunotherapy.  
Treg immunotherapy, or adoptive Treg transfer therapy, represent promising and novel 
approaches for treating human autoimmune diseases and preventing transplant rejection. 
Current therapies rely on nonspecific immunosuppressive drugs which produce serious side 
effects with long term use. In contrast, Treg immunotherapy has the potential to correct 
defects in Treg number or function which underlie the pathology of many human 
autoimmune diseases, providing more effective and specific therapy. Tregs for 
immunotherapy can be produced by expanding purified Foxp3+ thymic Tregs ex vivo or by 
inducing Tregs in vitro from isolated peripheral conventional CD4+ T cells. The difficulties 
associated with obtaining sufficient numbers of a purified thymic Treg population, 
particularly from patients with reduced Treg number or function, and the loss of suppressive 
function after several rounds of expansion, led many investigators to explore alternative 
approaches for obtaining sufficient Tregs including in vitro generation of Tregs.  This 
approach offers a more controllable system and produces Tregs that are functionally 
suppressive in animal models of autoimmune diseases. 
 In vitro generation of Tregs was investigated intensively by many studies using different 
strategies and agents. These studies provided experimental evidence for the potential 
application of in vitro induced Tregs in treating autoimmune disorders. However, functional 
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stability of these iTregs has not been thoroughly investigated so far and no comparison data 
are available to compare the efficiency of each method. This thesis attempts to address these 
issues. 
In the current study, the capacity of seven protocols or methods for induction of functionally 
stable Foxp3+ Tregs in vitro was examined. These protocols cover commonly used 
techniques and agents for in vitro induction of Tregs. Each protocol examined two or more 
culture conditions. The different culture conditions were evaluated for the frequency of 
Foxp3+ iTregs, Foxp3 protein expression and more importantly Foxp3 promoter 
demethylation.  
11.2   Foxp3 demethylation: an important measure of Treg stability and function. 
Foxp3 demethylation is currently, the most reliable method for identifying Treg lineage and 
quantifying Tregs in peripheral blood and solid tissues (44, 123, 145, 147, 149, 154). Foxp3 
demethylation was also linked to stable Foxp3 expression and suppressive function (17, 41, 
122, 414).  Weak CpG demethylation was found to correlate with poor Foxp3 stability (44).  
In addition, the degree of Foxp3 demethylation significantly correlated with the degree of 
suppression in tTregs and iTregs which showed a transient Foxp3 expression (122, 154, 351). 
These studies suggest that the methylation status of the Foxp3 locus would provide a clue to 
the extent to which a permanent conversion into Tregs did occur. Therefore, Foxp3 
demethylation provides the best measure for comparing Tregs induced by different methods 
and can identify which population of induced Tregs is more suitable for clinical use. 
An important confirmatory results in this study is the positive correlation of demethylation of 
the Foxp3 gene with the frequency of Foxp3+ iTregs (r = 0.55, p = <0.0001), Foxp3 mRNA 
expression ( r = 0.63, p = <0.0001) and Foxp3 protein expression (r = 0.31, p = <0.0001). 
These results are in agreement with other demethylation studies of human T cells which 
239 
 
showed a similar correlation (122, 147, 154). These correlation studies suggest that Foxp3 
demethylation promotes active transcription of Foxp3 protein, which subsequently introduces 
suppressive function in induced Tregs, as Foxp3 expression was shown to correlate with 
suppressive activity in  human activated T cells and thymic Tregs, and is essential for the 
acquisition of suppressive function (16, 67, 68, 415, 416). Foxp3 demethylation also 
enhances the accessibility of the Foxp3 promoter for transcription factors thereby, promoting 
active transcription of the Foxp3 gene. More importantly, methylation of DNA CpG rich 
sequences is heritable throughout cell divisions. Therefore, epigenetic modification of the 
Foxp3 locus can determine the transcriptional activity of the Foxp3 gene and is critical for 
stable Foxp3 expression and suppressive function. 
It is important to emphasise that the stability of induced Tregs referred to by different 
published studies included in this thesis was based on repetitive stimulation studies and not 
Foxp3 demethylation assay. This may explain the discrepancy with our findings which were 
based on the results of Foxp3 demethylation assay, a specific measure for permanent 
conversion into Tregs. 
The therapeutic effects of different types of in vitro induced Tregs were demonstrated by 
several adoptive transfer studies using various mouse models (56, 57, 417)  however, other 
studies failed to demonstrate similar efficiency (55, 73). As all types of induced Tregs are 
partially demethylated, this discrepancy may be explained by variation in the level of 
demethylation. This variation may affect the suppressive activities of the total Foxp3+ 
population.  
Partial demethylation may indicate that some of the cells in the Foxp3+ population are fully 
demethylated. However, if the majority of Foxp3 expressing cells are partially demethylated 
then, these cells will lose their Foxp3 expression and may revert to an inflammatory 
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phenotype, reducing the tolerogenic property of the total Foxp3+ population. This risk makes 
partially demethylated Foxp3+ T cells unsafe for therapeutic uses in human. Therefore, it 
seems that the proportion of Foxp3fully demethylated T cells and Foxp3 partially 
demethylated T cells presents the main key. This proportion may vary with different 
treatment conditions affecting the functional stability of the total Foxp3+ population. 
Unfortunately,  the Foxp3 demethylation assay measures  Foxp3 demethylation in  total DNA 
only and  it is impossible to differentiate between these two populations and isolate  the fully 
demethylated T cells. Having said that, the higher the demethylation level may still indicate a 
higher proportion of Foxp3 fully demethylated T cells and therefore , more functional Treg 
population. 
11.3   In vitro protocols vary in their abilities to induce Foxp3 expression and Foxp3 
demethylation: 
A total of seven in vitro conversion protocols and 24 different culture conditions were 
analysed for Foxp3 expression and demethylation.  However, only 16 culture conditions from 
the seven protocols produced a significantly higher frequency of Foxp3+ iTregs, with higher 
levels of Foxp3 protein expression when compared to control (Medium). These different 
culture conditions produced a variable mean frequency of iTregs ranging from 15% to 38%. 
Similar variability was observed in Foxp3 expression level with median fluorescence 
intensity ranging from 154 to 543.  However, the proportion of Foxp3 promoter 
demethylation was significantly increased only in seven culture conditions derived from five 
protocols. The demethylation level varies between 20 to 36% in treated CD4+ T cells and 
between 28 to 64% in Foxp3 expressing cells.  These results suggest that different stimulation 
conditions varied in their capacity to induce Foxp3 expression and demethylation. In 
addition, most culture conditions can induce Foxp3 expression without introducing additional 
changes to Foxp3 demethylation, apart from that induced by T cell receptor activation, which 
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also occurs in control cells. For instant, AZA treatment induced only 18% of CD4+ T cells to 
express Treg phenotype, but the proportion of Foxp3 promoter demethylation was 64% in 
these cells.  In contrast, TGFβ +VitD treatment induced 38% of CD4+ T cells to express Treg 
phenotype but the proportion of Foxp3 demethylation in these cells was only 26%. 
11.4   The possible molecular mechanisms underlying Foxp3 induction in various types 
of iTregs: 
These results indicate that the mechanisms leading to induction and maintenance of Foxp3 
expression may be different. Studies have highlighted DNA demethylation and histone 
modification as important epigenetic mechanisms involved in regulation of Foxp3 
expression.  Although the contribution of each mechanism and the interplay between these 
two mechanisms are still poorly understood, histone modifications might be the dominant 
mechanism involves in the initiation, or induction, of Foxp3 expression and DNA 
demethylation might control the maintenance and stabilization of Foxp3 expression. This 
view is supported by several studies that demonstrated that Foxp3 expression can also occur 
when Foxp3 DNA is methylated (44, 72).  Similarly, in this study,  most culture conditions 
(18 out of 25) failed to enhance Foxp3 promoter demethylation, despite inducing Foxp3 
expression in a significant proportion of CD4+ T cells, suggesting an alternative mechanism 
for induction of Foxp3 expression.   
The molecular mechanisms likely to underlie the induction of Foxp3 in human conventional 
T cells have been recently described for most agents used in this study. These agents activate 
several transcription factors that bind to the promoter or enhancer regions of the Foxp3 gene, 
regulating its transcriptional activity.  The Foxp3 enhancer contains three intronic CpG 
containing regions or conserved noncoding sequence elements (CNS1, CNS2 and CNS3) 
which have binding sites for different transcription factors (125).  The Foxp3 promoter 
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contains binding sites for  nuclear factors of activated T cells (NFAT) and activator protein-1 
(AP-1) which are activated following T cell receptor engagement (301). The Foxp3 promoter 
and CNS regions present the main targets for epigenetic regulation of Foxp3 expression 
which include CpG methylation and histone modification (acetylation or methylation) (418, 
419). 
IL-2 activates STAT5, which binds to the proximal conserved region of the Foxp3 promoter 
and TGF-β activates SMAD3, which binds to CNS1 in the Foxp3 enhancer region,  both  
have been shown to enhance histone acetylation and chromatin remodelling (419). TGF-β 
was also reported to decrease CpG methylation in the Foxp3 first intron by limiting the 
recruitment of DNA methyltransferase I (40, 420). Rapa inhibits the (PI3K)/Akt/mTOR 
signaling pathway, which antagonizes Foxp3 expression by inducing modification of histone 
3 (17, 39, 420). Retinoic acid induces the binding of retinoic acid receptor-retinoid X receptor 
(RAR/RXR) heterodimer to CNS1 which contains binding sites for RAR/RXR and SMAD3 
(121, 125). This binding promotes histone H4 acetylation and augments the TGF-β dependent 
pathway (17, 121, 420).   
The DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (5Aza) interferes with de novo 
DNA methylation  and  promotes demethylation of  the upstream Foxp3 enhancer,  but also 
induces acetylation of histone 3 in  the same enhancer region (41, 151). 1α,25-
dihydroxyvitamin D3 was also recently found to promote the  binding  of vitamin D receptor-
retinoid X receptor heterodimer to  vitamin D response elements (VDREs) in CNS 1 of the 
enhancer region (224). However, the epigenetic mechanisms involved in induction of Foxp3 
by VitD were not specifically investigated. Similarly, the underlying epigenetic modifications 
are still unknown for IFN-β andAZA. However, IFN-γ was shown to act as a negative 
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regulator for Foxp3 expression, activating interferon regulatory factor 1 (IRF-1), which binds 
to Foxp3 promoter to inhibit Foxp3 transcription (276). 
These studies suggest that the induction of Foxp3 expression is controlled by histone 
acetylation and CpG demethylation, but the contribution of each epigenetic mechanism may 
vary depending on the agents and culture conditions used. In addition, most of the above 
agents bind to CNS1, which is required for Foxp3 induction, and not CNS2, which is required 
for the heritable maintenance of Foxp3 expression, as described in murine studies (125). 
Therefore, there may be a need to identify new agents that can act specifically on CNS2 to 
induce complete demethylation of the Foxp3 locus. However, the majority of these findings 
were derived from murine studies which may not be applicable to human induced Tregs, as 
our study demonstrated enhanced Foxp3 demethylation in some culture conditions containing 
the above agents. Therefore, future studies need to evaluate the effect of both epigenetic 
mechanisms (demethylation and acetylation) and examine the three CNS elements in all types 
of induced Tregs.  
11.5   TGFβ + tRA protocol appears to be the best option: 
The TGFβ + tRA protocol was the most promising. This protocol consistently increased 
Foxp3 expression and demethylation in naïve CD4+ T cells. It converted 38% of naïve T 
cells into Foxp3 expressing T cells and induced Foxp3 demethylation in 36% of total T cell 
DNA. These Foxp3+ iTregs displayed a high level of Foxp3 expression and exhibited 54% 
demethylation of the Foxp3 promoter. These results indicate that TGFβ + tRA iTregs present 
a relatively more stable population of iTregs, when compared with other protocols. In 
addition, this method requires short term culture, is technically simple to perform, 
reproducible, and its efficacy was demonstrated in murine and human studies (56, 74, 308, 
314, 320, 421, 422). Furthermore, expansion experiments revealed that stimulation of 1x10
5
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naïve CD4+ T cells with TGFβ + tRA for five days, produced  2.8 fold expansion of total cell 
number with an average of 1 x 10
5
 Foxp3+ iTregs. The mean frequency of naïve CD4+ T 
cells estimated in this study was 0.4 x 10
5
 cells per ml of blood which is equivalent to 20 x 
10
6
 cells in a 500 ml of whole blood (one unit). Therefore, the TGFβ+tRA protocol could 
produce 20 x 10
6
 iTregs from one blood unit. This is equivalent to 3 x 10
5
 Tregs per kg body 
weight for an adult weighing 70kg. The phase I/II clinical trials of ex vivo expanded Treg 
immunotherapy in bone marrow transplant patients have shown that Treg infusion doses 
ranged from 1 x 10
5
  to 30 x 10
5
 per kg body weight (105, 106, 155).  
These results indicate that the TGFβ + tRA protocol has the potential to produce Foxp3+ 
Tregs in clinically useful numbers, without the need for further restimulation. The average 
frequency of naïve CD4+ T cells measured in this study lies within the expected frequency of 
naïve CD4+ T cells in  whole blood (0.08 -0.76 x 10
5
 cells/ml) (423). However, in 
comparison with peripheral blood derived thymic Tregs, TGFβ + tRA iTregs displayed 
partial demethylation of the Foxp3 promoter.  Studies have demonstrated that iTregs with 
partial demethylation of the Foxp3 locus, lack stable suppressive function and show transient 
Foxp3 expression, which progressively decreases overtime (44, 72, 151). Therefore, Foxp3 
expression in TGFβ + tRA iTregs is not epigenetically fixed and might be lost, reverting 
them into exFoxp3 cells. Despite high Foxp3 expression, these iTregs have not acquired a 
terminally differentiated phenotype which is a major concern in a therapeutic setting.  
In general, all in vitro iTregs generated from this study displayed only partial demethylation 
of the Foxp3 promoter, though in variable degree. Therefore, these iTregs are similar to the 
prototypic TGF-β iTreg which was previously reported to display partial demethylation and a 
transient Treg phenotype (44, 122, 151). Although all these in vitro induced Tregs will 
eventually lose their Foxp3 expression, the rate of reverting to Foxp3- phenotype may vary 
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depending on the degree of Foxp3 demethylation. This implies that Tregs with higher 
demethylation may maintain their Foxp3 expression and suppressive phenotype for a longer 
period as described for TGFβ + tRA induced Tregs.  
11.6   Strengths and limitations of the current study:  
As stated above this study compares various types of in vitro iTregs using the most clinically 
relevant criteria for Treg immunotherapy and to our knowledge, no such comparison study 
exists. The strength of this study specifically lies in the use of the Foxp3 demethylation assay 
to compare the functional stability of different iTregs. This assay currently presents the most 
specific measure for stable Foxp3 expression, a mandatory criterion for successful Treg 
therapy. It also acts as a quality control measure for evaluating Tregs generated by different 
methods and determines their suitability for cellular therapy. The current study also advances 
the knowledge of the methods used for in vitro generation of Tregs by describing two new 
additional protocols for generating Foxp3+ Tregs (AZA and TGFβ+VitD) and identifying the 
protocol (TGFβ+tRA) that has the potential to generate a more stable Treg population in a 
clinically-relevant cell numbers. In addition, the results from this study prove that current 
methods significantly vary in their performance and fail to produce a stable population of 
Foxp3+ Tregs with a completely demethylated Foxp3 promoter. 
The potential advantages of antigen-specific Tregs over polyclonal Tregs have been 
demonstrated in several studies. Antigen-specific Tregs provide specific suppression, 
effectively control immune activation and are potent, even at small numbers (424-428). Most 
protocols evaluated in this study focused on generation of human polyclonal Foxp3+ Tregs 
except for the 1α, 25-dihydroxyvitamin D3tolerogenic dendritic T cell protocol, which was 
specifically selected to generate antigen-specific Tregs. However, more challenges are 
associated with isolation, expansion and functional assessment of in vitro induced antigen 
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specific Tregs. In addition, in vitro generation of antigen-specific Tregs requires long term 
culture with complex techniques that are labour intensive and yield only a small number of 
Foxp3+ Tregs. These issues were clearly illustrated in the 1α, 25-dihydroxyvitamin 
D3tolerogenic dendritic T cell protocol. Similar limitations were seen in this study with the 
use of other dendritic cell protocols for generating antigen specific Tregs (data were not 
included).  IFN-β induced tolerogenic dendritic cells were generated and utilised to covert 
naïve T cells into Foxp3+ Tregs, combination of mature dendritic cells and polyclonal Tregs 
were also utilised to generate antigen specific Tregs, but neither protocol produced promising 
results. Furthermore, for many autoimmune disorders, the etiology and specific autoantigens 
involved in the pathogenesis are unknown (429-431). Therefore, the use of polyclonal Tregs 
for adoptive transfer immunotherapy presents the most feasible approach for treating 
autoimmunity 
Although the research has achieved its aims, it is important to be aware of its limitations and 
shortcomings. Flow sorting of T cell cultures into Foxp3+ and Foxp3- populations would 
provide more pure populations, for more  accurate determination  of  Foxp3 demethylation 
level,  particularly in Foxp3+ iTregs.  The lack of flow sorting facility for 18 months of the 
thesis period, and the failure to obtain sufficient DNA from some sorted samples, precluded 
the utilisation of this technique, though this was compensated by the use of specific 
calculations, based on the results of data flow analysis. Second, because of the time limit, 
protocols were evaluated on a small number of healthy controls and results may be affected 
by donor specific factors.  In addition, several preliminary experiments were performed for 
each protocol to obtain better conditions for Treg generation and many were based on one or 
two experiments. Therefore, more controls and experiments are needed to provide more 
accurate results and reduce the effect of inter-individual variability. Third, though the 
reliability of in vitro suppression assays and restimulation studies is doubted, these measures, 
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if standardized, and performed correctly, would provide valuable additions for the results 
obtained from this study. Finally, measuring histone acetylation and DNA demethylation in 
other important conserved regions of the Foxp3 gene such as TSDR would provide better 
understanding of the epigenetic effect induced by different treatments.  
11.7   Future directions: 
The results from this study imply that current methods used for generating Tregs lack 
efficiency and that in vitro induced Tregs at this stage lack the quality for adoptive therapy. 
However, the TGFβ+tRA protocol seems to be promising, with more work needed to 
optimize this protocol. These results provide the basic blocks and define an evaluation 
framework for future studies.  
However there are many challenges needed to be overcome, before translating these 
experimental findings to clinical settings. Functional stability is a major concern for the use 
of in vitro iTregs in cellular therapy, this requires generating iTregs that are functionally and 
phenotypically stable both in vitro and in vivo.  In addition, it may require manipulation of 
the patient immune system to create an in vivo microenvironment that can maintain Treg 
differentiation. Although the in vitro conversions approach is likely to obtain sufficient 
number of iTregs for clinical use, there is still a need to identify new markers for detecting 
cells with complete demethylation, so that only stable iTregs are separated for cellular 
therapy. There is also a need to store iTregs for future use by methods like cryopreservation 
and ensure that these cells have the ability to maintain their suppressive function during and 
after storage, which presents another challenge. In addition, adoptive transfer of iTregs 
requires the development of a reliable tracking method for the transferred cells to ensure that 
these cells can maintain their tolerogenic function in vivo.  
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Though both TSDR demethylation and Foxp3 promoter demethylation are relevant for 
determining Treg functional stability in human studies, there are no data comparing both 
methods or suggesting that one method is better than the other. This area is deficient and 
requires more investigation. However, at this stage, a main focus of future research should be 
on identifying new Foxp3 specific demethylating agents that can stabilise Foxp3 expression 
and produce a homogenous population of iTregs.    
Whilst the challenges ahead are still substantial, the goal of achieving a novel, safe and 
effective therapeutic tool to reduce the burden of autoimmune disease should drive a 
continuing global effort. It is hoped that the results of studies reported in this thesis will play 
a part, albeit small, in the journey towards so important an outcome.   
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